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Abstract 
This thesis provides the first account of the duties middle-income countries have to 
the global poor. More specifically, it argues for South Africa’s duty to support health 
research for the global poor. In 1999 the South African AIDS Vaccine Initiative 
(SAAVI) was given the task of developing and testing an affordable, effective and 
locally relevant HIV vaccine for southern Africa. This mandate appears to imply that 
South Africa has an obligation to support health research for the broader African 
region i.e. an obligation beyond its borders. South Africa has the means to fulfil, at 
least part of, this obligation, since it is a hub for both internally and externally 
sponsored health research. This prompts two questions. First, does South Africa 
really have an obligation to support health research whose intended beneficiaries lie 
beyond its borders? After all, South Africa is not a rich country but a middle-income 
country. Second, if there is an obligation, how far does it extend? 
Many theories of global justice accept that very rich countries have some obligation 
to those who are poor. The global justice literature has, however, been silent on the 
duties of middle-income countries. South Africa, and countries like it, occupies a 
unique position that has been neglected in the global justice literature. A middle-
income country might have significantly more resources and research capacity than 
low-income countries, but still struggles to meet internal needs that high-income 
countries have largely addressed. It is therefore not immediately apparent what the 
global justice duties of middle-income countries should be. To address this question, 
I first defend the assumption that, in most cases, prioritising investment in the worst-
off1 is the fairest way to allocate scarce health research resources, since, in most 
cases, adhering to this principle also serves to maximise total health benefits and 
increase global health equality. I then argue that when fulfilling duties to the worst-
off, neither political boundaries nor national allegiances are morally important, and 
                                            
1 The term “worst-off” is sometimes used as an indicator of relative deprivation. In this thesis, my reference to the worst-off 
is to the global worst-off. Since the global worst-off are absolutely poor, I do not use “worst-off” as a relative term. Those 
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should not be used to prioritise the needs of some over those of others. This is 
because the duty to the worst-off is a specific duty of rescue. This rescue duty is so 
pressing that it trumps justice duties and special duties to co-nationals. Recognizing 
this rescue duty essentially moves the worst-off outside our political borders inside 
our scope of moral concern. As a result, South Africa has equal duties to the worst-
off both within and beyond its borders. Given that a middle-income country, with 
limited resources, is not able to assist all the worst-off, I suggest a morally defensible 
way to prioritise within this set. Prioritising the worst-off in sub-Saharan Africa is 
morally permissible because it will, in most cases, produce a larger overall benefit. 
South Africa’s duties to the worst-off in the region are therefore equal to its duties to 
its own citizens who are among the worst-off, and can be prioritised over duties to the 
worst-off elsewhere. 
My account offers a morally sound way for South Africa to prioritise limited health 
research resources while fulfilling its duties to the global poor. Further, to inform 
how South Africa can begin to fulfil its duties, I identify gaps in global health 
spending, with a focus on the poor. I outline which populations are likely to be 
representative of the world’s worst-off. I identify what types of health research, in 
which disease categories, are priorities for these populations, and which of these are 
the most underfunded. This evidence base informs how South Africa can begin to 
focus its health research activities and resources. I recommend “next steps” for South 
Africa; offer suggestions for data collection, and insights on the duties of middle-
income countries more generally. Finally, since most of the time the fairest way to 
allocate scarce health research resources, is to prioritise investment in the worst-off, I 
analyse a selection of the World Health Organisation’s global health research 
priority-setting exercises to establish whether they adhere to this prioritarian 
principle. I recommend that future global health research priority setting exercises 
narrow the scope of their recommended health research priorities. 
                                                                                                                                       
populations who are worst-off are those whose well-being, as indicated by measures of wealth and/or health, is the lowest 
of all populations. 
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1 Introduction 
 
In 1999 the South African AIDS Vaccine Initiative (SAAVI) was tasked with 
developing and testing an affordable, effective and locally relevant HIV vaccine for 
southern Africa (1, 2). This mandate appears to imply that South Africa might have 
an obligation to take account of the research priorities of the broader southern African 
community, i.e. an obligation beyond its own borders. South Africa may have the 
means to fulfil this obligation since it is a hub for health research in the region. This 
prompts two questions: 1) Does South Africa have this obligation? and 2) If there is 
an obligation, how far does it extend? 
Theorists of global justice have written about what obligations very rich countries 
have to poor countries. They have not however thought about the obligations of a 
middle-income country like South Africa to poorer countries. This thesis provides the 
first account of the obligations middle-income countries have to the global poor. 
More specifically it explores whether South Africa has a duty to support health 
research for the global poor. The obligation of middle-income countries to the 
absolutely poor might be different from that of rich-country obligations. Rich 
countries have the resources to eliminate, or have already eliminated, absolute 
poverty domestically.2 They still have resources left over, which could be directed to 
the absolutely poor beyond their borders, or to the relatively poor domestically. We 
cannot assume the same for a middle-income country where resources are more 
limited and where there is often a section of the population that is still living in 
absolute poverty. South Africa’s health research institutions have insufficient 
                                            
2 When we say that a group of people are relatively poor, we mean they are poor in relation to the overall distribution of 
income within a country i.e poor relative to the rest of the country’s population. Absolute poverty on the other hand 
indicates that a group of people fall below some absolute standard of what a person should be able to count on in order to 
meet their basic needs of health and nutrition. They might not have enough to eat, nor are they enjoying good health. Since 
large sections of the populations of developing countries survive with the bare minimum or less, reliance on an absolute 
rather than a relative poverty line is more relevant. This distinction between absolute and relative poverty is consonant with 
other poverty research and with the measures used by international organizations such as the World Bank. See Deaton 
(2004). Measuring poverty. Research Program in Development Studies: Princeton University. Available at: 
www.rrojasdatabank.info/deaton_povertymeasured.pdf; Coudouel, A., Hentschel, J., and Quentin T. Wodon, Q. (2008). 
p.33 Chapter 1: Poverty measurement and analysis. Available online: 
siteresources.worldbank.org/INTPRS1/Resources/383606-1205334112622/5467_chap1.pdf   
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resources to fully address the health research needs for their own population in 
absolute need, neither do they have sufficient resources to completely address the 
health research needs of the worst-off outside the country. This makes the question of 
their obligations unique as directing resources to the absolutely poor beyond their 
borders may mean that some of the absolutely poor domestically are denied. 
1.1 The unique position of middle-income countries 
South Africa and countries like it occupy a unique position that has been neglected in 
the global justice literature. This section illustrates that a middle-income country 
might have significantly more resources and research capacity than its neighbours, 
but still struggles to meet internal needs that high-income countries have largely 
addressed. Because of this, it is not immediately apparent whether middle-income 
countries have any obligations of justice to people beyond their borders. 
Figure 1 shows gross domestic product (GDP) per capita for a selected number of 
countries. The green bars represent three examples of what are usually considered 
very rich countries (GDP $34100-58600 per capita): Germany, the US and Norway. 
The red bars represent four examples of what are usually considered very poor 
countries (GDP $900-1700 per capita): Mozambique, Uganda, Kenya and Lesotho. 
The blue bars represent some examples of what are generally considered middle-
income countries (GDP $3100-10200 per capita): India, China, Thailand, South 
Africa and Brazil. 
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Figure 1.1 Gross National Income (GNI) per capita, PPP (2010) 
 
Source: I sourced data for this graph from: World Bank (2009) Data and statistics: quick reference 
tables. Available at: 
http://econ.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20399244~
menuPK:1192714~pagePK:64133150~piPK:64133175~theSitePK:239419~isCURL:Y,00.html 
(Accessed 24 November 2011).  
 
Note: An international dollar has the same purchasing power over GNI as the U.S. dollar has in the 
United States. See http://web.worldbank.org 
 
South Africa is a middle-income country with a population of 50 million (3). The 
country has an abundant supply of natural resources and well developed financial, 
legal, communications and energy sectors. South Africa has its own drug industry 
with a sound infrastructure and expertise in research and development. The South 
African pharmaceutical market is the largest market in Africa. The current size of the 
market is estimated at about US$3 billion (4). South Africa is also known for its 
innovation in medicine. In 1967 the world’s first heart transplant was performed by 
Dr. Christiaan Barnard at Groote Schuur Hospital in Cape Town. Groote Schuur is 
the chief academic hospital of the University of Cape Town and is an internationally 
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acclaimed health research institution. Within the country there are a number of 
publicly funded health research institutions.3 
Researchers in South Africa continue to make major scientific contributions in the 
area of health research. South Africa still dominates sub-Saharan Africa in terms of 
number of publications, an indicator for research activity (5). This may be because 
the largest funders of health research are not the government but rather the private 
sector and foreign funders. For example, less than 5% of South Africa’s HIV research 
funding comes from the government’s three major funding sources, the Medical 
Research Council, The South African AIDS Vaccine Initiative, and the South African 
HIV/AIDS Research and Innovation Platform (6). Many clinical researchers now 
draw funding from the drug industry or international donors (5). There are a number 
of internationally funded health research institutions within South Africa (7), mostly 
located in universities. South Africa receives the majority of its international funding 
for health research from the United States (U.S.) and the United Kingdom. From 
within the U.S., the National Institutes of Health (NIH) is South Africa’s largest 
funder (7, 8). The NIH health research funding received by South Africa far 
outweighs that of the other top-ten countries to receive NIH funding in sub-Saharan 
Africa (Figure 1.2). This makes South Africa a hub for health research activity in the 
region, even if their principle source of funding is not their government. 
 
 
 
 
                                            
3 See for example, Human Sciences Research Council (HSRC) www.hsrc.ac.za/, South African Medical Research Council 
(MRC) www.mrc.ac.za/, Reproductive Health and HIV Research Unit (RHRU) www.rhru.co.za/  
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Figure 1.2 Top ten countries in sub-Saharan Africa with NIH funding for 
health research (average annual investment 2004-5) 
 
Source: The Fogarty International Center (2005). Report on NIH International Extramural Investments 
in Foreign Institutions FY 2004 – FY 2005 (p.101) 
 
While South Africa is a middle-income country with a well-resourced health research 
sector relative to poorer countries, it is also a country with extreme differences in 
incomes and wealth. Although the country is by far the richest in sub-Saharan Africa, 
millions of its residents remain desperately poor. Daunting social and economic 
problems remain from the apartheid era. Post apartheid economic growth has enabled 
a remarkable decline in poverty, but inequality across race, gender and location has 
still increased. Inequality between racial groups, as measured by the Gini coefficient 
for example, rose from 0.56 in 1995 to 0.67 in 2009 (9). The gap between rich and 
poor has essentially widened (10). In 2009, white South Africans were expected to 
live on average 23 years longer than blacks (11). Close to 60% of poor households in 
South Africa are in rural areas with compromised access to health care. Income 
inequality in South Africa continues to be one of the highest in the world (12). The 
richest 10% of the population accounts for 51% of income while the poorest 10% 
account for just 0.2% of income, including income from social grants (13). 
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The country’s unemployment rate is 23.6%, if we count only those who are 
unemployed and actively seeking work, and 37% if we add those who have become 
discouraged from seeking work. The economic outlook has worsened further after the 
global financial crisis.  In 2009 alone, an estimated half a million workers lost their 
jobs (13). 
Poverty is one of the most significant challenges facing the country with 43% of the 
population (approximately 20 million people) living on under $2 per day. Poor people 
have limited access to economic opportunities and basic services. They also bear a 
greater burden of ill health. The enormous number of people living under $2 per day 
is a good indicator that a significant proportion of South Africa’s population may 
have limited access to basic health services. Today, Groote Schuur hospital, and 
others like it, provide highly specialized, hi-tech health services available largely in 
the private sector.4 The private health sector however only provides care for around 
15% of the population. Eighty five percent of the population depends on the public 
health sector. In a recent Lancet series on health in South Africa, Kapp reports that 
5% of the 8.5% of GDP spent on health is directed towards the health of 7 million 
people and the remaining 3.5% provides for 41 million (14), echoing the stark 
inequality within the country. 
In South Africa health outcomes are widely disproportionate to overall spending. 
Despite the fact that South Africa spends more on health than many other African 
countries (Table 1.1), it is one of only 12 countries worldwide whose under-five 
mortality rate5 actually increased since 1990. Under-five mortality increased from 
62/1000 live births in 1990 to 77/1000 in 2000 (15). Namibia, Kenya and Uganda 
spend around half or less per capita on health than South Africa and still have slightly 
higher life expectancies (Table 1.1). South Africa spends roughly the same per capita 
                                            
4 The private sector caters to middle- and high-income earners who tend to be members of medical schemes (approximately 
20% of the population), and to foreigners looking for top-quality surgical procedures at relatively affordable prices. The 
private sector also attracts most of the country's health professionals. See http://www.hasa.co.za/ for a comprehensive 
listing of the private hospitals in South Africa. 
5 Under Five Mortality Rate indicates the annual number of deaths of children under 5 years of age per 1000 live births. 
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on health as Brazil, but has an under-five mortality rate (U5MR) that is almost three 
times greater and a life expectancy (LE) that is twenty years shorter (Table 1.1). 
  
Table 1.1 Life expectancy (LE), Under-five mortality rate (U5MR), and Health 
expenditure per capita, by GNI for selected countries 
 
 
GNI per 
capita  
PPP, Intl $ 
(2010)  
LE 
(1990) 
LE 
(2009) 
U5MR 
(1990) 
U5MR 
(2009) 
Health 
expenditure 
per capita 
(PPP; Intl $) 
       Norway 57130 77 81 9 4 5207 
USA 47020 75 79 11 8 7164 
Germany 38170 75 80 9 4 3922 
       
Brazil 10920 67 73 56 21 875 
South Africa 10280 63 54 62 62 843 
China 7570 68 74 46 19 265 
India 3560 57 65 118 66 122 
Thailand 8240 68 70 32 13 328 
Botswana 13910 66 61 60 57 1053 
       
Namibia 6580 60 57 73 47 440 
Zambia 1370 46 48 179 141 80 
Kenya 1610 61 60 99 84 66 
Uganda 1230 48 52 184 128 112 
Mozambique 920 48 49 232 142 39 
Lesotho 1910 60 48 93 84 119 
        
Source: I sourced data for this table from: The Henry J. Kaiser Family Foundation (2010). Health 
Expenditure Per Capita (PPP; International $) 2008. Available at: 
http://www.globalhealthfacts.org/data/topic/map.aspx?ind=66 (Accessed 21 November 2011); 
WHO (2011) World Health Statistics Report. Available at: 
http://www.who.int/gho/publications/world_health_statistics/en/index.html (Accessed 24 
November 2011); and World Bank (2009) Data and statistics: quick reference tables. Available 
at: 
http://econ.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20399244~
menuPK:1192714~pagePK:64133150~piPK:64133175~theSitePK:239419~isCURL:Y,00.html 
(Accessed 24 November 2011). 
 
Seventeen years since apartheid, South Africa faces multiple challenges in attaining a 
higher standard of health and in meeting the Millennium Development Goals 
(|MDGs). South Africa’s sound health policies and programmes in the last 17 years 
have led to some improvements in health but in some areas progress has been 
unsatisfactory or even reversed. Life expectancy at birth is now 54 years, a reduction 
of around 10 years since 1990 (Table 1.1). Among the numerous health challenges 
faced by the country are the severe HIV and TB epidemics. Eighteen percent of the 
South Africa’s duty to support health research for the global poor 
18 
population is HIV infected - one of the highest infection rates in the world. This 
means that 5.5 million people in the country are living with HIV. In 2010, there were 
close to 400,000 deaths from HIV and nearly one and a half million adults requiring 
treatment (16). 
Successes and failures in South Africa might not be representative of what happens 
elsewhere in sub-Saharan Africa. However, how South Africa fares is important for 
the rest of the region because of South Africa’s increasing influence across the 
region, and its place (along with China, India and Brazil) as an innovative developing 
country (17). Also, regardless of the multiple challenges that face the South African 
health system, community empowerment, non-governmental organisations (NGOs) 
and a strong civil society play a major role in advocating for people’s rights and set 
an example for other African countries (17). The strong voice of South African civil 
society has brought about many important changes in health (18). National 
investment in research amplified by external funding makes South Africa a hub for 
health research in the region. 
While South Africa has significantly more resources and research capacity than its 
neighbours, it still struggles to meet internal needs that high-income countries have 
largely addressed. South Africa has a relatively sound infrastructure and expertise in 
research and development, but has a limited pool of resources for research. Unlike 
rich countries, South Africa also has a section of its own population that is absolutely 
poor. South Africa’ s research institutions have insufficient resources to fully address 
the research needs for their own population in absolute poverty, and also lack 
sufficient resources to completely cover the research needs of populations in absolute 
need outside of the country.6 It is therefore not immediately apparent what South 
Africa’s obligations of global justice are with regard to prioritising health research. 
                                            
6 OECD countries have very few people in them who are absolutely poor, but they still have people dying from diseases. 
So, it is possible to bring someone out of absolute poverty without thereby ensuring that they are free of illness. However, it 
is also possible to alleviate poverty by providing health care, or by conducting research that will lead to better health care 
for the absolutely poor. 
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1.2 Thesis structure 
In this thesis I explore what obligations a middle-income country such as South 
Africa has to the global poor, as well as how South Africa can work towards these 
obligations by supporting health research. 
In chapter two I explore whether South Africa has duties to the poor only within its 
borders or whether it also has duties to the poor beyond them. To address this 
question, I first make the assumption that in most cases investing in the worst-off is 
the best way to allocate resources in order to treat any set of people fairly. I defend 
this assumption in chapter four. I then review the three major positions in global 
justice, cosmopolitanism, statism and nationalism, and set out what I believe would 
be their positions regarding how the limited resources of a middle-income country 
should be distributed. I argue that political and national boundaries are not morally 
important when it comes to addressing the health needs of the absolutely poor and 
should not be used to prioritise the needs of some over those of others. This is 
because the duty to the absolutely poor is a specific duty of rescue. This rescue duty 
is so pressing that it trumps duties of justice and special duties to co-nationals. The 
effect of recognizing this duty of rescue essentially moves people who are outside our 
political borders inside the scope of our moral concern. South Africa therefore has 
equal duties to the worst-off both within and beyond its borders. Given that a middle-
income country is not able to assist everyone who is among the worst-off, the duties 
have to be constrained by South Africa’s capacity to service the need. We must find a 
morally defensible way for prioritising the distribution of its limited resources 
amongst the worst-off. I argue that prioritising the worst-off in sub-Saharan Africa is 
morally permissible, because it will in most cases produce a larger overall benefit.  
So although South Africa has equal obligations to all the worst-off both within and 
beyond its state borders, it is morally permissible to focus its limited resources on the 
worst-off within sub-Saharan Africa. 
In chapter three I provide an overview of actual global health research priorities and 
how spending does or does not correspond. Given South Africa’s previously 
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established duty to the absolutely poor in the African region, the data presented in 
this chapter points to a number of gaps in global health research spending that could 
be tackled by South Africa as a means to fulfilling this duty. I frame the presentation 
of this data with four distinct but related questions: 1) How does global health 
research spending map onto global health research priorities? 2) How do South 
Africa’s health research priorities compare with Africa’s health research priorities? 3) 
How does global health research spending map onto health research priorities in 
South Africa compared to how it maps onto health research priorities in Africa? And 
4) How does global funding map onto the types of health research needed in low-
income countries? In each case, the answer to the question shows not just the 
distribution of spending according to health research priorities, but also points us to 
how South Africa’s duty to the absolutely poor in the African region can be 
instantiated. Mapping the distribution of funding for health research both by different 
disease groups and by the type of research funded illustrates to what degree funding 
is aligned with actual health research priorities. It also shows where there are gaps in 
funding by disease group and by type of research needed. Identifying gaps in health 
research spending, and particularly gaps in health research spending for Africa, 
informs how South Africa should fulfil its duty. 
In chapter four I defend my assumption from the first chapter that in most cases 
investing in the worst-off is the best way to allocate scarce health research resources 
in order to treat a set of people fairly. In the first section I outline three of the most 
commonly used and widely affirmed allocation principles: maximising overall health, 
increasing health equality, and prioritising the worst-off.  I argue that in the case of 
scarce resource allocation for health research globally, prioritizing the worst-off is 
the best way to treat the global population fairly, since it is also the best way to serve 
the other two principles. In the second section I outline what populations are likely to 
be representative of the worst-off globally, as well as what health research in which 
disease categories are priorities for these populations. I then analyse a selection of the 
major global health research priority-setting exercises conducted by the WHO over 
the last two decades. This analysis looks at the major disease areas and types of 
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research recommended by the WHO to see whether they correctly prioritise the 
worst-off. Finally, I make some recommendations for how these methods of priority-
setting could in the future incorporate the principle of prioritising the worst-off in 
recommendations for the allocation of scarce health research resources. 
In chapter five I outline South Africa’s special obligations. I review South Africa’s 
current list of health research priorities to see to what degree South Africa is fulfilling 
its duty according to my account. I make recommendations for which kinds of 
diseases and which specific types of research South Africa might consider including 
in an expanded list of health research priorities that address the health research needs 
of the worst-off across the region. I also offer some insights about the obligations of 
middle-income countries more generally.
 2 Does South Africa have obligations to the poor 
beyond its borders? 
Many theories of global justice accept that very rich countries have some obligation 
to those who are poor. However, there has been no discussion of what duties middle-
income countries such as South Africa have towards the global poor. A middle-
income country has limited resources and a section of its own population still living 
in absolute poverty, and therefore does not have the means to assist everyone in need. 
In this chapter I explore South Africa’s duties to the poor, including those outside its 
borders. The central question of this thesis is whether South Africa has a duty to 
support health research for the global poor.7 I explore the question of how a resource 
distributor, in this case the South African health ministry,8 should distribute a limited 
pool of resources. Later in the thesis I explore how resources for global health 
research ought to be distributed. I also explore how South Africa should distribute its 
limited pool of resources for health research. In this chapter I am going to deal only 
with the question of how to distribute a limited pool of resources, a necessary 
question to answer before I get to the health research questions. The focal question in 
this chapter will therefore be: How should a South African ministry distribute a 
limited pool of resources? 
A key part of this question is whether South Africa has duties to the poor only within 
its borders or whether it also has duties to the poor beyond. To address this question, 
                                            
7 The difficulty here is to show that investments in health research will actually have an impact on welfare. Like Sen and 
Nussbaum, I believe that health is an important component of overall well-being. Sen and Nussbaum call components of 
well-being capabilities. Following this approach, poor health is understood as a form of capability-deprivation. Those who 
have poor health could then be described as those who are lacking a certain basic capability, which negatively affects their 
well-being. Poor health is therefore an indicator of low welfare. Since the very purpose of health research is to develop or 
adapt interventions that would enhance health and contribute to improved welfare, for the purposes of this thesis, I assume 
that health research is liable to benefit the well-being of populations. Where there is data that deviates from that model, I 
will of course take this into consideration. Otherwise this assumption is warranted, since it is plausible that there is feasible 
health research that will improve the health, and consequently welfare, of a population. 
8 When I refer to how South Africa should distribute its limited pot of resources, I am referring to how a given ministry, in 
this case the health ministry, ought to distribute its limited pot of resources. Insofar as funds are available, or at the health 
ministry’s disposal, how should they be allocated? This does not refer to the bigger question of how to distribute all the 
country’s resources. 
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I first make the assumption that in most cases investing in the worst-off9 is the best 
way to allocate resources in order to treat any set of people fairly. I then provide an 
overview of each of the three major positions in global justice theory, 
cosmopolitanism, statism and nationalism. Each position has different views on what 
the principles of global distributive justice are. I do not provide a detailed account of 
every theory, but rather just enough to structure the question of interest. I then set out 
what I believe would be their positions regarding how the limited resources of a 
middle-income country should be distributed. The conclusions I draw are relevant for 
any resource distributor (or government department) tasked with allocating a limited 
pool of resources. 
I argue that when fulfilling duties to the worst-off, political boundaries do not matter. 
I further argue that national allegiances are not morally important when fulfilling 
duties to the worst-off. Since both political and national boundaries are not morally 
important when it comes to addressing the needs of the worst-off, they should not be 
used to prioritise the needs of some over those of others. This is because the duty to 
the worst-off is a specific duty of rescue. This rescue duty is so pressing that it trumps 
justice duties and special duties to co-nationals. Recognizing this rescue duty 
essentially moves the worst-off outside our political borders inside our scope of 
moral concern. As a result, South Africa has equal duties to the worst-off both within 
and beyond its borders. Given that a middle-income country like South Africa with 
limited resources is not able to assist everyone in absolute poverty, we must find a 
morally defensible way to prioritise within this set. I argue that prioritising the 
African region is morally permissible, because it will in most cases produce a larger 
overall benefit.  Although South Africa has equal obligations to all the worst-off, both 
within and beyond its state borders, this means that it is morally permissible to focus 
these resources on the worst-off in sub-Saharan Africa. 
                                            
9 The term “worst-off” is sometimes used as an indicator of relative deprivation. In this thesis, my reference to the “worst-
off” is to the global worst-off. Since the global worst-off are absolutely poor, I do not use “worst-off” as a relative term. 
Those populations who are worst-off are those whose well-being, as indicated by measures of wealth and/or health, is the 
lowest of all global populations. Since large sections of the populations of low-income countries survive with the bare 
minimum or less, reliance on an absolute rather than a relative measure of poverty is more relevant. 
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2.1 Distributing limited resources 
Theorists writing about global justice have focused on the question of what, if 
anything, is owed by rich countries to poor countries. But poor and rich are relative 
terms: one is always poor relative to those who have more, and rich relative to those 
who have less. In this respect, South Africa is poor relative to “the West” but rich 
relative to many other African countries. The global justice literature is silent on 
whether middle-income countries such as South Africa have obligations towards poor 
populations. In this chapter, I attempt to fill this gap. I explore what duties a middle-
income country such as South Africa has to the poor and what the scope of these 
duties is. 
The obligation of middle-income countries to the poor might be different from that of 
rich-country obligations. Few rich countries have significant numbers of absolute 
poor within their borders, whereas most middle-income countries have large numbers 
of absolutely poor people. This makes the question of middle-income country 
obligations unique. To put this problem starkly, distributing a limited pot of health 
research resources to the absolutely poor beyond its borders may mean giving less to 
the absolutely poor within the middle-income country. Given this limited pool of 
resources, one might ask: “why not simply address the needs of their own absolutely 
poor first?” The status quo after all, even in rich countries, is to address their own 
needs first and then see what is left over for others.10 While this might be true, at least 
for the most part, in terms of how states currently distribute resources beyond their 
own borders, it says nothing about what ought to be done from the standpoint of 
justice. 
 
                                            
10 For example, this is a position taken by Richard Miller (2010). Globalizing Justice:  The Ethics of Poverty and Power.  
Oxford:  Oxford University Press.  
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2.1.1 A key distinction: the “global justice question” and the 
“general allocation question”  
When considering questions of distributive justice, actors who are in a position to 
distribute a limited pool of resources must balance their special and general duties 
towards those they consider “their own” against any special and general duties they 
might have to “outsiders.” They must also decide how to fulfil these duties in the 
fairest way. Essentially, two central but distinct questions need to be addressed. The 
first is the question of “Who counts from the standpoint of justice?” when deciding 
on allocating a limited pool of resources. I will refer to this as the global justice 
question. The second asks, “How do we treat those who count from the standpoint of 
justice fairly?” and I will refer to this as the general allocation question. 
When deciding on how to distribute a limited pool of resources, the answer to the 
global justice question will determine the set or sets of people who have a priority 
claim on those resources. To determine which set of people count, we must consider 
the relevance of state borders and other markers that might separate “insiders” from 
“outsiders,” such as national or ethnic identity or religion. In this way, answering the 
global justice question allows us to articulate duties to fellow citizens, co-nationals, 
and foreigners. The resource distributor will have similar duties to all of those people 
who count from the standpoint of justice. They will have a different set of duties to 
those people who are outsiders.11 
Once we have answered the global justice question and determined which set of 
people count from the standpoint of justice, we can then move on to address the 
general allocation question. The general allocation question asks how we treat those 
who count fairly. Answering the general allocation question helps us determine what 
it means to treat a set of people fairly. So, given a set of people who all have claims 
on the distributor of resources, the general allocation question helps us determine 
how those resources should be distributed. If we have only a limited pool of 
                                            
11  For the sake of argument this is a simplification: there could be different groups to which different degrees of priority are 
owed. 
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resources, the general allocation question will help us to determine whom it is that 
gets priority within that set. 
In this chapter I will address both these questions. First, I will make an assumption 
about the general allocation question--i.e., how to treat those who count fairly 
(section 2.2). Second, I will address the global justice question--i.e., who counts from 
the standpoint of justice (section 2.3). 
 
2.2 Investing in the worst-off will be the right answer to the 
general allocation question most of the time 
At the heart of all plausible theories of justice is the idea that each person who falls 
within the scope of justice matters equally. The general allocation question then is not 
about whether to accept equality but rather about how best to interpret its application. 
The debate involves which specific kind of equal treatment is normatively required 
by the more abstract idea of treating people as equals. The best application of this 
ideal remains contested. For example, John Rawls, in his conception of equal respect 
for persons, argues for two, lexically ordered, principles. The first principle requires 
that each person have an equal right to the most extensive system of basic rights and 
liberties. The second principle has two parts. The first part, fair equality of 
opportunity, requires that citizens with the same talents and willingness to use them 
have the same educational and economic opportunities regardless of whether they 
were born rich or poor. The second part, the difference principle, requires that 
primary goods are to be distributed equally unless an unequal distribution is to the 
advantage of the least favoured in society (19). So while justice requires treating 
people equally in certain respects, this does not entail that they will be equal in all 
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respects. For example, for Rawls we expect that people will still have unequal 
amounts of primary goods.12 
Answering the general allocation question, i.e., deciding how to treat those who count 
fairly, usually requires balancing three resource allocation principles: the utilitarian 
principle of maximising total welfare, the egalitarian principle of increasing equality, 
and the prioritarian principle of investing in the worst-off. For maximizing total 
welfare, the morally right action in resource allocation is that which maximizes the 
total welfare of a population. For maximising equality, the morally right action is that 
which maximizes equality, either of resources or of some sort of outcome such as 
welfare. This might imply that one should attempt to distribute resources equally 
amongst a group of people, or that one should attempt to bring everyone to an equal 
level of welfare.13 For investing in the worst-off, the morally right action for resource 
allocation is considered to be that which offers the greatest advantage to the worst-off 
section of a population. 
Each of these three principles may offer guidance on the allocation of limited 
resources. So, if we had a limited amount of money to invest in the global population, 
what would be the fairest way to spend it? I assume that investing in the worst-off 
would be a just way of allocating these limited resources most of the time. This is 
because when distributing resources for health, prioritizing the world’s worst-off will 
also tend towards maximizing equality and maximizing the total health benefit. In 
other words, in most cases investing in the worst-off is also the best way to serve both 
the egalitarian and utilitarian principles. I sketch an argument, with detailed 
examples, to support this assumption in chapter 4, section 4.1. For the purposes of 
                                            
12 Treating people “as equals” is non-specific in its action-implications. Treating people “as equals” does not necessarily 
entail treating them equally, in the sense of giving them exactly the same share.  For example, a progressive income tax 
takes more in dollar terms from the rich than the poor, and a welfare state pays more to the poor.  But this is still a matter of 
treating them “as equals” (equal sacrifice, responding equally to people's needs, etc.). Having the same claim to be treated 
as an equal does not necessarily entail having the same claim to an equal share.  You might have the 'same claim' to care 
and attention from your government, but that can imply treating you differently from someone whose needs and resources 
differ from your own. 
13 This sense of equality in which the ideal is to distribute a pot of resources equally amongst the members of a group is 
different from the notion of “treating people as equals” in which the ideal is to distribute a pot of resources amongst the 
members of a group in a way that we consider to be the most just or fair. 
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this chapter, I assume this is true for most investments in health interventions and for 
most investments in global health research. 
There will invariably be a certain number of extreme cases where investing in the 
worst-off does not fulfil all three principles. One example is that of “resource black 
holes,” a situation in which no matter how many resources are invested into a 
particularly badly off population, you see little-to-no improvement in health 
outcomes.14 In these rare cases one might have to choose and follow one of the other 
principles, but for the most part investing in the worst-off will typically be the right 
answer to the general allocation question. 
Having made this assumption about the general allocation question, in section 2.3 I 
move on to address the relevance of borders in decisions of resource allocation, that 
is, answer the global justice question. I first divide the global poor into four distinct 
“in-need” populations for analytical reasons (section 2.3.1). I then outline the main 
positions in global justice (section 2.3.2), and finally I consider how each position 
would answer the global justice question with respect to South Africa’s limited 
resources, on the assumption I made above that improving the situation of the worst-
off is the best way to treat a set of people fairly (section 2.3.3). 
 
2.3 The global justice question: the relevance of borders 
2.3.1 Four “in-need” populations 
In considerations of global justice, particularly when asking the question of whether 
the rich have an obligation to the poor, theorists write about resource distributors’ 
duties to different kinds of poor populations. Two key distinctions are often made. 
                                            
14 One example of a resource black hole is the Intensive Care Unit (ICU). We often have cases in the ICU where we know 
the person is probably going to die, but we can sustain their life for a few weeks or months in the ICU, at a tremendous cost, 
despite the knowledge that we shall probably never raise their welfare to that of the average person. 
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The first is that of “domestic” versus “foreign” populations, in which duties to a 
particular group are articulated based on group membership, most commonly 
membership within a state or a nation. The second is that of the “absolute” versus 
“relative” poverty of a particular population, in which duties to a particular group are 
articulated based on exactly how badly off that group is. Combining these two main 
distinctions, four distinct “in-need” populations can be identified: 1) the relatively 
poor domestically (RD); 2) the absolutely poor domestically (AD); 3) relatively poor 
foreigners (RF); and 4) absolutely poor foreigners (AF). 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Four in-need populations 
 
RD = the relatively poor domestically 
RF = relatively poor foreigners 
AD = the absolutely poor domestically 
AF = absolutely poor foreigners 
 
For the purposes of allocating scarce resources it is often helpful to define different 
levels of poverty and apply these either within countries or globally. In general, 
poverty measures are widely used to make funding or resource allocation decisions. 
National poverty counts are often used for allocating domestic funds. In the United 
States, particular government benefits are confined to individuals or households that 
are “poor” as defined by their government. The Indian government subsidizes food 
provision to state governments according to the fraction of their population that is 
“poor.” Similarly, in South Africa the government funds municipalities according to 
estimates of the fraction of their population that is “poor.” 
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Levels of poverty are often defined by using poverty lines. Poverty lines are cut-off 
points separating the poor from the non-poor. While poverty is defined differently 
according to different governments, the important question is how “poor” ought to be 
defined. For example, at what level of income or welfare should someone be 
considered “poor” and eligible for certain benefits? Poverty lines can be set in a 
relative or absolute way. Relative measures of poverty are generally constructed by 
using poverty lines that move with population averages. So, when we say that a group 
of people are relatively poor, we mean they are poor in relation to the overall 
distribution within a country. In each case, “poor” is defined by these governments 
and is usually based on some relative measure of poverty. Those who are “poor” are 
only poor relative to the rest of the country’s population. Absolute poverty, on the 
other hand, indicates that a group of people fall below some absolute standard of 
what a person should be able to count on in order to meet their basic needs. They 
might not have enough to eat, or might not be enjoying good health. The way in 
which I have defined the two different types of poverty for the purposes of answering 
the global justice question, as absolute and relative, is consonant with other poverty 
research (20) and with the measures used by international organizations such as the 
World Bank (21, 22). With some idea of the four “in-need” populations to which 
resource distributors may or may not have duties, in the following sections I address 
the question of to whom resource distributors have global justice obligations. 
 
2.3.2 Three positions in global justice: varying degrees of 
international obligation 
Political philosophers remain divided on exactly how we should apply the concept of 
distributive justice beyond the borders of the state. There is little agreement on the 
question of what the people and governments of wealthier states owe to those outside 
their borders. Some argue that principles of distributive justice ought to apply in the 
same way internationally as they do domestically (23-27). Others argue that beyond 
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state borders there is no justice requirement,15 that duties of justice beyond state 
borders are weaker than domestic duties, or that all duties to aid beyond state borders 
are weaker duties of humanity rather than justice (19, 28-30). In this section, I outline 
the three main positions in global justice: cosmopolitanism, statism and nationalism. 
 
Cosmopolitanism 
 
Cosmopolitans are broadly in favour of distributive justice being applied 
internationally with no discrimination between fellow citizens and foreigners. 
Cosmopolitanism does not recognise any category of people as more or less morally 
important; nor does it regard states as having a self-contained morality.16 Rather, 
cosmopolitans assess actions by their effects on individual human beings. For them, 
individuals are the basic unit of value. Cosmopolitans argue that there should be 
global principles of distributive justice. They view justice-based rights and their 
corresponding duties as human rights, namely rights people hold by virtue of their 
humanity (24, 31, 32). Duties of justice therefore rest on the value of being human. 
Rawlsian cosmopolitans argue that duties of justice arise from structures like the 
state, but that such structures exist internationally (24, 27). Both Charles Beitz and 
Thomas Pogge take Rawls as their starting point and broadly speaking support a 
global version of his theory of justice.17 In general, cosmopolitans would agree that 
resource distributors have the same obligations to all human beings, independent of 
where they live. Because borders should not influence justice, states should focus on 
the worst-off in the world and not merely the worst-off within the state. 
                                            
15 Note that the duties of justice referenced in this chapter refer to duties of justice requiring the provision of assistance. 
This is different from the duty of reparations, which is also a duty of justice. Everyone would recognize 'reparations' as a 
duty of justice: if you've damaged someone else wrongly, you owe them compensation, whether it is someone inside your 
state or outside. 
16 Cosmopolitans don't deny that we have special duties toward certain sorts of people (family, people with whom we've 
signed contracts, etc.).  All they deny is that the relationship of 'co-citizenship' gives rise to any special duties. 
17 Yet other cosmopolitans recognise institutions as the most efficient and morally appropriate means of discharging duties 
to fulfil human rights globally. See Robert E. Goodin, Protecting the vulnerable: A re-analysis of our social responsibilities 
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Cosmopolitans would argue that the same general duties of justice apply to all of the 
four distinct “in-need” populations identified earlier: 1) the relatively poor 
domestically (RD); 2) the absolutely poor domestically (AD); 3) relatively poor 
foreigners (RF); and 4) absolutely poor foreigners (AF). 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 The cosmopolitan position on global justice 
 
Populations to which cosmopolitans recognise a duty of justice 
 
Populations to which cosmopolitans do not recognise a duty of justice 
 
 
Statism 
 
Statists18 argue that there is something morally important about the existence of a 
state. They maintain that distributive justice is only properly applied within state 
boundaries. This is because for statists, duties of justice apply to a state’s institutions. 
In their view there are no equivalent international institutions, and no global 
institutional agent capable of allocating international distributive duties. There is 
therefore nothing to which the concept of justice can be applied globally. Some 
statists recognise limited and weaker duties of justice globally (29, 30). However, for 
                                                                                                                                       
(Chicago: University of Chicago Press, 1985) and Henry Shue, ‘Mediating Duties’, Ethics, 94 (4) (1998), 687-704. For 
these cosmopolitans, institutions are not a condition for the duty of justice, but simply instrumental for their realisation. 
18 Note that the terms “statism” and  “statist” are not established labels. Statists don’t call themselves that and “statist” has 
other meanings. In this thesis the terms “statism” and  “statist” are used to refer to the position in global justice that 
maintains that the requirements of justice apply primarily within state boundaries. 
RD RF 
AD AF 
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the majority of statists, duties on a global level are largely seen as humanitarian 
duties to assist the absolutely poor, who face grave risks and have urgent needs. 
Statist positions can be differentiated in line with the degree to which they assign 
priority to the individuals within a state. Pure statists would not recognise any duties 
requiring the provision of assistance outside the borders of the state. This is, however, 
an extreme position that not many theorists are willing to espouse. Most statists are 
strong statists who argue that duties of distributive justice apply only within the state 
(28, 29), but recognise some duties outside their state borders. Specifically, statists 
recognise either weaker duties of justice or duties of humanity19 but not duties of 
distributive justice. The weaker duties of justice supported by statists aim to assist 
people in reaching a certain threshold only and are not underpinned by a principle of 
equality between people worldwide. In The Law of Peoples, for example, Rawls 
claims that inequality in the international setting does not matter in the same way that 
it does domestically. Rawls acknowledges a duty of assistance to states living under 
“unfavourable conditions” to establish just institutions, in order to secure basic 
human rights and meet basic needs. Beyond this minimal duty however, any further 
address of international inequality is considered unnecessary (29). Thomas Nagel, 
and Michael Blake, argue similarly that shared citizenship gives rise to a concern 
with relative poverty domestically that is absent in the international setting (28, 30). 
Likewise, duties of humanitarian assistance abroad are considered weaker than the 
duties of distributive justice owed to fellow citizens.20 A wealthy country has only a 
weaker duty of assistance to use its own resources to assist the poor outside its 
borders. 
Essentially, for statists, claims against other states are considered secondary to claims 
against one’s own state. Applying the standard strong statist position to the four 
                                            
19 Duties of humanity are also often referred to as duties of humanitarian assistance, duties of beneficence or duties of 
charity.  
20 The assumption is that a duty of justice is weightier than a duty of humanitarian assistance. Why, and to what extent, this 
is the case is however something that statists fail to explain. See Valentini, L (2009). Justice and assistance: Three 
approaches and a fourth one. Centre for the Study of Social Justice Working Paper Series, SJ009; See also T. D. Campbell, 
who questions the ‘priority of justice’ thesis in his ‘Humanity before Justice’, British Journal of Political Science, 4 (1) 
(1974), 1-16. 
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distinct “in-need” populations identified earlier, the statist would recognise a minimal 
duty of humanity, or a weak duty of justice, to assist the absolutely poor anywhere in 
the world to meet some baseline of adequacy. So, limited duties of humanity, or 
weaker duties of justice, would apply internationally but more stringent negative 
duties of justice would only apply domestically. Statists would agree that there is an 
obligation to the absolutely poor domestically (AD) and to absolutely poor foreigners 
(AF) based on duties of humanity in virtue of people’s moral status alone. Both these 
populations have a moral entitlement to a baseline of human decency. Statists would 
also agree that other more stringent duties of justice apply only to those who are 
citizens. Concerns about equality rather than merely absolute poverty – and hence 
with relative deprivation – would be confined to citizens. The duty to the absolutely 
poor (AD) and relatively poor domestically (RD) is based on the need to justify the 
state’s coercion of citizens, who ultimately have a right to autonomy. This makes the 
duties to all citizens (AD and RD) more stringent than those to foreigners. Statists 
would argue that there ought to be no similar concern for relatively poor foreigners 
(RF) because there is no coercion of the relevant sort on individuals globally.21 
 
RD RF 
 AD AF 
 
Figure 2.3 The standard statist position on global justice 
 
Populations to which standard statists recognise more stringent duties of justice 
 
Populations to which standard statists recognise humanitarian duties or weaker duties of justice 
 
Populations to which standard statists do not recognise a duty 
 
                                            
21 Blake (2002) and Nagel (2005) claim that there isn't any coercion, of the relevant sort, globally. This is a claim that might 
be hard to square with the exercise of military might and economic muscle, as Richard Miller argues in his book: Miller, 
Richard.  2010. Globalizing Justice:  The Ethics of Poverty and Power.  Oxford:  Oxford University Press. 
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Even for those who are sympathetic to statism, there is reason to believe that this 
particular statist view, in which duties to the absolutely poor domestically (AD) are 
more stringent than duties to the absolutely poor elsewhere (AF), is not the right 
position to take. Michael Blake (30) is the statist that in my opinion has best 
articulated the justification for statism. Similar to other strong statists, Blake claims 
that the duties owed to foreigners and the duties owed to fellow citizens are distinct, 
that shared citizenship gives rise to a concern with relative poverty domestically that 
is absent in the international setting. Blake, however, stands apart from strong statists 
in that he recognises general duties of justice (and not merely duties of humanity) to 
the absolutely poor, both within the state and beyond. For Blake, all human beings, 
domestic and foreign, have a moral entitlement to exist as autonomous agents. Each 
individual is entitled to those circumstances and conditions in which they are capable 
of selecting and pursuing their own plans of life, according to their own ideas of what 
a good life might be. For Blake, people can only be autonomous agents when the 
options available to them meet a certain baseline of adequacy.22 
Blake argues for two principles in line with the protection of autonomy. The first is a 
positive duty to promote autonomy for those individuals who are not yet autonomous 
agents. Individuals may be denied autonomy in a number of circumstances of 
absolute deprivation such as famine, extreme poverty and crippling social norms.  
Absolute deprivation can occur either within the domestic or global context. Blake 
argues that since the world does have the ability to maintain its inhabitants, and to 
prevent absolute deprivation, we should therefore accept a positive duty to provide 
individuals with the baseline of goods and circumstances under which they are able to 
live as autonomous agents. This positive duty, he argues, should apply globally. 
Borders are arbitrary when it comes to ensuring the basic autonomy of all human 
beings. We ought to be concerned with the absolute deprivation of foreigners as 
much as with fellow citizens. 
                                            
22 He also believes making more options available to a person beyond this baseline of adequacy does not necessarily 
increase an individual’s autonomy i.e. an individual’s autonomy does not depend upon the absolute number of options 
available to them. 
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The second principle argued for by Blake is a more stringent negative duty not to 
impinge on the autonomy of individuals. In general, individuals may have their 
autonomy limited through forms of coercion. The state coerces citizens through 
certain coercive political and legal practices. The imposition of this coercive system 
conflicts with the principle of autonomy. Blake argues that we cannot eliminate the 
state, given the (paradoxical) importance of government for the protection of citizens’ 
autonomy. Since the state is both coercive of individuals and required for individuals 
to live autonomous lives, these forms of coercion require moral justification. If the 
state actively impinges on an individual’s autonomy, then it has to be able to justify 
that impingement of autonomy to each individual person. The state essentially needs 
to show that the coercion is reasonable for each individual i.e. that these principles 
can be justified because they are in each individual’s best interests. A concern for 
relative deprivation, i.e. what the state could justify to its worst-off citizens, is a way 
of justifying state coercion. 
Blake concedes that coercion occurs at the international level but argues that it does 
not involve coercive practices against individual human beings. In the international 
arena, no institution comparable to the state exists. Institutions present at the 
international level do not engage in the same sort of coercive practices against 
individuals, no matter how substantive the links of trade, diplomacy or international 
agreement. Since autonomy of individuals is impinged on to different degrees in 
these different institutional contexts, Blake argues that there are distinct implications 
in these distinct institutional contexts. The type of coercion present internationally 
does not warrant a concern for relative deprivation in the same way that domestic 
coercion does. Therefore, no obligation to relative deprivation beyond state borders 
exists. 
Applying Blake’s position to the four “in-need” populations identified earlier: 1) the 
relatively poor domestically (RD); 2) the absolutely poor domestically (AD); 3) 
relatively poor foreigners (RF); and 4) absolutely poor foreigners (AF) gives us an 
indication of which populations he would recognise a duty to. Blake would recognise 
positive duties of justice to both the absolutely poor domestically and to absolutely 
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poor foreigners. He would additionally recognise a more stringent negative duty of 
justice to citizens, which translates into a duty of justice to those who are relatively 
poor domestically. Blake does not recognise a duty of justice to relatively poor 
foreigners. Again, Michael Blake is the statist that, in my opinion, has best articulated 
the justification for statism. I therefore adopt Blake’s position because it is the most 
plausible version of statism.23 
 
RD RF 
 AD AF 
 
Figure 2.4 Blake’s statist position on global justice 
 
Populations to which Blake recognises duties of justice 
 
Populations to which Blake does not recognise a duty of justice 
 
 
Nationalism 
 
Before giving an overview of nationalist theory, I should make an observation about 
the term “nationalism.” There is an important difference between the popular 
nationalism of political leaders and the academic nationalism defended by political 
                                            
23 While Blake recognizes weak, but equal, duties of justice to the absolutely poor, within and beyond the state, most other 
statists do not. The standard statist view is that there are weaker duties of justice toward anyone outside our own state. 
Statists also acknowledge duties of humanity to aid those in absolute poverty outside their own borders, but generally 
consider these duties weaker than the duties of justice owed to fellow citizens. A likely objection to Blake’s position is 
therefore that there are stronger duties to DA than to FA and therefore statists are justified in allocating scarce resources to 
the domestic person in absolute poverty rather than to the foreigner. I think that if this objection is to be supported, it 
remains to be argued from these opponents either for 1) a better justification for statism that shows one can prefer the 
domestic absolutely poor; or 2) an interpretation of Blake, contrary to my interpretation, that shows one can prefer the 
domestic absolutely poor. Given this, I argue for a statist position that looks more similar to Blake’s theory. As I will 
defend further in section 2.4.1, Blake’s position is the best able to account for duties of rescue. 
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theorists. The nationalist position described here does not support popular 
nationalism, as it is usually understood. Neither does it support the type of 
nationalism that defines a nation in terms of some arbitrary racial or ethnic group and 
claims that this nation is much more important than others. Rather, it focuses on some 
of the more compelling justifications for prioritising people who share a national 
identity. On most benign nationalist views, co-nationals have special duties to one 
another, but it is not the case that any particular nation is more important than any 
other. Analogously, it is generally agreed that family members have special duties to 
one another, but it is not the case that any particular family is more important than 
any other. 
Nationalists believe that co-membership in a nation is what is morally important. 
They maintain that the borders of the nation can be different from the borders of the 
state.24 A state may include more than one national grouping and people sharing a 
common national identity may be living in two or more states (33). For example, 
Quebec is one of many national groupings within Canada, and in 2006 was 
recognised as a nation in a symbolic motion passed by the Canadian House of 
Commons. Kurdistan could be considered a nation that spans more than one state. 
Kurdistan overlaps with four countries: Turkey, Iraq, Iran and Syria. Thus, a nation is 
a group distinct from the group of co-citizens. Co-nationals are a group of people 
who share a history of being shaped by, participating in, and sustaining their nation 
understood as a social group rather than a juridical entity (33, 34). 
Nationalists derive special obligations to co-nationals. While duties to non-nationals 
are not repudiated, the commitment to distributive justice “at home,” or what we owe 
to co-nationals, is viewed as more important than what is owed to non-nationals. 
Thomas Hurka argues that partiality to co-nationals is justified by special 
relationships between people. Hurka draws an analogy with the objective features of 
justified familial partiality, and argues that partiality to one's co-nationals is similarly 
                                            
24 Nationalists aim to bring the nation and the state into alignment, but they certainly think that the two can be out of 
alignment. 
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justified by both: 1) an accurate and favourable evaluation by co-nationals of their 
nation’s cultural activities; and 2) a shared history of working together to produce 
benefits (or a shared history of suffering). Co-nationals share a history of being 
shaped by, participating in and sustaining their nation. Hurka argues that if co-
nationals have a shared history of doing good, or suffering from evil, partiality 
between them is a way of honouring that good.25 While we should not be as partial to 
our co-nationals as we are to our families, being partial to some degree is justified. 
David Miller argues similarly that partiality to one’s co-nationals is justified by 
special relationships between people. Miller claims that any individual is 
fundamentally committed to particular persons, groups, practices and institutions. An 
individual is already deeply embedded in social relationships and is partly defined by 
these relationships and the commitments, duties and obligations that accompany 
them. For him a nation is made up of the shared beliefs of a group of people from a 
history of living together, in which each member recognizes a loyalty to the 
community, expressed in a willingness to sacrifice personal gain to advance the 
nation’s interests (33, 35). Miller, like Hurka, argues from analogy that loyalty to co-
nationals can be defended on the same grounds as other attachments, such as family 
membership. Miller outlines five elements that distinguish national identity from 
other identities and that imply that a particular community of people are a nation. For 
Miller, a nation is a community when it is: 1) constituted by shared belief and mutual 
commitment; 2) extended in history i.e. its connections have persisted for some 
significant length of time; 3) active in character; 4) connected to a particular territory; 
and 5) marked off from other communities by its distinct public culture. 
Nationalists believe it is justified that people are partial to, and want to help, their co-
nationals above others because they share a history with them and feel connected to 
them.26 The four “in-need” populations to be considered by nationalists are then 
                                            
25 Partiality among people who share a history of doing evil is for this reason not justified, as it calls for dishonour. 
26 What is important for these accounts is the relatedness of co-nationals. The relational nature of co-nationals denotes that 
it is an objective moral fact that people stand in specified relationship to each another because of their shared history of 
working together to produce benefits for their nation. It is important that partiality to co-nationals is based on an objective 
relatedness and not a subjective one. The relatedness should be one that holds independently of people’s subjective attitudes 
South Africa’s duty to support health research for the global poor 
40 
similar, but distinct, from the four populations considered by statists: 1) the relatively 
poor within the nation (RN); 2) the absolutely poor within the nation (AN); 3) 
relatively poor non-nationals (RF); and 4) absolutely poor non-nationals (AF). 
Nationalists would argue for special duties to co-nationals. This would include 
special duties to the relatively poor (RN) and absolutely poor (AN) domestically. 
Nationalists would also recognise more limited, general duties of humanity to 
absolutely poor foreigners (AF). Figure 2.5 and 2.6 show two interpretations of the 
nationalist position. The first is an example of the nationalist position illustrated as 
one nation within a state, for example that of Quebec in Canada. The second is an 
example of the nationalist position illustrated as one nation that falls across two or 
more states, for example Kurdistan in Turkey, Iraq, Iran and Syria. The point here is 
that the nation is another group, distinct from the group of co-citizens. 
 
 
 
 
 
 
 
 
 
Figure 2.5 The Nationalist position (one nation within a state) 
 
The nation = Populations to which nationalists recognise a special duty 
 
Populations to which nationalists recognise limited, general duties of humanity 
 
Populations to which nationalists do not recognise any duties 
 
 
 
 
                                                                                                                                       
to their co-nationals. A purely subjective basis could not rule out racial partiality, which is morally offensive. If we used a 
subjective relation as the basis of partiality, the fact that racists care more about people with their own skin colour would by 
itself make it right for them to do so. Also a subjective basis could not justify the duty to favour our co-nationals that would 
be binding on those who do not care about their co-nationals. 
RN  RF 
AN  AF 
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Figure 2.6 The Nationalist position (one nation across two or more states) 
 
The nation = Populations to which nationalists recognise a special duty 
 
Populations to which nationalists recognise limited, general duties of humanity 
 
Populations to which nationalists do not recognise any duties 
 
 
Key 
RN = the relatively poor within the nation 
RF = relatively poor foreigners 
AN = the absolutely poor within the nation 
AF = absolutely poor foreigners 
 
 
2.3.3 Interim conclusion: varying degrees of international 
obligation 
In the preceding section I gave a brief outline of the main positions in global justice. 
Although theorists have different views on the scope of the duties of global justice, 
there is substantial convergence by most on the existence of some duty to aid those in 
absolute poverty i.e. AN, AD & AF. Disagreement however remains about the extent 
of obligations internationally to the relatively poor (RF) i.e. those populations beyond 
the borders of the state who are able to meet their basic needs but who are still poor 
relative to other people in their country or globally.  Disagreements also surround the 
stringency of the duty to aid those in absolute poverty abroad, compared to 
domestically. 
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2.4 The global justice question with limited resources: 
prioritising the worst-off 
In this section, I consider how each of the three global justice positions would answer 
the global justice question with respect to distributing resources that are limited, for 
example the resources that South Africa has allocated to health research. This is an 
important question to answer because the amount of resources that South Africa 
currently makes available for health research are insufficient to fully address the 
health research needs of the poor domestically or internationally. The three positions 
in global justice described above are usually used to argue for rich-country 
obligations to the absolute or relatively poor in other countries. With this comes the, 
mostly accurate, assumption that these rich countries have sufficient resources to 
address the needs of the absolutely poor within their borders, and would still have 
resources left over to direct to those in need beyond their borders. When a country 
does not have enough resources to address the needs of all those in absolute poverty, 
even domestically, the question of obligations to those outside their borders becomes 
harder still. Resource distributors will have to carefully balance the duties to “their 
own” against any duties they have to “outsiders.”27 Given the limited resources in a 
middle-income country, allocating to populations in absolute need beyond their 
borders might mean that some of their own citizens in absolute need get denied. This 
prompts the question of how to allocate these limited resources fairly. 
 
2.4.1 Three positions in global justice: prioritising the worst-off 
I have up until now addressed the global justice question from each of the three 
positions, and shown which set of people count from their standpoint of justice. 
                                            
27 This points to the stringency consideration mentioned briefly above.  How stringent are duties toward absolutely poor 
foreigners (AF) compared to the absolutely poor domestically (AD)? If we adopt the strong statist or nationalist positions, 
duties to the absolutely poor domestically (AD) are more stringent than duties to absolutely poor foreigners (AF). The 
domestic person who is less deeply in absolute poverty would have a stronger claim on us than the foreign person who is 
more deeply in it. If we adopt the cosmopolitan position and/or my interpretation of the statist position, these duties are 
equally stringent. Anyone equally deeply in absolute poverty worldwide has the same claim on us. 
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Cosmopolitans argue that equal duties of justice apply both within and beyond the 
borders of the state, to the absolutely and the relatively poor. Blake’s statist position 
also recognises equal duties of justice to the absolutely poor both within and beyond 
the borders of the state.28 Concerns about relative poverty and the corresponding 
duties of justice are however confined to citizens and statists do not recognise similar 
duties to relatively poor foreigners. Nationalists recognise special duties to co-
nationals that are more stringent than the duties to non-nationals. Having established 
the scope of global justice duties according to each of the three positions – i.e. the set 
of people who count – I will next apply the general allocation principle which 
establishes how to treat this set of people fairly. Working within the assumption that 
investing in the worst-off is the fairest allocation principle, I apply this assumption to 
each of the three global justice positions. In so doing, resource distributors will be 
able to fairly delineate who it is that should be prioritised within the set of people 
who count. 
 
Cosmopolitanism 
 
The cosmopolitan position recognises that resource distributors have an equal duty to 
all of the four “in-need” populations: 1) the relatively poor domestically (RD); 2) the 
absolutely poor domestically (AD); 3) relatively poor foreigners (RF); and 4) 
absolutely poor foreigners (AF). These four populations represent the entire set of 
people who count for cosmopolitans. If we have limited resources and we invest 
these in the worst-off as a way of treating this entire set of people fairly, then the 
populations prioritised within this set would be the absolutely poor, domestically 
                                            
28 Some statists argue that duties to absolutely poor foreigners are less stringent duties of humanity. My interpretation of 
statism rests on Blake’s interpretation of duties of justice to the absolutely poor, independent of location. 
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(AD) and abroad (AF). Cosmopolitans might prioritise these populations by giving 
more to people in these populations.29  
 
 
 
 
 
 
 
 
 
 
Figure 2.7 The cosmopolitan position with limited resources - prioritising 
the worst-off 
 
  Global justice question: populations to which cosmopolitans recognise equal duties 
i.e. the set of people who count  
 
  General allocation question: investing in the worst-off  
i.e. who it is that gets priority within that set 
 
 
Statism 
 
Blake’s position on the global justice question recognises that resource distributors 
have equal duties of justice to the absolutely poor, both within and outside of the 
state. Additionally, Blake recognises a duty of justice to those who are relatively poor 
domestically and no justice duty to relatively poor foreigners. If these three 
populations (the relatively poor and absolutely poor domestically, and absolutely 
poor foreigners) represent the set of people who count, the next question is how we 
prioritise within that set if we have limited resources. Assuming we invest in the 
worst-off as a way of treating this set of people fairly, statists would then prioritise 
those who are absolutely poor. Since Blake’s more moderate statist position would 
                                            
29  Here I assume that cosmopolitans would prioritise the absolutely poor by giving more to people in those situations, while 
still giving something to the relatively poor. It does not have to be “all-or-nothing”. Of course they might give something to 
RD RF 
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recognise equal claims by the absolutely poor domestically and abroad, the resource 
distributor would have the same general justice duties to both of these populations. 
Applied to the four in-need populations, a moderate statist would support my analysis 
and recognise equal duties of justice to those who are absolutely poor both within and 
outside of the state. 
A strong statist would not endorse my view and might prioritise citizens over 
foreigners regardless. The strong statist position on the global justice question holds 
that resource distributors have more stringent duties of justice to the relatively poor 
domestically (RD) and to the absolutely poor domestically (AD). Some would 
recognise weaker duties of justice, and some weaker duties of humanity, to absolutely 
poor foreigners (AF). In consequence of that, strong statists would prioritise the 
absolutely poor domestically over absolutely poor foreigners.30 I now argue however 
that, even if one is a strong statist, there is reason to accept that when it comes to 
distributing limited resources to the absolutely poor, duties to foreigners are not 
necessarily weaker than duties domestically. 
 
Rescue duties trump justice duties 
 
Currently when theorists draw a distinction between duties of justice and duties of 
humanity, they think that duties of humanity are weaker. The basic assumption is that 
a duty of justice as a general rule trumps a duty of humanity. However, when we talk 
about the absolutely poor, it could be argued that this more general duty of humanity 
becomes the very specific duty to rescue. Those living in absolute poverty fall below 
some absolute standard of what a person should be able to count on in order to meet 
their basic needs. When it does not cause death, it still causes misery of a kind not 
                                                                                                                                       
the relatively poor, or nothing. 
30 Strong statists might also argue that since humanitarian duties of assistance are weaker than special duties of justice owed 
to fellow countrymen, the relatively poor domestically should also be prioritized over humanitarian duties to absolutely 
poor foreigners. 
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often seen in rich nations. If this duty of humanity is in fact a duty to rescue those in 
absolute poverty, either to prevent death or merely allow the basic fulfilment of 
needs, then it is not clear that this duty of humanity is trumped by the duty of justice. 
In fact, the specific duty to rescue trumps duties of justice even if other more general 
duties of humanity do not. 
This is best illustrated through a simple example. Let us imagine that there is a South 
African lifesaver, alone on the beach, watching over two people swimming in the 
waves.  He suddenly notices that both swimmers have been swept out by the current 
and need to be rescued. Without his intervention, they will certainly drown. He 
knows he can only save one of these people, the current is strong and he does not 
have enough time to get to both. One of these swimmers is South African, the other 
Zimbabwean, and the lifesaver knows this. Would it be fair for the lifeguard to 
choose which person to save based on citizenship? Surely not. In fact the duty of 
justice seems to be irrelevant in the case of rescue. Duties of justice are concerned 
with inequality i.e. the level of one person’s well-being relative to another’s. The 
fulfilment of justice duties is aimed at reducing this inequality. Duties of justice 
however tell us nothing about what we ought to do when choosing between people in 
need of rescue.31 This is because the duty to rescue is not concerned with how to 
reduce inequality but rather with the saving of lives. The fairest way to interpret the 
duty of rescue is that we owe each person an equal chance of being rescued based on 
need. In the case of the lifesaver, the need of the drowning South African is equal to 
that of the drowning Zimbabwean. To be fair, the lifesaver would therefore owe each 
of these drowning individuals an equal chance of being rescued. This duty of rescue 
is pressing enough that the claim for a chance of rescue trumps the duty of justice. 
The lifesaver would therefore not be allowed to choose to rescue the South African 
over the Zimbabwean, based merely on the existence of a shared state. 
                                            
31 If a statist believes that a particular resource distributor gets to prefer citizens in a rescue scenario, the onus rests on them 
to provide a compelling argument for this. 
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Analogously, in the case when there are many more people, or populations, who need 
rescue than can be rescued with our limited resources, we owe each person, or 
population, an equal chance of being rescued based on need. If all the populations in 
need of rescue are absolutely poor then their need is equally dire. The duty to rescue 
would again not be a means to decreasing inequality but rather an attempt to lift these 
populations above a reasonable definition of human decency, or at the least to save 
lives. Again, this duty of rescue is pressing enough that the claim for a chance of 
rescue trumps the duty of justice. The resource distributor would therefore not be 
allowed to choose to rescue the absolutely poor domestically (AD) over absolutely 
poor foreigners (AF). If political boundaries do not matter when it comes to the duty 
to rescue, then choosing amongst the world’s absolutely poor cannot be based on 
shared citizenship. So even if you are a strong statist, there is no reason to believe 
that the duty of justice trumps this rescue duty. One might not want to think of the 
duties to foreigners who are absolutely poor (AF) as weaker than duties to the 
absolutely poor domestically (AD). 
 
RD RF 
AD AF 
 
Figure 2.8 The statist position with limited resources - prioritising the worst-
off 
 
  Global justice question: Populations to which statists recognise a duty 
i.e. the set of people who count  
 
  General allocation question: Investing in the worst-off - equal claims by AD and AF  
i.e. who it is that gets priority within that set  
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Nationalism 
 
The nationalist position argues that resource distributors may give priority to co-
nationals. This translates into a special duty to two groups: 1) the relatively poor 
within the nation (RN); and 2) the absolutely poor within the nation (AN). 
Nationalists may also recognize other duties on different grounds than that of the 
duties to co-nationals, such as duties of justice and a general duty of humanity to the 
foreign poor. As with statists, nationalists would consider the stringency of these 
duties less than that of the special duty to co-nationals. Given the special case of a 
middle-income country in which there are not enough resources to address the needs 
of any one of these groups, nationalists would need to ask how we could further 
prioritise within this set of people who count for them. Assuming we invest in the 
worst-off as a way of treating this set of people fairly, the population that would be 
prioritised by the nationalist would be the absolutely poor within the nation (AN). 
Most nationalists maintain that the nation is smaller than, or roughly the same size as, 
the state. This would roughly translate into giving priority to the claims of South 
African citizens who are absolutely poor over the claims of the absolutely poor 
elsewhere. I argue however that, even if one is a nationalist, there is reason to accept 
that when it comes to distributing limited resources to the absolutely poor, duties to 
foreigners are not necessarily weaker than duties domestically. 
Earlier I argued that a person's stronger claim to rescue could not be legitimately 
defended by his or her shared citizenship with the resource distributor. In the case 
that there are more people in need of rescue than can be rescued, the resource 
distributor owes each person an equal chance of being rescued based on need. The 
duty of rescue is pressing enough that the equal claim for a chance of rescue trumps 
any duties of justice. If we accept that the existence of a shared state is not a 
legitimate reason to favour the absolutely poor domestically (AD) over the absolutely 
poor elsewhere (AF) in a rescue scenario, then it is also likely that a similar objection 
could be levelled against allegiances as a legitimate reason to favour some over 
others in a rescue scenario. If the duty of rescue is pressing enough that the equal 
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claim for a chance of rescue trumps the duty of justice, then it could also be true that 
the duty of rescue is pressing enough to trump priority being given to co-nationals. 
When we are talking about duties to those who are in absolute poverty, the specific 
duty of humanity, the duty to rescue, trumps any special duties of co-nationality. 
A committed nationalist might argue that South African national identity is 
permissible grounds for a South African resource distributor to prioritise absolutely 
poor South Africans over the absolutely poor elsewhere. Even if there is this equal 
duty to rescue when it comes to the absolutely poor, in the case that there are more 
people amongst the absolutely poor in need of rescue that can be rescued, the 
relationship between South African co-nationals would be a legitimate reason to save 
them first. Returning to the lifesaving example, this nationalist might ask us to 
imagine that of the two people in need of rescue, one is the lifesaver’s mother, and 
the other a stranger. Just like partiality to saving his mother is justified by his special 
relationship with her, so would partiality to his co-nationals be justified by his special 
relationship with them. 
In the following section I argue that there is still reason to believe that this committed 
nationalist’s account does not support special duties to South African nationals. I 
argue that even if the committed nationalist believes we are morally permitted to 
prioritise our co-nationals, this does not neatly translate into special duties to fellow 
citizens. This is because the nation does not always correspond with political borders. 
Co-nationals are not always co-citizens. In the case of South Africa, I argue that there 
are scarcely stronger national ties than regional ties. Since this is true, it is not 
defensible for nationalists to draw on a principle that results in “South African 
nationalism” when this same principle could equally result in “pan-African 
regionalism”. 
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Who are co-nationals? 
 
Even for the nationalist who argues that South African national identity is permissible 
grounds for a resource distributor to prioritise co-nationals in a rescue scenario, this 
does not neatly translate into special duties to fellow South African citizens. This is 
because the nation does not always correspond with political borders and therefore 
“co-nationals” are not always co-citizens. So who are co-nationals? Co-nationals are 
a group of people who share a history of being shaped by, participating in and 
sustaining their nation (34). Most nationalists maintain that the nation is restricted to 
a local community, either smaller than or roughly the same size as the state (33-35). 
If we were to accept this traditional interpretation of nationalism, then it seems to 
follow that it is permissible for a South African resource distributor to prioritise the 
needs of its fellow citizens above the needs of people beyond its own political 
borders. But this result only follows from a mistaken interpretation of nationalism, 
which assumes that we only have this shared history with citizens of our country or 
members of smaller communities. There is no reason to think that we do not also 
share this “nationhood” with members of groups much larger than those occupying 
states. 
The distinctive features of relatedness that constitute a nation, as drawn from the 
salient features of Hurka’s and Miller’s nationalist accounts, include: 1) an accurate 
and favourable evaluation of certain general qualities of the nation, or minimally a 
recognition of their distinct public culture; 2) a shared history of working together to 
produce benefits (or shared history of suffering); 3) being connected to a particular 
territory or geographical place; and 4) shared belief and mutual commitment. These 
same features could be shared by a group larger than the state. At least in some cases 
in which nationalists believe nationality is a relevant feature, the attributes that justify 
partiality to co-nationals are attributes that are also shared between (groups of) people 
that reside both inside and outside a country’s borders. If members of a group larger 
than a state share these attributes, then surely partiality among members of this larger 
group is also justified. 
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Consider the region of Sub-Saharan Africa. Individuals within the region conceive of 
themselves as “African” and have a favourable evaluation of what it means to be part 
of this African culture. The region is marked off from other communities by its 
distinct African culture. Individuals have shared a history of suffering historically, 
under colonial powers, as well as under apartheid, for though apartheid was confined 
to the borders of South Africa, its impact was felt across the entire Sub-Saharan 
region. The apartheid state did not just destabilise South Africa’s neighbours, but also 
the other countries of Southern Africa, which have a common history and geography 
and, thus, a common future (36). Individuals within the region have additionally 
shared a history of working together for mutual benefits. One important example is 
that of the abolition of apartheid. Many Southern African Development Community 
(SADC)32 members allowed the exiled African National Congress (ANC) and Pan 
Africanist Congress (PAC) to establish bases in their countries. Individuals within 
these countries assisted with the protection of important political figureheads and 
freedom fighters that lead to the abolition of South Africa’s apartheid. 
The people of Southern Africa are connected to a particular territory or what Miller 
refers to as a “homeland” which connects this group of people to a geographical 
place. An essential part of a national identity is that a people should permanently 
occupy that place. Miller argues that the actions nations aspire to perform must 
include that of controlling a chunk of the earth’s surface, to create a “political 
community,” something which the region of Southern Africa has both aspired to and 
achieved in its creation of and sustained membership in SADC. The region is also 
constituted by shared belief and mutual commitment. Members recognise one another 
as compatriots or fellow Africans. When we consider the very similar regional 
distribution of disease burden, for example malaria, HIV and AIDS, and tuberculosis 
(TB), people within the region are certainly mutually committed to addressing these 
                                            
32 SADC's vision is that of a common future, a future within a regional community that will ensure economic well-being, 
improvement of the standards of living and quality of life, freedom and social justice and peace and security for the people 
of Southern Africa. This shared vision is anchored on the common values and principles and the historical and cultural 
affinities that exist between the people of Southern Africa. See http://www.sadc.int/english/about-sadc/ 
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common challenges.33 Having to work together as a region creates a sense of 
belonging or solidarity--“one voice” for the people of the region, who all suffer under 
the same burden. Being co-contributors toward the advancement of a common goal 
creates a sense of unity. 
So, does this region share the features of a “nation”? The region does have a distinct 
public culture; a shared history of working together to produce benefits (and a shared 
history of suffering); being connected to a particular territory or geographical place; 
and shared belief and mutual commitment. Based on this, the region of Southern 
Africa effectively meets the criteria for a “nation” whose members may show 
partiality to each other.34 Applying the principles underlying nationalist theory would 
generate special obligations, not just to co-nationals as they are traditionally 
conceived of, but also to co-regionals.35 The effect of recognizing these regionalist 
duties essentially moves people who are outside our political borders inside our scope 
of moral concern. On this regionalist account of global justice, one would recognize 
special duties to the absolutely poor within the region, rather than just duties to South 
African citizens who are absolutely poor. This “regionalist” position might look 
something like Figure 2.9. 
 
 
 
 
 
                                            
33 One example of such a mutual commitment is that of the Southern Africa Roll Back Malaria Network (SARN). 
Established and launched by SADC in 2007, SARN is a partnership of government, private sector, NGOs, UN Agencies 
and Communities. It coordinates partner support on technical and operational issues for going to scale with effective 
malaria control interventions to 10 Southern African countries: Botswana, Madagascar, Malawi, Mozambique, Namibia, 
South Africa, Swaziland, Zambia, Zimbabwe and United Republic of Tanzania (Zanzibar) and also supports Angola, DRC 
and United Republic of Tanzania by bringing program managers, NPOs and military managers to the annual consultative 
meetings and through cross border collaboration initiatives, SADC Malaria Day and World Malaria Day. See 
http://www.sadc.int/english/regional-integration/shdsp/sarn/ 
34 See Miller (1995) p. 18 where he clarifies that there can legitimately be disagreement about whether a particular group of 
people, say the Scots or the Quebecois, form a nation or not, beyond the admitted vagueness or complexity of the criteria 
for being a nation. It is a matter of interpreting what people believe about themselves – and this is further complicated by 
the fact that the attitudes and beliefs that constitute nationality are very often hidden away in the deeper recesses of the 
mind, brought to full consciousness only by some dramatic event. So simple empiricism will not settle the issue, even if it is 
a direct survey of people’s beliefs about nationhood. 
35 If we see 'association' as the more generic term, then 'regionalism' is another form of 'associationalism', alongside 
'nationalism' -- grounded on the same fundamental associational logic. 
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(Where the “nation” is larger than the state/multiple states) 
 
 
Figure 2.9 Reinterpreting the nationalist position – Regionalism 
 
  Global justice question: populations to which nationalists recognise a special duty (RN+AN)  
i.e. the set of people who count  
 
  Populations to which nationalists recognise limited, general duties of humanity (AF) 
 
  General allocation question:  investing in the worst-off - equal claims by AN (across a region) 
i.e. who it is that gets priority within that set 
 
Since South Africa contains nearly as much diversity as can be found throughout the 
region,36 there are scarcely stronger national ties than regional ties. It is therefore 
difficult for nationalists to draw on a principle that applies South African nationalism 
to justify partiality to South Africans who are absolutely poor, when the same 
principle could equally apply to the region and justify partiality to the absolutely poor 
across the region. The resource distributor therefore has an equal duty of rescue to all 
the absolutely poor, domestically and abroad. 
 
 
 
 
 
 
 
 
 
Figure 2.10 The nationalist position with limited resources - prioritising the 
worst-off 
 
  Global justice question: populations to which nationalists recognise a duty 
i.e. the set of people who count 
 
  General allocation question: investing in the worst-off - equal claims to rescue by AN and AF 
i.e. who it is that gets priority within that set 
                                            
36 South Africa has 11 official languages, which along with ethnic differences, separate the population both geographically 
and culturally into smaller groups. 
RN 
 
RF 
AN 
 
AF 
 
 
 
RN  RF 
AN  AF 
 
 
South Africa’s duty to support health research for the global poor 
54 
2.4.2 Interim conclusion: equal claims by the absolutely poor 
domestically and abroad 
Up until this point, we have established how each of the three theoretical positions 
would answer the global justice question with respect to limited resources for 
assistance of any sort. Each theory delineated a set of people who count i.e. who it is 
that might get a share of those resources. The resource distributor has duties to all of 
those people within the set. Assuming investing in the worst-off is what treating this 
set of people fairly entails, we prioritise the absolutely poor. Since the specific duty 
to rescue trumps both duties of justice and special duties to co-nationals, then 
cosmopolitans, statists and nationalists alike would recognise equal claims (to 
rescue), based on need, by the absolutely poor domestically (AD), the absolutely poor 
within the nation (AN) and absolutely poor foreigners (AF). 
 
2.5 Reframing the global justice question as two separate 
questions 
As has been outlined above, theorists usually frame the global justice question as 
three positions addressing the same question, the question of which set of people 
count. The differences between, and within, these three theoretical positions are many 
and complex. For clarity, it might be better to reframe this as two separate questions. 
When it comes to addressing the needs of the absolutely poor: 1) Do political 
boundaries matter? and 2) Do allegiances, such as national allegiances, matter? 
 
2.5.1 Do political boundaries matter? 
The first question is whether or not political boundaries matter. Answering this 
question usually entails answering the question of whether some version of 
cosmopolitanism or statism is the right view. With respect to my question, whether 
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one thinks that political boundaries are important (statism), or not (cosmopolitanism), 
does not seem to matter. If investing in the worst-off is in fact the correct answer to 
the general allocation question, and if we accept that the duty to rescue trumps any 
duties of justice, then the cosmopolitan and statist arguments give the same 
conclusion: recognition of equal duties to the absolutely poor, independent of 
location. For South Africa this would translate into equal duties to the absolutely poor 
within their own country and the absolutely poor in other countries. This might 
include the absolutely poor in countries that are close geographically and politically 
such as Zimbabwe or Botswana or the absolutely poor in countries more removed 
such as India or Bangladesh. 
 
2.5.2 Do allegiances, such as national allegiances, matter? 
The second question is whether allegiances, such as national allegiances, matter. 
Should the ties between co-nationals make a difference?  In this respect, whether one 
believes that political boundaries matter or not, one might also think that national 
allegiances matter. So, even if one is a cosmopolitan who thinks that political 
boundaries do not matter, one might think that national allegiances do. Also, if one is 
a statist who thinks that political boundaries do matter, one might think that national 
allegiances matter too. 
Just as shared citizenship is not a morally defensible reason to favour the absolutely 
poor domestically over absolutely poor foreigners in a rescue scenario, neither is 
shared nationhood. If we accept that the duty to rescue trumps duties to co-nationals 
then a nationalist would recognise equal duties to the absolutely poor both within and 
beyond the nation. For South Africa, this translates into equal duties to the absolutely 
poor within and beyond their national borders. Again, this might include the 
absolutely poor in countries that are close geographically and politically such as 
Zimbabwe or Botswana or the absolutely poor in countries more removed such as 
India or Bangladesh. 
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2.5.3 A permissible way to prioritise spending: the efficiency 
principle 
Having established which people count, and knowing that we have an equal duty to 
the absolutely poor everywhere, it is still necessary to find a permissible way to 
prioritise spending. This is because a middle-income country does not have the 
resources to rescue the absolutely poor everywhere. So, while South Africa might 
have equal duties to all the world’s absolutely poor, they would practically not be 
able to help all these people given their limited resources. There are many more 
people amongst the global worst-off that need to be rescued than can be. Since 
prioritization within this set would not be morally permissible on the grounds of 
shared citizenship, nor on the grounds of nationhood, are there morally defensible 
grounds for narrowing this population that has a claim on South Africa’s health 
research resources? I believe there is a morally defensible principle we can use to 
prioritise amongst the world’s absolutely poor, namely the principle of efficiency. 
Once again I return to the lifesaving example, but this time let us imagine that there 
are three people drowning. Two of these people are relatively close to each other, as 
well as relatively close to the lifesaver, the third is further away from all. The South 
African lifesaver has a choice of saving two people vs. saving one. Because this is a 
rescue scenario, and because the best interpretation of the duty to rescue is that each 
person should be given an equal chance of being rescued based on need, all three 
people have an equal claim to being rescued. But faced with the choice of saving two 
lives rather than one, it would certainly be morally permissible for the lifesaver to 
choose to save two i.e. to get “the biggest bang for his buck.” Similarly, if there is a 
subpopulation of the absolutely poor, which South Africa can help more efficiently 
than other subpopulations i.e. they would be able to rescue more people in this 
subpopulation than in others for the same investment, then they are permitted to 
prioritise this subpopulation over others. I believe that this is true for the 
subpopulation of Sub-Saharan Africa. 
There are a number of facts about this African region that point to a rescue scenario 
in which more lives could be saved in this region compared with others, with the 
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same investment of resources. Relevant to the distribution of health research 
resources, shared disease burden is the first of these facts. Chapter 4 details regional 
similarities and differences in the disease burden of the worst-off, but for now, it is 
sufficient to note that South Africa’s disease burden is more similar to the disease 
burden of the Sub-Saharan Africa region than to any other. HIV and AIDS, and 
tuberculosis (TB), as well as respiratory infections and diarrhoeal diseases are shared 
by the worst-off across the region, so investing in health research to address the needs 
of the worst-off outside of South Africa might not be a far stretch from the research 
South Africa is already carrying out in these disease areas. Comparatively, the worst-
off in South Asia do not share the disease burden of South Africa to the same extent. 
Again, Chapter 4 illustrates regional similarities and differences in the disease burden 
of the worst-off but for now it is sufficient that South Africa would have to expand its 
current health research repertoire in order to meet the needs of the worst-off in South 
Asia, an exercise that would be far more costly than focusing only on the African 
region. 
Although the disease burden is largely similar, there are some diseases that South 
Africa does not share with the rest of the region. These include malaria, sickle cell 
disease, and some of the neglected tropical diseases (see chapter 4). This detracts 
from the degree to which this population can be efficiently served. Nonetheless, 
shared disease burden is not the only factor that makes it more efficient for South 
Africa to focus on sub-Saharan Africa. Economic links, a shared geographical space, 
shared resources, and a history of working together as a region all point to an 
established infrastructure for mutually beneficial action and result in South Africa 
being able to help more people for less cost. While South Africa would still recognise 
equal claims by the absolutely poor everywhere, given the greater efficiency of 
investment in Sub-Saharan Africa than in other subpopulations, it would be morally 
permissible for South Africa to prioritise the discharge of their duties within this 
region i.e. to discharge its duty to rescue absolutely poor foreigners who are African 
before absolutely poor foreigners everywhere else. 
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Given that a middle-income country like South Africa with limited resources is not 
able to assist everyone in absolute poverty, and that some “regionalist” priority is 
permissible, South Africa has equal duties to the absolutely poor inside and outside of 
its state borders, it is morally permissible, in line with the principle of efficiency, for 
South Africa to focus its limited resources on Sub-Saharan Africa. This would 
translate into equal duties to the absolutely poor within South Africa and to the 
absolutely poor in other countries within the region. It would make sense for South 
Africa to focus on their duties to these populations within the region, rather than on 
the absolutely poor in countries more removed such as India or Bangladesh.37 
 
2.6 Conclusion 
Many accept that rich countries have obligations to poor countries. In this chapter I 
considered what obligations a middle-income country like South Africa might have to 
poorer populations. With limited resources, a middle-income country cannot meet 
their duties to everyone in absolute need. What is needed, then, is a sound method, 
based on sound principles, for prioritizing the distribution of its limited resources. 
In this chapter I argued that when fulfilling duties to the absolutely poor, political 
boundaries are not morally important and cannot be used to prioritise some people’s 
needs over those of others.  Similarly, national allegiances are not a morally 
legitimate reason to favour absolutely poor co-nationals over absolutely poor non-
nationals. This is because the duty to the absolutely poor is a specific duty to rescue. 
This rescue duty trumps justice duties; it also trumps special duties of co-nationality. 
This translates into equal claims by the global absolutely poor everywhere on South 
Africa. Given that a middle-income country like South Africa with limited resources 
is not able to assist everyone in absolute poverty, however, we must find a morally 
                                            
37 The degree to which we may prioritize these populations is a complex question. Great needs of other people could 
outweigh the permission to prioritize small needs of our fellow Africans. However, given the limited resources and huge 
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defensible way to prioritise within this set. Focusing on the region is morally 
permissible because this is in line with the efficiency principle and so will in most 
cases produce a larger overall benefit. Applied to the original question of supporting 
health research, South Africa has an obligation to support health research for the 
absolutely poor beyond its state borders, and it would be permissible for South Africa 
to prioritise the health research relevant to the absolutely poor in sub-Saharan Africa. 
                                                                                                                                       
needs of the worst-off in sub-Saharan Africa, this is likely not to be an issue. 
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3 Global health research priorities and how 
spending corresponds 
Health is an important component of general welfare; poor health is one of the most 
important causes of material deprivation.  Aspiring to meet health needs is therefore 
instrumental in improving general welfare. Health research is one mechanism that 
can contribute to health improvement and health systems enhancement.38 One of the 
critical roles of health research is to ensure that measures proposed to address health 
are based on evidence so that resources available to finance these measures are used 
in the most efficient way. One way to effectively utilize resources is through ensuring 
that appropriate funding is directed towards health research priorities. Although this 
is of paramount importance in order to address diseases of poverty, it is also 
important in resource-rich settings, as shown by the report on priority setting within 
the United States National Institutes of Health (37). 
The significance of appropriately directing funds to health research priorities is 
however, much more acute in terms of global justice. Scarce health research funding 
is a challenge for many countries, but is particularly acute in low- and middle-income 
countries, which have limited financial resources to fund necessary research 
themselves and a low priority given to their national health problems by the global 
health research community. Health research in many of these countries faces two key 
challenges: 1) a lack of clarity on actual national health research priorities and/or a 
lack of the research governance and management systems needed to develop, 
communicate and implement them; and 2) the influence of international health 
research programmes, that often pay insufficient attention to these health research 
priorities as they design and implement their programmes. International health 
research programmes and donors can distort country research agendas and sometimes 
undermine national health research systems. Consequently, health research in low- 
                                            
38 There is a balance between investing money in health research vs. investing in other interventions that might improve 
health. For the purposes of this chapter, I will take it as fixed that there will be a certain amount of money directed at health 
research. I will address how this money ought to be used. 
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and middle-income countries is often not aligned with the actual health research 
priorities in these countries (38). In the cases that research does fit some of these 
priorities, there are often not enough of the relevant types of research needed within 
these categories. Not only do low- and middle-income countries need to develop 
capacity to identify health research priorities and conduct relevant health research, 
but there also needs to be a greater sense of accountability of health research globally 
(39). Historically, there has been a pervasive global disparity between disease burden 
and health research funding with an imbalance in the application of research 
resources to address the health needs of poor populations (40). Essentially, too little 
funding for research was, and for the most part still is, being devoted to the health 
problems of poor and disadvantaged populations. 
Tracking the distribution of global funding for health research is an important 
mechanism for assessing to what degree funding maps onto actual health research 
priorities. It helps to identify specific gaps in needed health research with regard to 
specific diseases and geographical areas. In the previous chapter I argued that South 
Africa has equal duties to the world’s absolutely poor, but that it would be morally 
permissible to prioritise the absolutely poor in the African region. In this chapter I 
provide an overview of established health research priorities39 and how spending does 
or does not correspond. I frame the presentation of this data in answers to four 
separate, but related, questions: 
1. How do global health research investments map onto global health research 
priorities? 
2. How do South Africa’s health research priorities compare with Africa’s? 
3. How do global investments in South Africa’s health research priorities 
compare to global investments in Africa’s health research priorities? 
4. How do global health research investments map onto the types of health 
research needed in low-income settings? 
                                            
39 For clarity, when I refer to “established” or “documented” health research priorities, this points to health research 
priorities that have been determined by a responsible institution or organization. This is distinct from the health research 
priorities that I believe a government ought to endorse. 
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By addressing these questions I will show not just distribution of spending according 
to health research priorities but also how South Africa’s previously established duty 
to the absolutely poor in the African region is being, and can be, met. 
 
3.1 How do global health research investments map onto 
global health research priorities? 
In this section I provide an overview of how global spending on health research maps 
onto global health research priorities. Looking at this data is informative in 
identifying gaps between established health research priorities and global funding 
efforts. Identifying these gaps provides an evidence base from which global health 
programmes, funding organisations, and governments can better appreciate and focus 
their activities and resources on specific health research needs, particularly if these 
health research needs represent under- or unaddressed health research areas. More 
relevant specifically to this thesis, this evidence base helps to inform how South 
Africa should fulfil its previously established duty to the absolutely poor. Before 
reviewing the data we could surmise that if South Africa has equal duties to all the 
world’s absolutely poor, and if global spending does not map onto global health 
research priorities, for example, if it is skewed to high-income countries’ health 
research priorities, then one way in which South Africa might begin to fulfil its duty 
is to advocate for a shift in funding to health research priorities relevant to the 
absolutely poor. 
So what are the global health research priorities? The reality is that no global health 
research priorities have been established. This in itself is telling of a general lack of 
alignment in global efforts relevant to health research planning, activities and 
resource allocation. This is so for a number of reasons, including that proposed 
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methods for health research priority setting are not all the same.40 As a proxy for 
global health research priorities, one can look to global burden of disease data. This 
data is however not ideal because global burden of disease does not map exactly onto 
health research priorities. When identifying health research priorities one should not 
only consider burden of disease in isolation. Other considerations include: the extent 
of previous research, the potential for the research to have an important effect on 
disease burden, cost-effectiveness, feasibility of research, the likelihood that the 
research will be successful, and the particular type of research needed – for example 
implementation and operational research versus biomedical.41 
Nonetheless, working with the data that we do have the closest proxy data for global 
health research priorities is global burden of disease data. With this in mind it is 
necessary to reword the original question to represent the data that is available. So, 
instead of asking how global health research spending maps onto global health 
research priorities, the question becomes: How does global health research spending 
map onto global burden of disease? Again, relevant to the broader thesis question, we 
could surmise that if South Africa has equal duties to all the absolutely poor in the 
African region, and if global health research spending does not map onto global 
burden of disease, for example, if it is skewed to high income countries’ burden of 
disease, then one way in which South Africa may be able to instantiate its duty might 
be to advocate for a shift in funding to the comparatively neglected burden of disease 
affecting the absolutely poor in the African region. 
The WHO Commission on Health Research for Development conducted the first 
exercise to track global health research funding (40). Published in 1990, their report 
was the first to draw attention to the disparity between global disease burden and 
global health research funding. Poor and disadvantaged populations had the highest 
disease burden globally but received a very small share of global resources. 
                                            
40 A number of methods have been proposed for health research priority setting over the last two decades. Not all of them 
are in agreement as to the best method for setting health research priorities. Table 4.1 in Chapter 4 provides an overview of 
global health research priority-setting exercises. Appendix B provides a more detailed description of some of the major 
global health research priority setting exercises conducted over the past two decades. 
41 This list represents some of the common features and criteria of most of the tools and methods for priority setting. 
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Symbolised by the now well-known expression “10/90 gap,” this imbalance 
essentially indicated that 90% of worldwide resources for health research were being 
spent on 10% of the global disease burden. Twenty years after the 10/90-gap report, a 
gap between health research funding and burden of disease still exists and has 
become widely recognised. In an attempt to bring attention to the need for focused 
health research in the areas in which it is most needed, a number of publications, 
websites and conferences have further addressed health research priorities and the 
Global Forum for Health Research has continued to regularly track where and on 
what health research resources are spent. The regular tracking of these resources 
reported in annual reports by the Global Forum identifies specific gaps in funding for 
diseases according to geographical area (41). In the following section I first give an 
overview of the current data on global disease burden, both by cause type42 and 
income sector. I then give an overview of global health research funding flows. 
 
3.1.1 Global burden of disease - an imperfect proxy 
One summary measure of health that gives a good indication of the burden of disease 
is the disability adjusted life year (DALY). One DALY represents one year lost of 
healthy life. It is used in burden of disease reports as a single measure to quantify the 
burden of diseases, injuries and risk factors. DALYs essentially combine years of life 
lost due to death and equivalent years of life lost through being in a state of poor 
health or disability. The more DALYs reported for a given condition in any 
population, the worse the population is affected by that condition. The following 
section reports on DALYs by cause type and by income-sectors globally. There is 
considerable variation in burden of disease between high- and low-income countries. 
There are two salient differences: 1) The cause type of disease is different; and 2) 
                                            
42 The Global Burden of Disease study classifies disease burden into three broad cause types: Group I – communicable, 
maternal, perinatal and nutritional conditions; Group II – noncommunicable diseases; and Group III – injuries. 
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There is a vastly different magnitude of disease burden by income sector. DALYs in 
low-income countries are seven times higher in total than in high-income countries. 
 
Burden of disease cause type differs by income group 
 
The two leading causes of disease burden globally are infectious diseases: lower 
respiratory infections and diarrhoeal diseases. Together these two causes account for 
167.3 million DALYs globally (11% of the total global disease burden). HIV/AIDS is 
now the fifth cause of disease burden globally. Unipolar depressive disorders and 
ischaemic heart disease feature prominently as leading noncommunicable diseases 
and together account for 128.1 million DALYs globally (8.4% of global disease 
burden). Both make a large contribution to disease burden, being at third and fourth 
place globally, eighth and ninth place in low-income countries and the leading causes 
in high- and middle-income countries.43 The leading causes of disease burden in low-
income countries are broadly similar to those globally, apart from malaria and TB. 
Eight of the top ten causes in low-income countries and six of the top ten causes 
globally are Group I causes, i.e. communicable diseases, maternal, perinatal, and 
nutritional conditions. The leading causes in high-income countries are however 
different. With the exception of road traffic accidents, all the top ten causes of disease 
burden in high-income countries are Group II causes, i.e. noncommunicable diseases 
(Table 3.1). 
 
 
 
                                            
43 Both Unipolar depressive disorders and Ischaemic heart disease could plausibly be reduced given the availability of 
effective treatments and prevention packages: effective treatments for depression are available, and cigarette smoking is a 
major and entirely preventable contributor to the burden of disease from Ischaemic heart disease. 
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Table 3.1 Leading causes of disease burden by income sector (2004) 
 
 Disease or injury DALYs (million) 
% of 
total 
DALY
s 
 Disease or injury DALYs (million) 
% of 
total 
DALYs 
 World    Low-income countries   
1 Lower respiratory infections 94.5 6.2  Lower respiratory infections 76.9 9.3 
2 Diarrhoeal diseases 72.8 4.8  Diarrhoeal diseases 59.2 7.2 
3 Unipolar depressive disorders 65.5 4.3  HIV/AIDS 42.9 5.2 
4 Ischaemic heart disease 62.6 4.1  Malaria 32.8 4.0 
5 HIV/AIDS 58.5 3.8  Prematurity and low birth weight 32.1 3.9 
6 Cerebrovascular disease 46.6 3.1  Neonatal infections and other § 31.4 3.8 
7 Prematurity and low birth weight 44.3 2.9  Birth asphyxia and birth trauma 29.8 3.6 
8 Birth asphyxia and birth trauma 41.7 2.7  Unipolar depressive disorders 26.5 3.2 
9 Road traffic accidents 41.2 2.7  Ischaemic heart disease 26.0 3.1 
10 Neonatal infections and other § 40.4 2.7  Tuberculosis 22.4 2.7 
 Cumulative  568.1   Cumulative 380.0  
        
 Middle-income countries    High-income countries   
1 Unipolar depressive disorders 29.0 5.1  Unipolar depressive disorders 10.0 8.2 
2 Ischaemic heart disease 28.9 5.0  Ischaemic heart disease 7.7 6.3 
3 Cerebrovascular disease 27.5 4.8  Cerebrovascular disease 4.8 3.9 
4 Road traffic accidents 21.4 3.7  Alzheimer and other dementias 4.4 3.6 
5 Lower respiratory infections 16.3 2.8  Alcohol use disorders 4.2 3.4 
6 COPD * 16.1 2.8  Hearing loss, adult onset 4.2 3.4 
7 HIV/AIDS 15.0 2.6  COPD * 3.7 3.0 
8 Alcohol use disorders 14.9 2.6  Diabetes mellitus 3.6 3.0 
9 Refractive errors 13.7 2.4  Trachea, bronchus, lung cancers 3.6 3.0 
10 Diarrhoeal diseases 13.1 2.3  Road traffic accidents 3.1 2.6 
 Cumulative 195.9   Cumulative 49.3  
        
 
* COPD, chronic obstructive pulmonary disease 
§ This category includes other non-infectious causes in the perinatal period apart from prematurity, low birth 
weight, birth trauma and asphyxia. These non-infectious causes are responsible for about 20% of DALYs 
shown in this category. 
 
Group I: Communicable, maternal, perinatal and nutritional conditions 
Group II: Noncommunicable diseases 
Group III: Injuries 
 
Source: I adapted this table from WHO’s Global Burden of Disease 2004. Available at: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part4.pdf; 
Leading causes of disease burden essentially capture approximately 40% of burden of 
disease 
 
While low-income countries are to a great extent more heavily burdened by 
infectious diseases and conditions related to childbirth and pregnancy (Group I 
causes), they also suffer from some of the problems that affect high-income 
countries. Essentially they are affected by a dual burden of disease. Group II causes 
(noncommunicable diseases) now account for a third of the disease burden in low-
income countries and over half of the burden of disease in middle-income countries. 
The only region that this is not true for is Africa, whose disease burden is still 
dominated by Group I causes (71%). Despite this dual burden of disease in many 
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low- and middle-income countries, the distribution of causes of disease burden 
remains largely different by income sector (Figure 3.1). 
 
 
 
Figure 3.1 Distribution of causes of disease burden 
 
Source: I sourced the data for this figure from: WHO Burden of disease 2004. Annex A: Deaths and 
DALYs 2004 Annex tables. Available at: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_AnnexA.pdf 
 
 
Burden of disease magnitude differs by income group 
 
There is not only a large difference in the distribution of causes of disease burden 
between low and high-income countries, but also, and perhaps more importantly, in 
the quantity of DALYs in each income sector of the world. The top ten causes of 
disease burden in low-income countries account for 380 million of the world’s 
DALYs, while in high-income countries the top ten causes account for 49.3 million 
DALYs (Table 3.1). The magnitude of total disease burden in each income sector 
reflects similar disparities. The magnitude of disease burden in low-income countries 
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(827 million DALYs) is more than the magnitude of disease burden for middle- and 
high-income countries combined (700 million DALYs) (Figure 3.2). 
 
 
 
Figure 3.2 Magnitude of total disease burden by cause by region (DALYs in 
millions) 
 
Source: I sourced the data for this figure from: WHO’s Burden of disease 2004. Annex A: Deaths and 
DALYs 2004 Annex tables. Available at: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_AnnexA.pdf 
 
The distribution of causes of disease burden in low-income countries is markedly 
different than that of middle- and high-income countries, as is the magnitude of 
disease burden. These differences are relevant since, at least for cosmopolitans, there 
must be a very good reason for global health research funding not to reflect and 
respond to these disparities. 
 
3.1.2 The distribution of global health research funding 
In this section, I present data on the distribution of global health research funding. 
Data on investments in health research provide an indicator of how funders are 
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prioritizing their investments, as well as trends, overlaps and gaps. The Global Forum 
for Health Research, the organisation that has continued to regularly track where and 
on what health research resources are spent, reports a continued increase in global 
health research funding since their original report in 1986 (41). As an indicator of 
funding sources, the 2008 report of the Organisation for Economic Cooperation and 
Development (OECD) indicates that of the US$160.3 billion spent on global health 
research in 2005: 
1. $81 billion (51%) was invested by the private-for-profit sector (72% of this, or 
$59 billion was invested by US pharma); 
2. $ 66 billion (41%) was invested by the public sector (53% of this, or $35 
billion was invested by the US government); and 
3. $ 13 billion (8%) was invested by the private not-for-profit sector 
 
Of this US$160.3 billion spent on global health research, $155 billion (97%) is high-
income country spending. Low- and middle-income countries invest the remaining $5 
billion (3%). Most of the $155 billion spent by high-income countries goes towards 
products, processes and services tailored to their own health-care markets. For 
example, of the $81 billion invested by the private-for-profit sector, two percent was 
spent on health research in low and middle-income countries.44 The United States is 
the largest funder of the world’s health research, both in the private and public 
sectors. As one of the major players, it is illustrative to outline where funding from 
the US is going, as an indicator of distribution of global health research funding. 
 
 
                                            
44 In 2007 research and development investments by Pharmaceutical Research and Manufacturers of America (PhRMA) 
member companies totalled US$44.5 billion. Most of this (US$35.4 billion; 79.5%) was spent on domestic research and 
development. US$9.1 billion (20.5%) of investments were spent abroad. See Burke, M. and Matlin, S. (eds). (2008). Global 
Forum for Health Research, Monitoring Financial Flows for Health Research 2008: Prioritising research for health equity. 
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Table 3.2 United States funding for biomedical research by therapeutic area 
(2005) 
 
    US$ (billions) %    
 
Neuroscience  13.6 
 
25.3 
   
Oncology  8.8 16.4         Group II: US$36.6 billion (68%) Cardiovascular  8.4 15.6  
Endocrine  5.8 10.8    
Infectious disease  5.4 10.0    
HIV/AIDS  5.0 9.3  Group I: US$ 15.5 billion (29%) Gastrointestinal  2.9 5.4  
Respiratory  2.2 4.1    
Genitourinary 
   
1.7 3.2    
Total   53.8  100.0    
 
Source: I sourced data for this table from: Dorsey ER, Thompson JP, Carrasco M, de Roulet J, 
Vitticore P, et al. (2009) Financing of U.S. Biomedical Research and New Drug Approvals 
across Therapeutic Areas. PLoS ONE 4(9): e7015. Available at: 
http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0007015  
 
Dorsey et. al., (2009) report on US financing of biomedical research across 
therapeutic areas by both industry and the National Institutes of Health (42). They 
sought first to estimate United States funding by therapeutic area and second to 
determine whether this funding is aligned with disease burden. This report gives us 
only a rough indicator of just how much funding is being directed to different causes 
of disease burden as the authors focused on just nine therapeutic areas. Their findings 
show that 68% ($36.6 billion) of the funding directed at these nine areas goes towards 
four of them: neuroscience, oncology, cardiovascular, and endocrine research (all 
Group II disease causes). Infectious disease, HIV/AIDS, gastrointestinal and 
respiratory research (Group I causes) received $15.5 billion (29%) of total funding. 
Dorsey et al found total funding to be broadly correlated with disease burden in high-
income countries. Funding was not aligned with global burden of disease.45 Funding 
                                            
45 Interestingly, if we look at funding distribution separately by industry and NIH, industry funding was more strongly 
aligned with disease burden in high-income countries than with global disease burden. NIH funding, however, was more 
strongly aligned with global disease burden. This makes sense knowing that the principle difference between NIH and 
industry is the differential funding of HIV/AIDS and infectious diseases.  Industry funds the majority of research as a 
whole; however NIH provided the majority of support for HIV/AIDS (59%) and infectious diseases (54%). Overall 
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was also not aligned with the disease burden of the poor (Table 3.3). Spending by the 
United States on global health research therefore did not reflect the disparities in 
disease burden cause type and magnitude discussed in section 3.1.1 above. 
This discrepancy accentuates the importance of foundations, such as the Bill and 
Melinda Gates Foundation, the Rockefeller foundation, and the Global Fund, whose 
health research funding priorities reach beyond the needs of high-income countries. 
Funding by these foundations is however extremely small relative to private-for-
profit and public investments. The Global Fund for example spent on average US$3.2 
billion annually between 2008 and 2010. Approximately four percent (US$128 
million) of this went towards research (43). Other philanthropic funding for health 
research amounted to $538 million in 2007 (44). These amounts are just a drop in the 
ocean of the US$160.3 billion reported spent on global health research in 2005. They 
are even small relative to the US$15.5 billion spent by the United States 
pharmaceutical industry and National Institutes of Health in 2005. Even if we add 
philanthropic health research funding to the spending reported by Dorsey, one can see 
that they do not sway the global distribution of health research funding to reflect the 
global distribution of disease burden (Table 3.3). 
 
 
 
 
 
 
                                                                                                                                       
however, the distribution of funding for health research remains skewed to the burden of disease in middle- and high-
income countries. 
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Table 3.3 Cause of disease burden as a percentage of total burden of 
disease in each income sector, compared with funding by cause of 
disease burden 
 
  Cause of disease as a percentage of total Burden of Disease  
US public 
and private 
funding 
 
US 
public/private 
funding AND 
Philanthropic 
funding 
  Global Africa LIC MIC HIC     
Group I:  40% 71% 57% 22% 6%  29%($15.5b)  29.8%($16.038b) 
Group II:  48% 21% 33% 62% 85%  68%  68% 
Group III:  12% 8% 10% 16% 9%  -  - 
 
Source: I sourced the data for this table from: WHO’s Burden of disease 2004. Annex A: Deaths and 
DALYs 2004 Annex tables. Available at: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_AnnexA.pdf; 
Dorsey ER, Thompson JP, Carrasco M, de Roulet J, Vitticore P, et al. (2009) Financing of U.S. 
Biomedical Research and New Drug Approvals across Therapeutic Areas. PLoS ONE 4(9): 
e7015. Available at: 
http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0007015; The Global 
Fund (2010). The Global Fund Annual Report 2009. Available at:  
http://www.theglobalfund.org/en/library/publications/annualreports/; and G-Finder. (2009). 
Neglected Disease Research and Development: New Times, new trends. Available at: 
http://www.georgeinstitute.org/g-finder-2009-neglected-disease-research-and-development-
how-much-are-we-really-spending (p.63) 
 
From the data presented in Table 3.3, we see that United States health research 
spending, the largest contributor to global health research spending, is largely aligned 
with the distribution of disease burden in middle-income countries, and at least 
broadly aligned with the distribution of disease burden in high-income countries. The 
distribution of health research funding does not map onto the global distribution of 
disease burden, nor does it reflect the disease burden of the poor. The majority of 
United States funding is directed at Group II causes. The burden of disease in low-
income countries (especially in the African region) is skewed to Group I causes. 
United States spending on global health research is therefore not aligned with the 
disease burden of low-income countries. 
Since these poorer countries suffer a dual burden of disease, and since the biggest 
health research spenders are investing mostly in Group II causes, then some might 
assume that the resources directed to health research on these Group II causes will 
not only benefit high-income countries, but also ultimately low-income countries. I 
believe this would be true only on the assumption that the type of health research 
needed for each economic region is the same. Many evidence-based innovations 
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researched and developed in high-income countries fail to produce results when 
transferred to lower-income settings, mostly because their implementation has not 
been tested or is unsuitable. Low-income countries need research into products that 
can be used specifically in low-income settings, implementation research to ensure 
that already existing interventions can be effectively integrated into resource-poor 
health systems, and research to improve health systems themselves (see section 3.4 
for a more detailed discussion of this point) (45, 46). The fact that high-income 
countries are investing in Group II causes therefore does not mean that these 
investments can be counted as beneficial to low-income countries. 
 
3.1.3 Global health research investments do not map onto global 
burden of disease 
High-income countries account for 97% of spending on health research globally. 
Since most research is funded by high-income countries, or sponsored by 
pharmaceutical companies linked to the industry of high-income countries, it is not 
surprising that the interventions developed by these sponsors are mostly for the 
benefit of high-income countries. The data presented above shows that causes of 
disease burden in high-income countries are different from those globally. Causes of 
disease burden in high-income countries are also different from those in low-income 
countries. Additionally, the magnitude of disease burden in low-income countries is 
significantly higher than in high-income countries. This might indicate that a 
significantly higher amount of research funding should be directed towards them. 
United States’ investments, which are the largest contribution to global health 
research spending, do not however indicate a higher amount of research funding 
directed to this higher magnitude of disease burden. Rather, these investments are 
skewed towards the smaller disease burden in high-income countries. If we assume 
that U.S. funding is a good indicator of global funding, then this data indicates that 
global health research funding does not map onto global disease burden. Although the 
gap may not be as large as when the 10/90-gap was originally reported in 1990, the 
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majority of funding is still going towards health research for high-income country 
burden of disease. If South Africa has equal duties to all the world’s absolutely poor, 
and if global health research spending does not map onto global disease burden, or 
onto the disease burden of the poor, then one way in which South Africa might begin 
to fulfil this duty is to advocate for a shift in global health research funding. 
 
3.2 How do South Africa’s health research priorities 
compare with Africa’s? 
In this section I compare South Africa’s health research priorities with the health 
research priorities of sub-Saharan Africa.46 Since South Africa has equal duties to the 
worst-off in South Africa and the region, identifying where their health research 
priorities do and do not overlap is important. Especially for those regional priorities 
that are not priorities for South Africa, it will make a difference on my account if 
South Africa pursues only the health research priorities of its worst-off citizens or 
includes those more broadly relevant to the worst-off in the region. Before looking at 
the data we could infer that if South Africa has a duty to sub-Saharan Africa’s 
absolutely poor, and if South Africa’s established health research priorities are 
currently different from those of sub-Saharan Africa, then one way in which South 
Africa may begin to fulfil its duty is to incorporate some of sub-Saharan Africa’s 
established health research priorities into its own research agenda. This would entail a 
shift in its research focus on national priorities to some combination of national and 
regional health research priorities. 
                                            
46 Statistics for the WHO African Region include data from all the sub-Saharan African countries (except for Sudan, 
Djibouti and Somalia). In addition they include data from one country outside of sub-Saharan Africa, Algeria. The WHO 
data for “Africa” essentially represents “sub-Saharan Africa,” rather than the broader African region. See Appendix A for a 
map and list of countries in the WHO African Region. 
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3.2.1 Health research priorities for South Africa and Africa 
Unlike in the global setting, where health research priorities have not been 
established, health research priorities for both South Africa and the African region 
have been established.47 In South Africa, health research priority setting exercises 
were first undertaken in 1994 during the country’s first Essential National Health 
Research (ENHR) meeting. Preliminary workshops in 1995 and 1996 identified a 
number of priority research areas, and developed the criteria and process on 
prioritisation, which were used to guide further ENHR work. The first national 
ENHR Congress on priority setting was held in 1996. A list of health research areas 
were identified which served to guide health research in South Africa for the 
subsequent years. The second ENHR Congress was held in 2002. Its aim was to 
popularise the National Health Research Policy, create awareness of the policy and to 
adopt a new priority setting framework, which incorporated health problems and 
health system issues that would need to be considered when setting priorities. In 
2006, The National Conference on Priority Setting for Health Research built on the 
work done at the previous conferences. It was decided that research priority setting 
was to be reviewed at least every 5 years (47). The 2006 conference listed fifteen 
leading health problems or challenges for research in South Africa. Table 3.4 shows 
these health research priorities. 
 
 
 
 
 
                                            
47 For clarity, when I refer to “established” or “documented” health research priorities, this points to health research 
priorities that have been determined by a responsible institution or organization. This is distinct from the health research 
priorities that I believe a government ought to endorse, something I touch on later in the chapter. 
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Table 3.4 South Africa’s health research priorities (2006) 
 
Condition 1996 Ranking 
2006 
Ranking 
HIV and AIDS 4 1 
Injuries 1 2 
Tuberculosis 2 3 
Diarrhoea 7 4 
Perinatal and neonatal mortality - 5 
Nutrition 3 6 
Common risk factors  
(Hypertension, smoking, overweight, alcohol etc.) 
- 7 
Cardiovascular diseases - 8 
Orphans and child-headed households - 9 
Maternal morbidity and mortality - 10 
Mental Health 9 11 
Cancer 6 12 
Malaria 10 13 
Respiratory infections 8 14 
Sexually Transmitted Infections 
 
5 15 
 
For Africa as a whole there has been only one health research priority setting 
exercise. During a High Level Ministerial Meeting on Health Research in Africa in 
2006, Ministers of Health and Heads of Delegations identified key domains for health 
research in the African region (Table 3.5) (48). During a two-day technical 
consultation attended by 39 African delegates48 and 15 representatives from 
development partners,49 delegates made presentations on the current status of health 
research in their respective countries. Subsequent discussions in background papers 
and country situation analyses focused on, among other things, the strengths, 
weaknesses, challenges and needs of African health research systems with respect to 
priority setting and the role of research in the attainment of internationally agreed 
health targets, especially health Millennium Development Goals (MDGs). The 2006 
meeting listed 6 key domains for health research in the region. 
 
 
                                            
48 From the following 11 African countries: Algeria, Cameroon, Ethiopia, Ghana, Kenya, Malawi, Mozambique, Nigeria, 
Senegal, South Africa and Sudan. 
49 Namely WHO, World Bank, UNICEF, COHRED, NEPAD, and REPRONET-Africa. 
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Table 3.5 Africa’s health research priorities (2006) 
 
Key domains for health research 
1 Infectious diseases,  
including malaria, tuberculosis, HIV and AIDS, emerging infections and neglected 
tropical diseases  (e.g. African trypanosomiasis, Buruli ulcer, leishmaniasis and 
lymphatic filariasis) 
2 Reproductive and sexual health 
3 Child health 
4 Non-communicable diseases,  
including cardiovascular disease, diabetes, cancers, sickle cell disease, injuries etc. 
5 Malnutrition 
6 Mental health, 
 including drug and substance abuse 
 
 
There is little detail on the methods used for priority setting during this Abuja 
meeting, and no indication of whether the list is ranked. Burden of disease data that 
provides estimates of the magnitude and urgency of a particular disease can be used 
as an imperfect proxy for health research priorities.50 So, although the Abuja priorities 
are not explicitly ranked, burden of disease estimates can indicate whether they in 
fact reflect a rational ranking. One can therefore use both the disease prioritised and 
the relative ranking as a basis for African priorities. Table 3.6 below displays the 
leading causes of disease burden in Africa. 
 
 
 
 
 
                                            
50 As mentioned earlier, disease burden does not always map exactly onto health research priorities because health research 
priorities are most soundly determined by a number of considerations over and above the magnitude of disease burden. 
These additional considerations include: the extent of previous research and gaps in knowledge about ways to address the 
health problem; the possibility of addressing the problem through health research; the feasibility and cost of the proposed 
research; and the potential outcome, impact and cost-effectiveness of interventions resulting from the proposed research. 
Disease burden is, however, a good enough proxy when health research priority setting data is not available or when we 
have reason to question its reliability. 
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Table 3.6 Africa’s leading causes of disease burden (2004) 
 
Disease or injury DALYs (millions) 
% of total 
DALYs 
1 HIV/AIDS    46.7 12.4 
2 Lower respiratory infections  42.2 11.2 
3 Diarrheal diseases  32.2 8.6 
4 Malaria   30.9 8.2 
5 Neonatal infections and other  13.4 3.6 
6 Birth asphyxia and birth trauma  13.4 3.6 
7 Childhood cluster diseases 12.5 3.3 
8 Prematurity and low birth weight  11.3 3.0 
9 Tuberculosis    10.8 2.9 
10 Road traffic accidents  7.2 1.9 
11 Protein-energy malnutrition  7.1 1.9 
12 Violence 6.3 1.7 
13 Tropical cluster diseases 6.0 1.6 
14 Unipolar depressive disorders 5.7 1.5 
15 Meningitis 5.3 1.4 
16 Cerebrovascular disease 4.9 1.3 
17 Cataracts 3.9 1.0 
18 Ischaemic heart disease 3.5 0.9 
19 STDs excluding HIV 3.4 0.9 
20 Iron-deficiency anaemia 2.9 0.8 
 
Source: I sourced data for this table from WHO’s Burden of disease in DALYs by cause in WHO 
regions, Table A2. Available at: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_AnnexA.pdf 
 
If we map the health research priorities established at the Abuja meeting against 
magnitude of disease burden for the region, they are broadly aligned (Table 3.7). 
Also, although it is not specifically stated that the rank of health research priorities 
corresponds with the order in which they were listed, it appears that this is indeed the 
case. Infectious diseases and neglected tropical diseases account for 47% of total 
DALYs in Africa51 and are listed first in the established health research priorities. 
Reproductive and sexual health accounts for the next largest percentage (7%)52 of 
total DALYs and is listed second in the established health research priorities, and so 
                                            
51 I calculated this percentage by adding the % of total DALYs for: HIV, lower respiratory infections, diarrheal diseases, 
malaria, tuberculosis, tropical cluster diseases, meningitis and STDs. 
52 I calculated this percentage by adding the % of total DALYs for: birth asphyxia and birth trauma, and prematurity and 
low birth weight. 
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forth. Throughout the rest of this section I will use both burden of disease data and 
documented health research priorities to compare South Africa and Africa. 
 
Table 3.7 Africa’s health research priorities mapped onto disease burden 
 
Key domains for health research DALYs % of total DALYs 
1 Infectious diseases 177.5 47.1 
2 Reproductive and sexual health 24.7 6.6 
3 Child health 25.9 6.9 
4 Non-communicable diseases 15.6 4.1 
5 Malnutrition 7.1 1.9 
6 Mental health 5.7 1.5 
 
 
3.2.2 A comparison of South Africa and Africa’s disease burden 
and health research priorities 
The distributions of disease burden in South Africa and in the broader region are 
roughly aligned. The WHO reports that for both South Africa and Africa, close to 
80% of years of life lost are attributable to communicable diseases, 15% to non-
communicable diseases, and 6% to injuries (49). Some estimates for South Africa 
show a more moderate burden of communicable disease at around 60%, with 
approximately 30% of disease burden attributable to non-communicable disease and 
the remaining 10% to injuries (50). Nonetheless, the disease burden for South Africa 
and the rest of Africa overlap significantly. There is a greater burden of disease due 
to communicable diseases than there is due to non-communicable disease and 
injuries. This makes sense since we know that communicable diseases burden the 
poorest populations and 40% of South Africa’s population, along with substantial 
sections of the populations of many African countries are amongst the worst-off in 
the world. Figures 3.3 and 3.4 show the maternal mortality ratio and the prevalence of 
infectious and parasitic diseases globally. For both these indicators it is clear that 
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Africa is burdened more severely than other regions in the world, and that South 
Africa and Africa are burdened similarly. 
 
 
 
Figure 3.3 Maternal mortality ratio per 100,000 live births (2008) 
 
Source: World Health Organisation (2011). Global Health Observatory Map Gallery. Available online: 
http://gamapserver.who.int/mapLibrary/Files/Maps/Global_MDG5_2011_MaternalMortality.png  
 
 
 
 
Figure 3.4 Infectious and parasitic disease prevalence (2006) 
 
Source: Fondation Mérieux (2005). Infectious diseases map. Available at: http://www.fondation-
merieux.org/infectious-diseases-map 
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Health research priorities shared by South Africa and Africa 
 
Within this category of communicable diseases, HIV and tuberculosis are two clear 
examples of infectious diseases that similarly burden South Africa and other African 
countries. Figures 3.5 and 3.6 below show the most recent prevalence data on these 
two diseases. South Africa suffers the highest prevalence of HIV in the world and 
HIV also heavily burdens many other sub-Saharan African countries. The prevalence 
of tuberculosis across all of sub-Saharan Africa is also high at between 500-750 per 
100,000 population for most countries, including South Africa. 
 
 
 
Figure 3.5 HIV prevalence (2009) 
 
Source: UNIADS (2010). A global view of HIV infection: HIV prevalence map. Available at: 
http://www.unaids.org/documents/20101123_2010_HIV_Prevalence_Map_em.pdf 
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Figure 3.6 Tuberculosis prevalence (2005) 
 
Source: Fondation Merieux (2011). Prevalence of malaria. Available online: http://www.fondation-
merieux.org/tuberculosis-map,105 
 
HIV and tuberculosis are ranked at or near the top of established health research 
priorities for both South Africa and the region and both represent a significant 
proportion of DALYs in each region. Other causes of disease in the communicable 
disease category which burden South Africa and other African countries similarly 
include diarrheal disease, respiratory infections and other causes related to child 
health. These similarities are reflected in their currently documented health research 
priorities (Table 3.8). 
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Figure 3.7 Malaria prevalence (latest available data) 
 
Source: Fondation Mérieux (2011). Malaria map. Available at: http://www.fondation-
merieux.org/malaria-map 
 
 
 
 
Figure 3.8 Countries or areas at risk of malaria transmission (2010) 
 
Source: World Health Organisation (2011). Global Health Observatory Map Gallery. Available online: 
http://gamapserver.who.int/mapLibrary/Files/Maps/Global_Malaria_2010.png 
 
Based on prevalence and risk, malaria is not a priority disease for South African 
citizens (Figures 3.7 and 3.8).  It does not even feature in the top 20 causes of death 
for the country (51). Malaria in South Africa is also confined to three specific 
geographical areas: 1) the low altitude border areas of the Limpopo province, which 
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borders on Zimbabwe and Mozambique; 2) Mpumalanga, which is the main 
thoroughfare to South Africa from Mozambique; and 3) the north-eastern parts of 
KwaZulu-Natal, although prevalence here is less now due to the successful 
reintroduction of DDT in 1999 (52). Malaria has been labelled primarily as a border 
and population movement problem, supported with evidence of a great number of 
imported malaria cases reported each year (52, 53). Although the prevalence of 
malaria in South Africa is relatively low compared to the rest of the region, malaria is 
still included in South Africa’s currently documented health research priorities (Table 
3.8). 
 
Table 3.8 A comparison of Africa and South Africa’s health research 
priorities 
 
Africa South Africa 
1. Infectious diseases  
(Malaria, TB, HIV) 
Neglected tropical diseases  
(African trypanosomiasis,  
Buruli ulcer, 
Leishmaniasis,  
lymphatic filariasis) 
2. Reproductive and sexual health 
3. Child health 
4. Non-communicable diseases 
(Cardiovascular disease,  
Diabetes,  
Cancers,  
Sickle cell disease, 
 Injuries) 
5. Malnutrition 
6. Mental health including drug and 
substance abuse” 
1. HIV 
2. Injuries 
3. TB 
4. Diarrhoea 
5. Perinatal and neonatal mortality 
6. Nutrition 
7. Common risk factors  
(hypertension, smoking,  
overweight, alcohol) 
8. Cardiovascular diseases 
9. Orphans and child headed households 
10. Maternal morbidity and mortality 
11. Mental health 
12. Cancer 
13. Malaria 
14. Respiratory infections 
15. Sexually transmitted infections 
 
 
Health research priorities for Africa but not South Africa 
 
While there is clearly considerable overlap in the established health research 
priorities and burden of disease for both South Africa and the broader region, there 
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are other diseases that cause significant disease burden in one and not the other. Most 
of these are diseases that burden other African countries and not South Africa. 
Among these are malaria (Figures 3.7 and 3.8), sickle cell disease, and the cluster of 
neglected tropical diseases, including African trypanosomiasis, Lymphatic filariasis, 
Leishmaniasis and Buruli ulcer. Figures 3.9 through 3.13 below give us an idea of the 
distribution of these diseases across the region. 
 
 
 
Figure 3.9 Global distribution of haemoglobin disorders, births of affected 
infants per 1000 births (2012) 
 
Source: WHO (2012). Genes and human disease: Monogenic diseases - Sickle cell anaemia. 
Available online: http://www.who.int/genomics/public/geneticdiseases/en/index2.html#SCA 
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Figure 3.10 Distribution of human African trypanosomiasis (2008) 
 
Source: World Health Organisation (2011). Global Health Observatory Map Gallery. Available online: 
http://gamapserver.who.int/mapLibrary/Files/Maps/Global_trypanosomiasis_gambiense_2008.
png 
 
 
 
Figure 3.11 Proportion of global population requiring preventive 
chemotherapy for lymphatic filariasis (2009) 
 
Source: WHO (2009). Lymphatic filariasis:  Proportion of global population requiring preventive 
chemotherapy for lymphatic filariasis 2009. Available at: 
http://apps.who.int/neglected_diseases/ntddata/lf/lf_status/lf_status.html 
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Figure 3.12 Distribution of visceral leishmaniasis (2009) 
 
Source: World Health Organisation (2011). Global Health Observatory Map Gallery. Available online: 
http://gamapserver.who.int/mapLibrary/Files/Maps/Global_leishmaniasis_visceral_2009.png 
 
 
 
 
Figure 3.13 Buruli ulcer - number of new cases reported (2010) 
 
Source: WHO (2010). Buruli ulcer, Number of new cases reported 2010. Available at: 
http://apps.who.int/neglected_diseases/ntddata/buruli/buruli.html 
 
Malaria, sickle cell and the neglected tropical diseases represent a significant burden 
of disease in Africa and are ranked high on Africa’s established list of health research 
priorities. South Africa does not have a high prevalence of malaria, sickle cell 
disease, or of the neglected tropical diseases and has therefore not listed these as 
health research priorities, with the exception of malaria. The case of malaria is an 
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interesting one. Although South Africa has malaria listed as one of its health research 
priorities, there is in fact not a high prevalence of this disease within the country. 
To summarise, burden of disease and established health research priorities for South 
Africa and Africa are similar for some causes of disease burden, including many 
infectious diseases and maternal and perinatal conditions. There are however some 
causes of disease burden that are health research priorities for Africa but not for 
South Africa, including sickle cell disease and the neglected tropical diseases. 
 
3.2.3 Implications for South Africa’s duty to the absolutely poor in 
the region 
Knowing that there are these similarities and differences in health research priorities 
helps to inform how South Africa could fulfil its previously established duty to the 
absolutely poor in the sub-Saharan African region. South Africa has equal duties to 
all the world’s absolutely poor, and it is morally permissible for it to focus on sub-
Saharan Africa. If South Africa’s health research priorities are different from those of 
Africa, it makes a difference whether South Africa focuses only on enacting its own 
national priorities or whether it focuses also on regional health research priorities. 
Since South Africa’s health research priorities do not map exactly onto the health 
research priorities for Africa, and South Africa has a duty to the absolutely poor in 
Africa, one has to consider what it would take for South Africa to fulfil this duty. 
Would it be sufficient for South Africa to continue with its focus only on national 
health research priorities such as HIV and TB, since these do indeed overlap with 
priorities in the region? Or would it also be necessary for South Africa to include 
some of Africa’s health research priorities that are not priorities domestically, such as 
malaria, sickle cell disease and the so-called neglected tropical diseases? In other 
words, should South Africa begin to fulfil this duty by adjusting its health research 
focus to include some combination of both national and regional health research 
priorities? 
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If we consider South Africa’s duty to the absolutely poor in sub-Saharan Africa as 
equal to its duty to the absolutely poor within its own state, then this duty would not 
simply be fulfilled by South Africa continuing to conduct health research relevant 
only to South Africa. While pursuing health research on overlapping causes of 
disease burden such as HIV and TB would inevitably contribute to tackling diseases 
that are prominent across the continent, this alone might not be sufficient, for two 
reasons. First, whether this is a way of fulfilling its duty depends on the type of 
research being conducted. For example, if South Africa is already investing in 
research for HIV, and HIV is also a health research priority for the region, it does not 
automatically follow that South Africa’s pursuit of research for HIV will ultimately 
benefit other African populations, unless of course the type of research is relevant. 
Some relevant questions might include: if South Africa is investing in HIV drug 
research, will the end products be accessible and/or affordable for people in other 
African countries?; If they are doing vaccine research, will the vaccine work for 
clades or types of HIV in other African countries?; If they are carrying out 
implementation or operational research on how to successfully implement proven 
interventions for HIV, then are the results of these studies specific to smaller local 
populations in South Africa, or would the results be generalizable to other African 
populations? The answers to each of these types of questions would determine to 
which extent South Africa is actually fulfilling its duty to the region’s absolutely 
poor. 
Second, let us imagine that South Africa commits to conducting the type of research 
relevant to both South Africa and the region on these overlapping health research 
priorities. This alone might still not be considered sufficient to fulfil its duty to the 
absolutely poor in the region. If the absolutely poor in South Africa and the region 
have equal claims to South Africa’s health research resources, then in order to meet 
these claims, South Africa ought to commit to some of the health research priorities 
relevant to the absolutely poor in Africa, that do not affect the absolutely poor in 
South Africa, such as malaria, sickle cell disease and some of the neglected tropical 
diseases. Recognising equal duties to the absolutely poor across the region constitutes 
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a substantially higher commitment. South Africa would have to decide what 
proportion of funds to invest in regional priorities that are distinct from and therefore 
compete with its own. It might be that South Africa could fulfil this duty without 
conducting the needed research itself, for example through directing grants or donor 
funding towards these diseases or by advocating for needed research. South African 
researchers could also work with researchers in other African countries and apply for 
grants for research on these diseases—thereby using South Africa’s greater research 
capacity to build capacity in the region. These would impact less on its own health 
research budget. 
 
3.3 How do global investments in South Africa’s health 
research priorities compare to global investments in 
Africa’s health research priorities? 
In this section I first provide data on donor funding for health research in South 
Africa compared to other countries in the African region (section 3.3.1). Knowing the 
funding allocations to South Africa versus the region is informative for how South 
Africa might fulfil its previously established duty to the absolutely poor in sub-
Saharan Africa. If South Africa is receiving more than its fair share of resources 
compared to other African countries, this might increase South Africa’s already 
existing obligation to absolutely poor Africans beyond its borders. Second, I provide 
an overview of global funding of neglected diseases of the developing world (44). 
Specifically I report on how this funding is distributed by disease (section 3.3.2). 
Knowing how global investments in various developing country diseases are 
distributed allows a comparison of which of these diseases are receiving more or less 
funding through overall global investment. Finally, I map out which of these 
neglected diseases of the developing world are shared as health research priorities by 
South Africa and Africa (section 3.3.3) and which are health research priorities for 
Africa but not South Africa (section 3.3.4). For those diseases that are shared as 
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health research priorities by South Africa and Africa, if South Africa has a duty to the 
absolutely poor in the region, and if South Africa is receiving more than its fair share 
of resources for these shared priorities, then one way in which South Africa might 
begin fulfilling its duty is to ensure that the funds it receives for research into these 
diseases are used to conduct research that will benefit not only its own population but 
also the region as a whole. For neglected diseases that are health research priorities 
for Africa but not South Africa, if South Africa has an equal duty to the absolutely 
poor domestically and in the region, and if funding for Africa’s priorities is severely 
short, then one way that South Africa could fulfil its duty is to advocate for 
international funding for these, or include them in its own research priorities. 
3.3.1 A comparison of donor investment in South Africa and Africa 
The United States is the largest funder of health research globally, accounting for 
72% of private-for-profit spending, and 53% of public spending globally (41). It is 
therefore illuminating to outline where funding from the United States is going, as an 
indicator of the distribution of global health research funding. Within the United 
States, the National Institutes of Health (NIH) is South Africa’s largest funder, so I 
assume that the distribution of funding from other US sources follows roughly the 
same pattern (8). Figure 3.5 shows the top 10 countries in sub-Saharan Africa that 
receive funding for health research from the NIH. In 2005 South Africa received $25 
million for HIV research and another $7 million for other health research. The 
funding received by SA for health research far outweighs that of the other top 10 
countries to receive NIH funding in the region. 
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Figure 3.14 Top 10 sub-Saharan Africa countries with NIH health research 
funding (2005) 
 
Source: Fogarty International Center. Report on NIH international extramural investments in foreign 
institutions FY 2004- FY 2005. 2009 (p.101) 
 
From the figure above South Africa might be getting more than its fair share of 
resources compared to other leading African countries that are recipients of NIH 
funds. It could be that since South Africa has more people living with HIV (an 
estimated 5.6 million) than any other country in the world (54), there is a legitimate 
reason for this differential funding, at least for HIV research. South Africa’s HIV 
infections constitute one quarter of the HIV infections in sub-Saharan Africa (22.9 
million). It might also be that the greater investment in South Africa is merely a 
function of South Africa’s larger capacity for research. It is unclear from this data 
whether all of this funding received by South Africa is spent only on research 
intended to benefit the South African population, or whether some of this funding is 
directed at health research relevant to the African region more broadly. 
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3.3.2 A comparison of investments in various neglected diseases 
of the developing world 
The G-Finder reports specifically on global investment into research of new products 
to prevent, diagnose, manage or cure 31 neglected diseases of the developing world.53 
The scope of “neglected diseases” covered by G-Finder is determined by applying 3 
criteria: 1) The disease disproportionately affects people in developing countries; 2) 
there is a need for new products i.e. there is no existing product or improved or 
additional products are needed; and 3) there is market failure i.e. there is no 
commercial market to attract research and development by private industry. The total 
reported health research funding for these 31 neglected diseases of the developing 
world was $2.96 billion in 2008. This amounts to 1.8% of the total global spending 
on health research reported in 2005 ($160.3 billion) reported earlier.54 
In this section I provide an overview of how this $2.96 billion is distributed by 
disease. This data provides a means to compare which of these neglected diseases of 
the developing world are receiving more or less funding through overall global 
investment. Table 3.9 lists the eight leading neglected diseases of the developing 
world. I rank these eight diseases by severity (DALYs) alongside the funding 
received by each disease in a given year. Presenting the data in this way allows one to 
get a sense of how many dollars are spent per DALY for each disease. The dollar-
per-DALY measure gives a more accurate reflection of to what degree the amount of 
investment is aligned with the impact of the disease. The neglected diseases receiving 
the highest number of dollars-per-DALY are the kinetoplastids. Kinetoplastid 
infections are caused by related parasites and include three diseases: Chagas’ disease, 
                                            
53 These neglected diseases of the developing world are not the same as what are more commonly known as the neglected 
tropical diseases. Based on the G-Finder’s inclusion criteria, the neglected diseases referred to here include:  HIV/AIDS, 
Malaria, Tuberculosis, Kinetoplastids, Diarrhoeal diseases, Dengue, Bacterial pneumonia & meningitis, Helminth 
infections, Salmonella infections, Leprosy, Rheumatic fever, Trachoma, and Buruli ulcer. See: Health Policy Division 
(2009). G-Finder: Neglected disease research and development: New times, new trends. The George Institute for 
International Health: Sydney, Australia. Available at: http:www.georgeinstitute.org/monitoring-global-rd-investment-
neglected-diseases  
54 $2.96 billion (for all neglected diseases) is a much lower figure than that reported by Dorsey et. al. (2009). Dorsey et. al. 
reported that US spending on Group I causes was $15.5 billion (for infectious disease, HIV/AIDS, Gastrointestinal, and 
Respiratory). The reason for this discrepancy is that spending reported in G-finder reports only on research investments 
specifically targeted at developing-country research and development needs i.e. excludes research into products that are 
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leishmaniasis, and African trypanosomiasis (also known as African sleeping 
sickness). Kinetoplastids receive $34 per DALY in research funding; this is almost 
one and a half times more than what is devoted to HIV/AIDS ($20 per DALY), 
which is often cited as the disease capturing the lion’s share of funding. Relatively 
substantial research investments are also going into HIV/AIDS, malaria and 
tuberculosis. HIV/AIDS receives $20 per DALY, malaria $16 per DALY and 
tuberculosis receives $13 per DALY. Comparatively, helminth infections receive 
much less at $5.6 per DALY. Those neglected diseases that receive the lowest 
number of dollars per DALY for research are rheumatic fever ($0.5 per DALY), 
bacterial pneumonia/lower respiratory infections ($1 per DALY) and diarrhoeal 
disease ($1.8 per DALY). The latter two are particularly problematic as they 
constitute the two leading causes of disease burden among neglected diseases, and 
receive an extremely low number of dollars per DALY. Incidentally these two causes 
of disease burden are also the two leading causes of global disease burden. 
 
Table 3.9 Global investments in the 8 leading neglected diseases 
 
Neglected disease 
2004 
DALYs  
(millions) 
2008 
Global 
funding  
(US$ 
millions) 
$ per  
DALY 
     
1 Bacterial pneumonia (lower respiratory infections) 93.3 90.8 1.0 
2 Diarrhoeal diseases 72.3 132.2 1.8 
3 HIV/AIDS 57.8 1164.8 20.2 
4 Tuberculosis 34.0 445.9 13.1 
5 Malaria 33.9 541.7 16.0 
6 Helminth infections  12 66.8 5.6 
7 Rheumatic  5.1 2.2 0.4 
8 Kinetoplastids (Chagas, leishmaniasis and African 
trypanosomiasis) 
4.1 139.2 34.0 
     
 
Source: I sourced the data for this table from: Health Policy Division (2009). G-Finder: Neglected disease 
research and development: New times, new trends. The George Institute for International 
Health: Sydney, Australia. Available at: http:www.georgeinstitute.org/monitoring-global-rd-
investment-neglected-diseases 
                                                                                                                                       
aimed to benefit populations in High-Income countries, such as commercial investments in drugs or vaccines for Group I 
causes that target Western markets. 
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It is only when we compare this spending with what is spent on other disease groups 
that we get a real sense of how severely underfunded some neglected diseases are. 
Ischaemic heart disease and cerebrovascular disease are two examples of diseases 
that really do receive the lion’s share of global funding. Together they accounted for 
109 million DALYs globally in 200455 and from U.S. pharma and the NIH alone 
these two diseases received $8.4 billion in 2005 (42). This amounts to $77 per 
DALY, more than double the funding received by the top earner amongst neglected 
diseases, kinetoplastids ($34 per DALY). Ischaemic heart disease and 
cerebrovascular disease, which are listed at 4th and 5th in the leading causes of global 
disease burden, receive 77 times more funding than the leading cause of disease 
burden globally, lower respiratory infections ($1 per DALY). 
In the following two sections I attempt to tease out just how much global funding 
goes to those diseases that are common health research priorities for South Africa and 
the region. I compare this to global funding for those diseases that are priorities only 
for Africa. For those health research priorities common to both, even if South Africa 
receives the lion’s share of funding for these disease groups, other African 
populations have the potential to benefit indirectly from this funding because their 
health research priorities overlap.56 Those disease groups that are research priorities 
for Africa but not for South Africa have the potential to both be underfunded in 
general through donor funding, but also do not stand to indirectly benefit from 
funding currently directed to South Africa. 
 
                                            
55 WHO Global Burden of Disease 2004 reports that Ischaemic heart disease accounts for 62.2 million DALYs globally and 
cerebrovascular disease accounts for 46.6 million DALYs globally. See WHO Burden of disease (2004) Part 4, p.43. 
Available at http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part4.pdf 
56 This is of course contingent on whether the types of research will be relevant to other African populations, as discussed in 
Section 3.3 above. 
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3.3.3 Neglected developing world diseases that are shared as 
health research priorities by South Africa and Africa 
Five of the eight leading neglected diseases of the developing world are shared 
established health research priorities for South Africa and the broader region. These 
include the bolded diseases in Table 3.10: lower respiratory infections, diarrhoeal 
diseases, HIV/AIDS, tuberculosis, and malaria. In section 3.3.1, I established that 
three of these diseases (HIV, tuberculosis, and malaria) are receiving relatively 
substantial funding, relative to the others. HIV receives $20 per DALY, tuberculosis 
receives $13 per DALY and malaria $16 per DALY. Lower respiratory infections and 
diarrhoeal diseases, are receiving disproportionately low health research investments 
compared to the others. Lower respiratory infections receive just $1 per DALY and 
diarrhoeal diseases $1.8 per DALY. 
 
Table 3.10 Neglected diseases that are health research priorities for South 
Africa and Africa 
 
Neglected disease 
2004 
DALYs  
(millions) 
2008 
Global 
funding  
(US$ 
millions) 
$ per 
DALY 
     
1 Bacterial pneumonia (lower respiratory infections) 93.3 90.8 1.0 
2 Diarrhoeal diseases 72.3 132.2 1.8 
3 HIV/AIDS 57.8 1164.8 20.2 
4 Tuberculosis 34.0 445.9 13.1 
5 Malaria 33.9 541.7 16.0 
6 Helminth infections  12 66.8 5.6 
7 Rheumatic  5.1 2.2 0.4 
8 Kinetoplastids (Chagas, leishmaniasis and African 
trypanosomiasis) 
4.1 139.2 34.0 
     
 
If South Africa has equal duties to all the absolutely poor in the region, and if South 
Africa is receiving more than its fair share of resources for these shared priorities, 
then there are a number of ways in which South Africa can start to fulfil its duties. 
The first is to advocate and secure funding for more research into these two disease 
groups, an action that will benefit both its own population and that of the region. 
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Given the relatively low funding allocations to lower respiratory infections and 
diarrhoeal diseases, advocacy for increased international funding is needed. The 
second is to ensure that the funds it already receives for research into these diseases 
are used to conduct research that will benefit the region as a whole, and not only 
benefit South African citizens. In the case of malaria, South Africa has essentially 
prioritised research into a disease that for the most part only affects other Africans. 
Whatever the reasons for malaria’s inclusion in South Africa’s health research 
priorities, this might indicate that South Africa is already, to some extent, fulfilling its 
duty to the region. 
 
3.3.4 Neglected developing world diseases that are health research 
priorities for Africa but not South Africa 
Three of the eight leading neglected diseases of the developing world are health 
research priorities for the African region, but not for South Africa. These include the 
bolded diseases in Table 3.11: Helminth infections, rheumatic fever, and 
kinetoplastids. These are the class of neglected diseases that do not stand to benefit 
either directly or indirectly from any research that South Africa is already conducting. 
Also, because other African countries in general receive less donor funding than 
South Africa, these diseases have the potential for being generally underfunded. 
Kinetoplastids were identified earlier as the highest earners of research funds 
amongst neglected diseases of developing countries. Measured in dollars-per-DALY, 
this disease group receives more than HIV, tuberculosis, or malaria. But helminth 
infections and rheumatic fever receive very little funding. Measured in dollars-per-
DALY, helminth infections and rheumatic fever combined receive less than one fifth 
the funding that kinetoplastids do. 
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Table 3.11 Neglected diseases that are health research priorities for Africa but 
not South Africa 
 
Neglected disease 
2004 
DALYs 
(millions) 
2008 
Global 
funding  
(US$ 
millions) 
$ per 
DALY 
     
1 Bacterial pneumonia (lower respiratory infections) 93.3 90.8 1.0 
2 Diarrhoeal diseases 72.3 132.2 1.8 
3 HIV/AIDS 57.8 1164.8 20.2 
4 Tuberculosis 34.0 445.9 13.1 
5 Malaria 33.9 541.7 16.0 
6 Helminth infections  12 66.8 5.6 
7 Rheumatic  5.1 2.2 0.4 
8 Kinetoplastids (Chagas, leishmaniasis and African 
trypanosomiasis) 
4.1 139.2 34.0 
     
 
If South Africa has equal duties to all the absolutely poor in the region, and if funding 
for these two disease groups (helminth infections and rheumatic fever) is very low 
relative to the others, then one way that South Africa could fulfil its duty is to 
advocate for international funding for these, or adopt them into their own research 
priorities. Another option would be for South African researchers to work with 
researchers in other African countries and apply for grants for research on neglected 
diseases—thereby using South Africa’s greater research capacity to build capacity in 
other places. 
 
3.4 How do global health research investments map onto 
the types of health research needed in low-income 
settings? 
For two decades the imbalance in global health research spending commonly referred 
to as the 10/90-gap has been cited as justification for a need to change the current 
global health research paradigm. The focus of the discussion has been on which 
disease groups are receiving more or less funding globally. While there is still 
evidence of this gap, in which priority health research for particular diseases in low- 
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and middle-income countries is underfunded, the imbalance in research spending is 
not as simple as that. Beyond the rhetoric of the 10/90-gap, which points to which 
disease groups ought to receive more or less research funding, is a more specific 
question of what types of research ought to be funded within these disease groups in 
order to address the unique health research priorities of lower-income populations. 
Even if health research into diseases that affect low-income countries is being funded, 
it does not automatically follow that the fruits of that research will benefit low-
income countries. This is because it does not follow that the type of research being 
funded is suitable to low-income country needs. For many of the diseases that 
predominantly affect low-income countries, successful interventions and products 
already exist and are readily available in higher-income settings. In many of these 
cases, the types of research that are most needed are implementation research on how 
to successfully integrate these existing interventions into low-income country 
settings, health systems research to ensure successful integration and scale-up of 
interventions into a country’s health infrastructure, and in some cases research to 
develop similar products that suit local contexts (45, 46). 
Knowing what types of research are needed to address the health priorities of low-
income populations provides an evidence base from which health research funders 
can focus their resources. A research agenda that reflects the specific types of health 
research needed in low-income populations, rather than merely noting which disease 
groups need research, can inform an effective global research effort on diseases of 
poverty. Relevant to this thesis, knowing that different types of research are needed in 
the poorest populations informs how South Africa should fulfil its previously 
established duty to the absolutely poor in the region. If South Africa has equal duties 
to the absolutely poor in sub-Saharan Africa, and if global spending on health 
research does not reflect the type of research needed in Africa, then one way in which 
South Africa may be able to instantiate its duty is to advocate for, or fund a shift to, 
the specific types of research needed to address diseases affecting the absolutely poor 
in sub-Saharan Africa. 
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3.4.1 Low-income countries need different types of research than 
high-income countries for the same disease groups 
Health research activities go far beyond the well-known areas of developing new 
products such as medicines, treatments and technologies. Health research also 
includes research aimed at strengthening weak health systems struggling to 
effectively provide health care to populations in need, as well as research to test the 
implementation of existing products or interventions. Product research and 
development is of course essential for health and includes drugs, vaccines, 
diagnostics, microbicides, vector-control products57 and platform technologies58 that 
can be potentially applied to a range of disease areas. New tools and interventions are 
however not enough to tackle disease, particularly in low-income settings, where 
there is a growing gap between the availability of tools, products and knowledge 
about disease and what is actually done to make use of these in disease-endemic 
settings. 
Despite an increased global investment in diseases that affect low-income countries 
over the last two decades, there is still an alarming gap between innovations in health, 
such as vaccines, drugs and interventions, and their delivery to these poorer 
populations who need them most. Scientific advances in Group I diseases have 
enabled prevention, treatment, and in some instances eradication of certain diseases 
in high-income countries. Unfortunately, many of these innovations have yet to reach 
the places where they could have the largest impact on health. As an example, a 
pneumococcal vaccine able to dramatically reduce the number of children dying was 
approved in the US in the year 2000. Ten years later the vaccine remained expensive, 
was still marketed in a highly unfeasible form, and was still not available in most 
low-income countries where it could have made the biggest difference in reducing 
unnecessary death (55). 
                                            
57 Examples of vector control products include pesticides, biological control agents and vaccines targeting animal 
reservoirs. 
58 Examples of platform technologies include adjuvants, diagnostic platforms and delivery devices. 
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Many evidence-based innovations developed in high-income countries fail to produce 
results when transferred to lower-income settings. This is for the most part because 
their implementation has not been tested or they are unsuitable. Populations in low-
income countries confront a plethora of social constraints and health threats that 
make the implementation of effective health prevention and treatment programs more 
difficult. People often have limited knowledge of preventive health practices and 
inadequate access to good quality healthcare. In addition, health is regularly undercut 
by other challenges such as inadequate water and sanitation infrastructure, high 
pathogen loads and socio-economic obstacles to behaviour change. In low-income 
countries health systems are also underfinanced and undermined by severe health 
worker shortages. A lack of both financial and human resources in the health sector 
implies a need to find ways to best use the limited resources available. For these 
reasons it is difficult to successfully adapt, implement and sustain new interventions 
in many low-income settings (56). To be effective, any new health-related products 
or interventions need to be usable within a given health system and implemented 
appropriately so that the end user is able to benefit from them. 
In order for the funding invested into health research to reach its potential for 
improving health, low-income countries need three particular types of research. The 
first is research into products that can be used specifically in low-income settings. In 
some cases, products developed through health research in high-income countries can 
be used with relative ease in middle- and low-income country settings. However, in 
others, these products are inappropriate because they are unaffordable, inaccessible or 
unable to be used in a setting lacking the similar hi-tech infrastructure seen in higher-
income contexts. Research is therefore needed to develop more affordable or less 
technology-dependent versions of the same product. One example of biotechnology 
research directed at health in low-income settings is research on modified molecular 
technologies. A PCR-based HIV test has been simplified to use filter paper to process 
and store blood samples. Samples stored in this way are heat-stable and can be used 
for many months. Simple hand-held test devices to diagnose malaria and HIV are 
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being researched for their adaptability to settings without running water, refrigeration 
or electricity (57). 
The second and third are implementation research to ensure that already existing 
interventions can be effectively integrated into resource-poor health systems, and 
research to improve health systems themselves (58). Implementation research aims to 
develop strategies for effective health interventions in order to improve access to, and 
use of, these interventions (59). Health systems research focuses on the performance 
of a country’s health services and interventions in the health sector. It can help 
identify best practices and prioritize areas that need strengthening. Implementation 
and health systems research are needed to establish the most efficient way of 
integrating successful products and interventions into a new and different 
environment. In many low- and middle-income countries, children under five years of 
age still account for a disproportionately large share of the disease burden. 
Communicable diseases such as lower respiratory infections, diarrhoeal diseases and 
perinatal conditions persist. These diseases can largely be prevented through 
relatively low-cost, already proven interventions. Therefore research into how best to 
implement these interventions in lower income countries has been advocated as a 
priority for global health research (58). 
With the emergent double-burden of disease in low- and middle-income countries, 
cardiovascular disease, diabetes and depression are now also relevant to developing 
countries. Chronic diseases account for 60% of all deaths globally, and 80% of these 
deaths occur in low- and middle-income countries, where populations are 
disproportionately burdened during youth and middle age. Cost-effective preventive 
strategies and therapeutic approaches to reduce the burden of cardiovascular disease, 
diabetes and mental health disorders have been researched and developed in high-
income countries. Vast knowledge is therefore already available on how to prevent 
and manage a major portion of these diseases, yet most countries, even within the 
high-income sector, do not implement that knowledge successfully. Much of this 
accumulated knowledge is likely to be relevant to low- and middle-income countries. 
However very few epidemiological studies have quantified the impact of major risk 
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factors for these chronic non-communicable diseases in low-income countries, and 
even fewer trials have been conducted to assess the efficacy of different intervention 
strategies. Implementation research to explore the transferability of these cost-
effective interventions from high- to low-income settings is a priority (58). For 
example, cost-effective community-based antihypertensive and antidepressive 
treatments could have a profound effect in lower-income settings (58). Crucial 
implementation research that combines operations research and health 
services/systems research is also essential to ensure the success of rapid scaling-up of 
cost-effective interventions. Because of their multiple interacting causes and due to 
their chronic nature, non-communicable diseases challenge current paradigms of 
health care organisation and delivery. High-, middle- and low-income countries alike 
are struggling to find solutions at the levels of policy and health care delivery. The 
challenge is to close the gap between the existing evidence that supports proven 
interventions and the translation of this knowledge into policy and practice. 
The specific types of research most needed in lower-income settings are the same 
across different causes of disease burden. Whether Group I or Group II diseases, low-
income countries need research into products that can be used specifically in low-
income settings, implementation research to ensure that already existing interventions 
can be effectively integrated into resource-poor health systems, and research to 
improve health systems themselves. Recommendations from the World Health 
Organisation, the Global Forum for Health Research and the International AIDS 
Society recommend that between 5% and 10% of development assistance should be 
directed towards implementation research to optimize interventions utilised and 
health outcomes achieved (60, 61). This indicates that governments and donors can 
spend relatively little money on this type of research and achieve large results. 
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3.4.2 Global spending on health research does not reflect the types 
of research needed in low-income countries 
Low-income countries need different types of research than high-income countries. 
This applies even in the cases where the research is targeted at the same disease. As 
noted earlier in the chapter, high-income countries fund most health research 
globally. They also invest this funding predominantly in the causes of disease burden 
that affect high-income populations. Only a very small proportion of overall global 
spending on health research goes towards those diseases that predominantly affect 
populations in low-income settings. It might therefore be reasonable to assume that 
the types of research conducted by high-income countries are also those most suited 
to high-income population needs. This section examines to what extent the types of 
research conducted globally are those that would meet the health research needs of 
low-income settings. In the previous section I argued that low-income countries 
specifically need three types of research: 1) research into products that can be used 
specifically in low-income settings i.e. products that are more affordable, accessible, 
or less dependent on hi-tech infrastructure; 2) implementation research to ensure that 
already existing interventions can be successfully integrated into resource-poor health 
systems; and 3) research to improve health systems themselves (58). 
Data on how much funding is directed at different types of research within any 
particular disease group is scant. In this section I report on the data that does exist to 
give some insight into the proportion of global health research funding that goes 
towards these specific research types. I then use a couple of specific disease examples 
to illustrate the distribution of funding invested into different types of research within 
and across disease types. 
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Products that can be used in low-income settings 
 
The G-Finder reports on global investment into the research of new products targeted 
specifically at developing-country needs. The report excludes funding into disease 
areas that affect developing countries where the research constitutes commercial 
research and development, such as new HIV drugs and pneumonia vaccines targeting 
Western markets. The G-Finder is a great first step towards mapping the funding 
going towards products targeted specifically at the health research priorities for low-
income settings. It provides valuable data on how health research funding is currently 
being allocated, not only by disease but also within a given disease. It gives an 
impression of how much funding is being directed specifically to the needs of lower-
income settings, rather than a mere reporting of total global investments into a 
disease area, which would traditionally also include investments targeting Western 
markets. A cursory look at global investment into particular disease areas compared 
to investment targeted specifically at low-income country needs helps to illustrate just 
what proportion of global funding has the potential to meet the unique needs of these 
low-income settings. Again, since the U.S. is the major funder of global health 
research, and because the data on HIV research is accessible, I report here on U.S. 
funding for HIV research. Table 3.12 below shows U.S. funding directed specifically 
at low-income country HIV research as a proportion of total U.S. funding for HIV 
research. 
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Table 3.12 U.S. funding for HIV research specific to developing-country needs 
 
U.S. funding for HIV research  US$ (millions) 
  
Total funding (2005) US$ 5000  
Funding targeted at developing country research needs (2007) US$   858  
  
Proportion targeted at developing country research needs 17% 
 
Source: “Total funding (2005)” is the figure reported by Dorsey ER, Thomspson JP, Carrasco M, de 
Roulet J, Vitticore P, Nicholson S, et al. Financing of U.S. Biomedical Research and New Drug 
Approvals across Therapeutic Areas. PLoS ONE [serial on the Internet]. 2009 [cited 2009 May 
2]; 4(9): Available from: 
http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0007015 
 
“Funding targeted at developing country research needs (2007)” represents spending by U.S. 
National Institutes of Health (NIH), Bill and Melinda Gates Foundation, United States Agency for 
International Development (USAID), and aggregate pharmaceutical and Biotechnology 
Company respondents in the U.S. and globally. See p.17 of Moran M, Guzman J, Henderson K, 
Ropars A-L, McDonald A, McSherry L, et al. G-Finder: Global funding of innovation for 
neglected diseases 2009: Neglected disease research and development: New times, new 
trends. Sydney: The George Institute for International Health; 2009. Available from: 
http://www.policycures.org/projects.html 
  
The NIH and U.S. pharmaceutical industry are the two largest funders of HIV 
research in the United States (42). Together they invested $5 billion in HIV/AIDS 
biomedical research in 2005 (42, p.3, Table 1). It does not however automatically 
follow that the products of this research will be relevant to the populations in lower-
income countries that are most severely affected by HIV/AIDS. The G-Finder shows 
that in 2007 just over $850 million was invested by the U.S. in HIV/AIDS research 
specifically targeted at developing countries,59 less than one fifth of total U.S. 
investments in research for this disease. Only a small percentage (17%) of total 
funding into a disease that affects predominantly low- and middle-income countries is 
actually spent on research and development needed in these countries. The majority 
of the funding, around $4 billion (83%), we can assume is directed to HIV/AIDS 
research targeted at high-income markets. Unfortunately, the G-Finder report does 
not provide an estimate of the total funding needs for product research in low-income 
                                            
59 This figure represents spending by U.S. National Institutes of Health (NIH), Bill and Melinda Gates Foundation, United 
States Agency for International Development (USAID), and aggregate pharmaceutical and Biotechnology Company 
respondents in the U.S. and globally. See p.17, Table 3 in Moran M, Guzman J, Henderson K, Ropars A-L, McDonald A, 
McSherry L, et al. G-Finder: Global funding of innovation for neglected diseases 2009: Neglected disease research and 
development: New times, new trends. Sydney: The George Institute for International Health; 2009. Available from: 
http://www.policycures.org/projects.html 
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settings and we therefore do not know the extent to which products for particular 
diseases are under-funded. G-finder also does not report on how funds should be 
disbursed, nor does it address the vital question of access to the products developed 
as a result of the research. The reality is that even if research does take place, access 
to the end products by those who need them the most is uncertain. This is because it 
depends largely on the pricing or registration policies pursued (55) and on whether 
implementation and scale-up within a health system is feasible. 
Since low-income countries suffer a dual burden of disease, research into non-
communicable diseases specifically targeted at low-income country needs is also 
necessary. Unfortunately, there are no data on the proportion of global funding 
devoted to non-communicable disease product research targeted at low-income 
country needs. A middle-income country, India, funded one example of an innovative 
non-communicable disease product that has the potential for a positive health impact 
in low-income settings. Phase 2 of the Indian Polycap Study assessed the safety of a 
combination pill containing a generic statin, an antihypertensive agent and aspirin. 
This product could have significant effects globally in lowering costs, enhancing 
adherence and improving control of multiple risk factors in cardiovascular disease. 
While this example surely demonstrates a positive move to product research specific 
to the needs of lower-income settings, it is not the norm. 
 
Implementation and health systems research 
 
Biomedical research has had impressive successes in the past because it has attracted 
substantial financial investment. The same is not true for the much-needed 
implementation and health systems research in low-income countries.  Health 
systems research was recently referred to as the poor cousin of biomedical research, 
with just 0.02% of health spending in low- and middle-income countries invested in it 
(62). 
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A move to focus on implementation and health systems research, the specific types of 
research needed to address the unique needs of low-income countries, is a goal 
supported by the World Health Organisation’s Special Program for Research and 
Training in Tropical Diseases (TDR) (63), COHRED (64), and the U.S. National 
Institutes of Health’s initiative in Dissemination and Implementation Research in 
Health (65). The Global Symposium on Health Systems Research recently launched a 
platform for promoting implementation research by a new collaboration of several 
organisations. This marks a great first step in the push to fund implementation 
research in low-income settings (66). Seven countries were the first to receive 
funding through the platform and will each carry out a specific research project suited 
to the needs of their own population. However, programs like these need to be 
expanded. 
The Global Fund, an organisation that funds research into HIV, tuberculosis and 
malaria (three disease groups for which the burden of disease in low-income 
countries is high, particularly in the African region) encourages the inclusion of 
operational and implementation research in programs it supports (59). In a recent 
review, they report that the proportion of the budget allocated to operational and 
implementation research over the total Global Fund portfolio for grants initiated in 
2006 and 2007 is 1.3%. While this represents a three-fold increase on earlier rounds, 
where the proportion was 0.4%, it still falls far short of the 5-10% recommended by 
the WHO, The Global Forum for Health Research and the International AIDS Society 
(67). This data shows that while resources from organisations like the Global Fund 
encourage and enable researchers to conduct operational and implementation 
research, its potential is not being fully realised.60 So while there are promising signs 
of increasing commitment to funding of operational and implementation research, 
this has not yet translated into serious capacity development initiatives for this 
research (68). 
                                            
60 Remme et al. (2010) provide welcome clarity on the distinct conceptual definitions of operational, implementation and 
health systems research. Although Korenromp et al (2007) refer only to operational research in their Global Fund report, 
based on their description of the types of research labelled as operational, these include both operational and 
implementation research according to Remme et al’s definitions. 
Nicola W Barsdorf 
 109 
Malaria 
 
In 2008 there were 250 million cases of malaria and nearly 1 million deaths globally, 
most of them in African children (69). In Africa, a child dies every 45 seconds of 
malaria; the disease accounts for 20% of all childhood deaths. Malaria can be 
prevented, diagnosed and treated with a combination of already existing and available 
tools and interventions. These include long-lasting insecticidal nets, indoor residual 
spraying, and intermittent preventive treatment for pregnant women to prevent 
malaria infection in high transmission settings. Vector control measures such as 
larviciding and environmental management are also used when appropriate. 
Medicines and diagnostics are used for case management. Malaria can be diagnosed 
by either microscopy or a rapid diagnostic test. Artemisinin-based combination 
therapies are the recommended treatment against P. falciparum malaria and 
chloroquine and primaquine are the treatments of choice for P. vivax malaria. 
Following an aborted Global Malaria Eradication campaign in the 1950s to 1970s, 
malaria received little attention until recently. Over the past decade, there has been 
substantial progress in raising awareness about malaria, and several countries have 
achieved a substantial reduction in malaria-related morbidity and mortality. 
Following expanded coverage with long-lasting insecticidal nets and artemisinin-
based combination therapies, malaria morbidity and mortality in health facilities in 
Rwanda was reduced by over 50%. The Roll Back Malaria Partnership recently 
developed the Global Malaria Action Plan, which outlines a global strategy towards a 
substantial and sustained reduction in the burden of malaria globally. Research into 
new tools and approaches to support global control and an eventual elimination effort 
forms an integral component of the plan. There is still a lot to do in order to achieve 
the Roll Back Malaria targets and extend the benefits to more countries. Country 
level capacity building and health systems strengthening will be critical to ensure that 
health systems can deliver the needed interventions to at-risk populations (70). 
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Three types of research are needed to support effective malaria control and 
elimination: 1) research and development of new tools; 2) research to inform policy; 
and 3) operational and implementation research. Research and development is needed 
to create new and improved anti-malarial interventions including drugs, vector-
control tools, diagnostics and vaccines. Research to inform policy will define the 
types of interventions best suited for different contexts. Operational and 
implementation research is needed to understand the use and effectiveness of 
interventions in the field and improve the delivery and quality of interventions. 
GMAP estimates that about $750-900 million per year should be spent on product 
research. Funding for malaria research and development has increased over the past 5 
years. In 2007 an estimated $422 million was invested. The two major donors (the 
U.S. NIH and the Bill and Melinda Gates Foundation) account for 40% of estimated 
funding for product research (i.e. $169 million). More than 60% of these funds are 
directed to drugs and vaccines (70). The G-Finder reports a similar amount of 
spending ($468 million) for malaria product research in 2007 (71). This spending is 
on products alone, and yet it still represents only around half of what Roll Back 
Malaria says is needed to stay on track. This does not include an estimate for 
spending on the needed policy, operational and implementation research. 
There seem to be few data and little direction on what policy and operational research 
is being and should be funded. GMAP confirms that while consultative processes 
have been set in place to define the research agenda for new tools for malaria, a 
similar process is not yet underway for policy or implementation research (70). 
Implementation research is essential, however, particularly in low-income settings, to 
identify solutions to bottlenecks that limit program effectiveness in these contexts. 
Limited funding has made it difficult for implementation research to keep pace as 
new interventions for malaria have been scaled up resulting in current intervention 
field effectiveness being considerably lower than its potential. Non-adherence to drug 
regimens, improper use of long-lasting insecticidal nets and washing walls after 
indoor residual spraying are just some of the examples GMAP cites as causes of the 
lower effectiveness that need to be assessed. 
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The Global Fund provides resources to enable countries to conduct operational 
research, but opportunities are not yet fully utilised. While the Global Forum for 
Health Research, WHO, and the International AIDS society have advocated for 5-
10% of development assistance funds to be dedicated to operational research, of the 
$400 million budget for malaria research grant proposals submitted to the Global 
Fund in 2007, just 2.75% ($11 million) was earmarked for operational research 
components (67). This is up from the 0.27% reported in the previous 5 funding 
cycles, but still falls short of the recommended 5-10%. Incidentally, malaria was the 
disease group with the highest percentage of the research budget allocated to 
operational research. The two other diseases reported on by the Global Fund, HIV 
and tuberculosis, had only 0.75% and 1.42% allocated to operational research. Over 
the total Global Fund portfolio, the budget allocated to operational research was 1.3% 
(67). 
Malaria drug and vaccine research is booming, and after many decades there are now 
new anti-malarials in the pipeline. The onus now rests on donors and developing 
countries to research which of these new drugs offer the best cost-benefit for African 
populations. Research is also needed to ensure that these new drugs are appropriately 
absorbed by already strained health systems and delivered to end-users. Both NIAID 
and GMAP identify gaps in the current malaria research paradigm. NIAID lists 
implementation research as one of their four priority gaps in malaria research (72). 
GMAP notes that significant additional financial resources and human capacity are 
needed to address all of the operational and implementation research priorities for 
malaria (70). 
 
 Mental health 
 
Since low-income countries suffer a dual burden of disease, research into 
noncommunicable diseases specifically targeted at low-income country needs is also 
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needed. Mental illness affects around 30% of the population globally. Two thirds of 
these cases receive no treatment. The proportion of people with mental disorders who 
are treated in low- and middle-income countries is even lower. These low treatment 
rates cannot be accounted for solely by scarcity of evidence from low- and middle-
income countries. There is now solid evidence for the effectiveness of various forms 
of mental health treatment and prevention, especially for pharmacological and 
psychological interventions for depressive, anxiety disorders, and schizophrenia (73). 
These interventions have been shown to be affordable in low-income countries and 
are just as cost-effective as antiretroviral treatment for HIV/AIDS (74). Still the 
coverage of evidence-based services for people with mental illnesses is extremely 
low in most low- and middle-income countries (74). There is a relative paucity of 
trials that assess interventions to prevent and treat mental illness in lower-income 
settings, and especially of research to assess the effectiveness of scaling-up 
interventions. A recent priority setting exercise indicates that funding should 
concentrate on research to address this evidence gap. Specifically, research is needed 
to develop and assess interventions that do not need to be delivered by mental health 
professionals and to assess how health systems can effectively scale up feasible 
interventions (75). This however stands in contrast with trends in the allocation of 
most research funding.  In 2006 the National Institutes of Mental Health (NIMH) 
allocated only 0.6% of its research funding to mental health research related to low- 
and middle-income country needs. It also stands in contrast with the listed priorities 
of organisations such as the NIMH whose main priority for research in mental health 
is the development of new interventions (76). New and highly efficacious drug 
treatments, to be effective, will still require well functioning health systems to deliver 
them and psychosocial interventions to accompany them. The bottom line is that 
without capacity building for mental health research in low- and middle-income 
countries, merely increasing research funding into mental health will be wasted. 
While data on the proportion of global health research funding invested into the types 
of research most needed in lower-income settings is scant, the available data reveals 
that this proportion is generally very low. This is true for research into products 
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specifically targeted at low-income country research needs. It is also true for 
implementation and health systems research needed in low-income countries. In 
addition, it is true for both communicable and non-communicable diseases. The data 
shows that regardless of whether a particular disease group is a priority only for low-
income countries or for both high- and low-income countries, global research 
investment does not necessarily mean that the fruits of that research will benefit low-
income countries. 
The question then is: How can global health programmes and organisations better 
appreciate and focus their activities and resources on the specific health research 
needs of low- and middle-income countries? The goal is ultimately to bring about 
more efficient approaches to combat diseases in contexts of poverty. Until now, far 
too few resources have been spent on research into what makes these systems tick. 
The data point to the urgent need for more implementation and health systems 
research, both for communicable and noncommunicable disease groups. 
Knowing that these specific types of research are needed to address the health 
priorities of lower-income countries provides an evidence base from which health 
research funders globally can focus their resources on the specific health research 
needs of low-income countries. Relevant to this thesis, knowing that specific types of 
research are needed informs how South Africa should fulfil its previously established 
duty to the absolutely poor. If South Africa has a duty to the absolutely poor, and if 
global spending on health research does not reflect the type of research needed in 
low-income countries, then one way in which South Africa may be able to fulfil its 
duty might be to advocate for or fund a shift to the type of research needed to address 
diseases affecting the poor. This could include research into products that are targeted 
at low-income country populations as well as implementation and health systems 
research. 
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3.5 Conclusions: Spending does not correspond with global 
health research priorities 
Scarce health research funding is a challenge for many countries, but is particularly 
acute in low-income countries, which have limited financial resources to fund 
necessary research themselves and a low priority given to their national health 
research needs by the global health research community. This chapter provided an 
overview of established health research priorities and presented data on the very 
skewed distribution of health research spending by different causes of disease burden 
and by different types of research. Mapping the distribution of funding for health 
research, both by different disease groups, and by the type of research funded within 
a given disease group, illustrates the degree to which global funding is still not 
aligned with established health research priorities. It also points to examples of gaps 
in funding by disease group and by type of research needed. Using data to identify 
the gaps in health research spending globally, and particularly the gaps in health 
research spending in low-income settings, provides an evidence base that guides 
South Africa in how to fulfil its duty to the absolutely poor. Before outlining some of 
the possible actions South Africa can undertake, it is worth noting that there is a need 
for more data on health research spending, particularly for those diseases and types of 
research most relevant to low-income settings. 
 
3.5.1 More data on health research spending is needed 
What became apparent when searching for data on health research priorities and on 
how much was being invested in health research was that in many cases this data has 
not yet been collected or reported. To my knowledge there has been no priority 
setting exercise conducted on a global scale for health research, and global health 
research priorities have therefore not been established. This in itself is telling of a 
general lack of alignment in global efforts relevant to health research planning, 
activities and resource allocation. A similar lack of globally compiled data is evident 
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when it comes to spending. In many cases, to illustrate a trend, I would assume that 
data on U.S. funding was a “good-enough” proxy for global investment. Since the 
U.S. continues to dominate global investments in health research, accounting for 50% 
of investments, trends in their spending are probably a “good-enough” proxy. At the 
least spending by the U.S. is a better proxy than spending by other countries; the 
second largest contributor after the U.S. is Japan at 10% (41, p.29). Reports on 
composite global health research spending in different disease categories would 
however be more informative. 
While organisations such as the Global Forum for Health Research and G-Finder 
have continued to track where and on what health research resources are spent, there 
are important pieces of information that are not currently part of their general 
reporting. The first is an indication of how much more investment is needed for 
health research for specific diseases, particularly the diseases most prevalent in low-
income settings. The second is data on spending for different types of research other 
than product research i.e. reporting on investments in implementation and health 
systems research. 
My account of global justice offers a morally sound way of focusing resources, but at 
present there is not enough data to work out the details. This of course has 
implications for the certainty with which I can make recommendations. In many 
cases there is not comprehensive enough data to state with absolute certainty the 
amount of investment into a particular disease, or type of research relevant to that 
disease. The recommendations I make for how South Africa can begin to fulfil its 
duty then represent examples of the kinds of research or advocacy that South Africa 
ought to undertake. While the recommendations provided here are certainly not 
comprehensive, they do provide a starting point for South Africa’s support of health 
research for the global poor. 
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3.5.2 A starting point: How South Africa might begin to fulfil its 
health research duties 
At the start of this chapter I asked four separate but related questions:  
1. How do global health research investments map onto global health research 
priorities? 
2. How do South Africa’s health research priorities compare with Africa’s? 
3. How do global investments in South Africa’s health research priorities 
compare to global investments in Africa’s health research priorities? 
4. How do global health research investments map onto the types of health 
research needed in low-income settings? 
 
In each case, the answer to the question points us to how South Africa’s duty to the 
absolutely poor might be fulfilled. The first question asked how global health 
research investments map onto global health research priorities. Since there is not yet 
an established list of global health research priorities, disease burden was used as a 
proxy. From the data available to us, it is clear that global health research spending 
does not map onto global disease burden. Disease burden in high-income countries is 
different from disease burden globally. It is also different from disease burden in low-
income countries. Most global health research (97%) is funded by high-income 
countries or sponsored by pharmaceutical companies linked to the industry of high-
income countries. The majority of this spending goes towards health research to 
address causes of disease burden in high-income countries. Health research spending 
globally therefore maps onto disease burden in high-income countries. The burden of 
disease in low-income countries (particularly in Africa) is skewed to communicable 
diseases and global spending on health research is not adequately addressing these. 
Essentially, a gap in funding appropriate to global disease burden is still there. 
Although this gap may not be as large as it was when the 10/90-gap was reported in 
1990, the majority of funding for health research globally remains directed at the 
causes of disease burden in high-income countries. Since South Africa has equal 
duties to all the world’s absolutely poor, and global health research spending does not 
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map onto global disease burden, or onto the disease burden of the poor, then one way 
in which South Africa might begin to fulfil this duty is to advocate for a shift in 
global funding to the comparatively neglected burden of disease affecting the poor. 
The second question asked how South Africa’s health research priorities compare 
with Africa’s. There are some diseases that are shared as health research priorities by 
both, for example, HIV, tuberculosis, respiratory infections and diarrhoeal diseases. 
There are other diseases that are research priorities for Africa but not South Africa, 
for example, malaria, sickle cell disease and the neglected tropical diseases. For those 
diseases that are priorities for both, we are not certain that the types of research being 
conducted by South Africa are relevant to the region. South Africa has equal duties to 
the absolutely poor within and beyond its borders, and it is morally permissible to 
focus this duty on the absolutely poor in Africa. South Africa should therefore 
commit to conducting types of research relevant both nationally and regionally on 
these overlapping health research priorities. For those diseases that are research 
priorities for Africa but not South Africa, it makes a difference if South Africa 
pursues only its own priorities or those more broadly relevant to the region. Since 
there are some diseases that are health research priorities for the region but not for 
South Africa, one way in which South Africa can begin to fulfil its duty is to 
incorporate these health research priorities into its own research agenda. This would 
entail an expanded research focus that is some combination of national and regional 
health research priorities. In the case of malaria, South Africa has prioritised research 
into a disease that for the most part only affects other Africans. This shows that South 
Africa is already to some extent fulfilling its duty to the region. 
The third question asked how global investments in South Africa’s health research 
priorities compare to global investments in Africa’s health research priorities. Global 
spending on health research priorities reflects more spending in South Africa 
generally, more spending on the health research priorities shared by South Africa and 
the rest of the region, and less spending on the health research priorities unique to 
African countries outside of South Africa. Among those diseases that are shared as 
health research priorities by South Africa and Africa, lower respiratory infections and 
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diarrhoeal diseases are receiving disproportionately low health research investments 
compared to the others. While we do not have data on how much research on these 
conditions is needed, the Child Health and Nutrition Research Initiative advocate for 
research to improve understanding of how to efficiently and creatively delivery 
existing interventions in low-income settings. One way in which South Africa can 
begin to fulfil its duty to Africa’s absolutely poor is to ensure that the funds it 
receives for research into this category of diseases, particularly lower respiratory 
infections and diarrhoeal diseases, are used to conduct research that will benefit not 
only its own population but also the region as a whole. South Africa should also 
advocate for increased global funding to address these particularly underfunded 
priorities, an action that will benefit both its own population and that of the region. 
Among those diseases that are health research priorities for Africa but not South 
Africa, helminth infections and rheumatic fever are receiving disproportionately low 
health research investments. In addition to incorporating these diseases into its own 
health research agenda, one way that South Africa could begin to fulfil its duty is to 
advocate for increased global funding into these two severely underfunded disease 
groups. 
The final question asked how global health research investments map onto the 
specific types of health research needed in low-income settings. Of the lesser 
percentage of overall global health research spending that is going towards causes of 
disease burden in low-income countries, an even smaller proportion goes towards the 
types of research most needed in low-income settings. Both for products specifically 
targeted at low-income country research needs, and especially for implementation 
and health systems research, the proportion of global health research spending 
relevant to low-income settings is staggeringly low. So even though some health 
research is being conducted on the causes of disease burden predominantly affecting 
low-income countries, the fruits of that research will not necessarily benefit low-
income countries. Not only does global spending fall short of global health research 
needs by disease group, but also within disease groups. Since global spending does 
not in fact reflect the type of research needed in low-income countries, one way in 
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which South Africa may be able to instantiate its duty to the absolutely poor is to 
advocate for or fund a shift to the types of health research needed to address diseases 
affecting these populations. This would include research into products specifically 
targeted at low-income country needs, implementation research and health systems 
research. 
 
Degrees of impact on the health research budget 
 
There are various actions that South Africa might take in order to fulfil its duties to 
the absolutely poor. Some of these will impact on South Africa’s limited pot of 
research resources more than others. The action that would impact on South Africa’s 
research budget the most would of course be the expansion of its research priorities to 
include those of the broader region. This would require redirecting some of its budget 
to diseases that it might not yet be investing in. It might be that South Africa could at 
least partly fulfil its duties without conducting the research itself, for example 
through directing grants or donor funding towards these diseases, by advocating for 
more research where appropriate, or disseminating its relevant research findings to 
other African researchers.  South African researchers could additionally work with 
researchers in other African countries and apply for grants for research on diseases 
relevant to African priorities—thereby using South Africa’s greater research capacity 
to build capacity in other places. These obligations are separate from those that 
require sharing the pot of health research resources. They would impact less on its 
own health research budget, but are still going to be necessary for research to happen. 
Deciding which of these actions to undertake will require careful consideration and is 
distinct from choosing to get out of the duty, which would be unacceptable.
 4 The best way to treat a set of people fairly: 
Allocating limited resources for health research. 
 
In this chapter I argue that in most cases investing in the worst-off is the fairest way 
to allocate scarce health research resources. In section 4.1, I outline three of the most 
commonly used, and widely affirmed, allocation principles: maximising overall 
health, increasing health equality, and prioritising the worst-off.  I argue that in the 
case of allocating scarce resources for health research, prioritizing the worst-off is 
the best way to treat the global population fairly, most of the time, since it is also the 
best way to serve the other two principles most of the time. In section 4.2, I identify 
populations that are likely to be representative of the world’s worst-off, as well as 
what types of health research, in which disease categories, are priorities for these 
populations. In section 4.3, I give an overview of global health research priority-
setting exercises to draw out some of their central features and results. I analyse a 
selection of these exercises conducted by the World Health Organisation (WHO) over 
the last two decades. This analysis looks at the major disease areas and types of 
research recommended by the WHO to see whether they capture the priorities of the 
worst-off. 
 
4.1 Prioritising the worst-off is the best way to treat a set of 
people fairly 
The focus in this section is on how best to invest limited resources for health 
research. This is an attempt to find permissible ways to prioritise spending, when 
there are many more people who need help than can be helped. If not all health needs 
can be met, the chosen distribution of resources must at least be fair. 
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Principles to achieve a just allocation of scarce resources can be classified into three 
widely affirmed categories: maximising total benefits (the utilitarian principle), 
maximising equality (the egalitarian principle), and prioritising the worst-off (the 
prioritarian principle). Methods for allocating health resources are ways to put these 
principles into practice. Each of these principles recognises morally relevant values. I 
outline each briefly below. 
When we aim to maximize total health benefits what is of primary moral importance 
is the total health of a given set of people irrespective of the distribution of health 
outcomes among the people. This criterion for allocating health resources tells us that 
we should allocate health resources in such a way that the total beneficial impact on 
health is as large as possible. If we apply health maximisation to the allocation of 
health resources generally, then health investments might simply look at DALYs61 
averted or QALYs62 gained by various allocations of health interventions. Investors 
would choose the most cost-effective way to avert DALYs or gain QALYs. The 
obvious appeal of using this utilitarian principle is that it means producing the 
greatest health benefit that we can, given the limited resources available. One 
significant drawback however is that applying only this principle does not address 
how these health benefits are distributed. Sometimes, applying the utilitarian 
principle, the available resources could produce the greatest overall health benefit if 
they were spent helping people who are already well-off, which seems unfair. 
The principle of equality requires treating people equally. There are two possible 
interpretations of this principle. The first is distributing an existing pot of health 
resources as equally as possible. Based on the principle that people are owed equal 
respect and that equality in resources is the best way to reach this ideal, this 
interpretation of the egalitarian principle says that every person should receive the 
                                            
61 The Disability-adjusted life year (DALY) is an indicator that measures the disease burden in a population. It is used as a 
single measure to quantify “loss of healthy years due to premature death and disability”. One DALY represents one year 
lost of healthy life. The more DALYs reported for a given condition in any population, the worse the population is affected 
by that condition i.e. the higher the reported DALYs, the higher the disease burden. 
62 The Quality-adjusted life year (QALY) is an indicator that is used in the assessment of health interventions. It is used as a 
single measure to quantity the number of years of life, of a reasonable quality, a person might gain as a result of the 
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same level or bundle of resources so that people are treated equally by treating them 
the same. But the reality is that people do not start off equal with respect to health or 
welfare. Therefore I propose that a second interpretation is in fact the most plausible 
interpretation of this egalitarian principle. Applying the principle of equality entails 
that we should try to increase equality in health i.e. bring everyone to an equal level 
of health. On this interpretation, when we aim to maximize health equality the 
morally right action is that which produces the most equal distribution of health in a 
given population. One way to implement this interpretation of the egalitarian 
principle is to advocate for an equal chance for everyone to achieve a basic level of 
health.63 
According to the principle of investing in the worst-off, the morally right action is 
considered to be that which offers the greatest advantage to the worst-off section of a 
population. A preference for the worst-off is commonly referred to as prioritarianism 
(77). The crucial issue for this principle is the severity of the condition of the worst-
off. As long as it is feasible to improve the health of these individuals, resources 
would be directed to them, irrespective of the relinquished improvements for others 
who are better-off. Applying this principle will entail the provision of health on the 
basis of who is already badly-off, rather than on the basis of who would benefit the 
most (as in health maximisation). This principle is most plausible when the worst-off 
can be helped relatively easily. It does not work as well when investing in the worst-
off would be a severe drain on resources, for example if one person requires 
continuous and extensive treatment for relatively little gain. 
Each of these three principles may offer guidance on the allocation of limited 
resources for health. So, if we had a limited amount of money to invest in global 
health, what would be the fairest way to spend it? I argue that investing in the worst-
off would be a just way of allocating these limited resources for health, most of the 
                                                                                                                                       
intervention. One QALY represents one year of perfect health lived. The more QALYs reported for a given medical 
intervention, the better the intervention. 
63 There are good reasons for moving from ‘achieving overall health equality’ to ‘getting an equal chance for everyone to 
attain a basic level of health.’ For example, some people will never get to a level of basic health and will become a black 
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time. This is because when distributing health resources, prioritizing the world’s 
worst-off will also tend towards maximizing equality and maximizing total health 
benefits. In other words, in most cases investing in the worst-off is also the best way 
to serve both the egalitarian and utilitarian principles. I believe this is true for most 
investments in health interventions and for most investments in global health 
research. In the next section (section 4.1.1), I make this argument for investment in 
health interventions. In section 4.1.2, I make the same argument for investment in 
health research. 
 
4.1.1 Allocating scarce resources for health interventions 
If we apply the prioritarian principle, our goal is to direct our limited resources for 
health interventions to the world’s worst-off. The concept of worst-off is in some 
respects a vague term. We might define those who are worst-off as those who are the 
sickest either now, in terms of illness severity, or over a lifetime. From the standpoint 
of justice, the most plausible conception of worst-off in this respect is a person’s 
welfare over a lifetime i.e. their life trajectory, rather than the severity of their illness 
at a fixed point in time.64 We might alternatively define those who are worst-off as 
those who are the poorest, even if their health is not necessarily the worst. While 
concepts like well-being, income-poverty and poor health are distinct, they are 
related. Health is an important component of overall well-being, and poor health is 
therefore an indicator of low welfare. Economic poverty, where a person lacks 
financial resources and is therefore unable to engage in economic transactions, is also 
generally an indicator of low welfare. Sen and Nussbaum call these components of 
well-being capabilities.65 Following this approach, both poverty and poor health are 
                                                                                                                                       
hole of resources. For this reason, it is reasonable to assume that the best way to implement this principle is to advocate for 
an equal chance for everyone at having the same access to achieving a basic level of health. 
64 This is because everyone is worst-off right before they die. 
65 Sen and Naussbaum’s capabilities approach to human well-being emphasises the multi-dimensional nature of a person’s 
welfare. The emphasis is on human beings’ having the capability to function in important ways if they so wish. This 
approach underscores the importance of the quality (or “well-ness”) of the person’s existence, determined by a set of 
interrelated elements such as adequate financial resources, education, adequate nutrition, good health, avoiding escapable 
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understood as forms of capability-deprivation. Those who are worst-off could be 
described as those who are lacking certain basic capabilities, or those lacking the 
most basic capabilities. Aggregate statistics for income (such as GDP per capita) and 
health (such as DALYs or QUALYs) are often used as indicators of a population’s 
well-being. Those populations who are worst-off would therefore be those whose 
well-being, as indicated by measures of wealth and/or health, is the lowest of all 
populations. Whether we identify the global worst-off as those populations who are 
poorest, or as those populations who are sickest over a lifetime, we know that at least 
some populations in low-income countries would qualify.66 
In most cases investing in health interventions for the worst-off i.e. serving the 
prioritarian principle, is also the best way to serve both the egalitarian and utilitarian 
principles. The goal of the utilitarian principle is to maximise total health gains. 
Applied to health interventions, this principle would support packages of 
interventions that attain the greatest health improvements for the most people at the 
lowest cost. Those populations that are worst-off generally suffer the greatest disease 
burden. Many of the health interventions most needed in these populations are also 
the most cost-effective compared to the health interventions needed in better-off 
populations. Health interventions targeted at these populations thus stand to produce 
the most health benefits overall. So applying the utilitarian principle, we should 
therefore often allocate scarce resources for health interventions to the worst-off, 
since this would produce a larger overall health benefit from an equivalent 
investment of resources. 
This is best illustrated through examples of actual health interventions. The two 
leading causes of global disease burden are infectious diseases: lower respiratory 
infections and diarrhoeal diseases. They are also the leading causes of disease burden 
                                                                                                                                       
morbidity and premature mortality. These elements are constitutive of a person’s being and any evaluation of wellbeing has 
to include an assessment of these constituent elements. See Sen (1992). Inequality re-examined. Harvard University Press: 
Cambridge. 
66 Some populations in the low-income category are the world’s poorest. They also have the worst health in terms of 
absolute numbers of DALYs lost. One DALY represents one year of healthy life lost. It is used in burden of disease reports 
as a single measure to quantify the burden of diseases, injuries and risk factors. DALYs essentially combine years of life 
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in low-income countries. Treatment and prevention interventions for respiratory 
infections or diarrheal disease are cheap, simple and effective. Interventions to treat 
infectious diseases in general have been highly cost-effective in the past and remain 
so despite new challenges, such as drug-resistant pathogens and vectors. The Disease 
Control Priorities Project has shown that for respiratory infections, vaccination 
strategies can be cost-effective in lowering the disease burden (under $10 per DALY 
averted).67 Case management may also be an efficient use of financial resources: 
treating non-severe pneumonia at health care facilities using a combination of oral 
antimicrobials and acetaminophen costs US$24 to US$424 per DALY averted (58, 
p.45). A more integrated approach to the management of many childhood illnesses, 
including respiratory infections and diarrheal disease, in a low-income setting such as 
sub-Saharan Africa costs approximately US$38 per DALY averted.68 These 
intervention options represent examples of cost-effective approaches to improving 
overall health. 
Just how cost-effective they are becomes apparent when we compare them to the 
cost-effectiveness of health interventions for cancer, one of the leading causes of 
disease burden in high-income countries to which currently a significant proportion 
of overall global investments in health interventions are made. Initial treatment for 
cancer in low- and middle-income countries is reported to cost between US$1,300 
and US$6,200 per year of life saved. This is for the more treatable cancers of the 
cervix, breast, oral cavity, colon, and rectum. For the less treatable cancers of the 
liver, lung, stomach, and oesophagus, cost-effectiveness is even lower at between 
US$53,000 and US$163,000 per year of life saved (58, p.46). Thus, for the cost of 
one year of life saved, even for one of the more treatable cancers, we could avert 
                                                                                                                                       
lost due to death and equivalent years of life lost through being in a state of poor health or disability. The more DALYs 
reported for a given condition in any population, the worse the population is affected by that condition. 
67 This is the cost cited for national immunization programs, which have traditionally included vaccines against TB, 
diphtheria, tetanus, pertussis, poliomyelitis, and measles. See p.44 of Bloom BR, Michaud CM, La Montagne JR, Simonsen 
L. Chapter 4: Priorities for global research and development interventions. In: Jamison DT, Breman JG, Measham AR, 
Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington 
(DC): World Bank; 2006. 
68 This intervention package consists of exclusive breast-feeding; vitamin A and zinc supplementation; screening for 
immunization; and case management of pneumonia, malaria, and diarrhoea including oral rehydration therapy. See p.50 of  
Bloom et. al., (2006). 
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between 34 and 163 DALYs in a comprehensive intervention package for the 
management of childhood illnesses.69 These reported cost-effectiveness analyses are 
for costs in developing countries. The costs for cancer treatment in a high-income 
country are higher. These examples are a few illustrations of the many investments in 
health interventions most needed in the worst-off populations, which are more cost-
effective than health interventions most needed in populations who are better off. We 
could plausibly save hundreds, if not thousands of lives investing in child health 
interventions in sub-Saharan Africa for the same cost as if we were to invest in 
extending the life of one (or maybe a few) late-stage cancer patient(s) living in a 
high-income country such as the United States for a few years. If we follow the 
utilitarian goal of packages of interventions that attain the greatest health 
improvements for the most people at the lowest cost, then, in most cases, we should 
allocate scarce resources to the worst-off. This is because the worst-off typically 
suffer the greatest disease burden and one is required to invest relatively little 
compared with the outcome. The worst-off benefit more from an equivalent 
investment of resources. 
Under the egalitarian principle, our goal is to produce the most equal distribution of 
global health. Life expectancy is a relatively good indicator of socio-economic 
development and is vital for understanding the health situation in a country (78). 
There are variations in life expectancy among social classes within countries (79). 
Globally, there are also variations in life expectancy by region and country. People 
living in low-income countries tend to have lower life expectancies than people living 
in middle- and high-income countries. Variation in life expectancy is an indicator for 
inequality in health. The most efficient way of closing the gap in global life 
expectancy (without levelling down) would be to save the people who are dying 
youngest i.e. those who have the lowest life expectancy. Allocating resources for 
                                            
69 One DALY is almost always worth more than one year of life saved. The data used in these examples comes from the 
DCPP, and some are reported as $ per DALY averted, while others are reported as $ per year of life saved. The difference 
in the measures used does not undermine the argument put forward here; in fact, it actually serves to strengthen it. In 
essence, 1 DALY could be considered more valuable than one year of life saved. The year of life saved measure fails to 
capture the morbidity and disability that are also important aims of health interventions. So one year of life saved might not 
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health interventions to the worst-off is likely to increase overall life expectancy 
within these populations. Equality overall would therefore be increased. Returning to 
the examples above, let us imagine that we have $100,000 to invest in increasing 
equality of life expectancy. An intervention package for the management of 
childhood illnesses in sub-Saharan Africa costs US$38 per DALY averted.70 For 
$100,000 we could therefore, theoretically, avert 2632 DALYs.  Initial treatment for 
the more treatable cancers71 in low- and middle-income countries is reported to cost 
between US$1,300 and US$6,200 per year of life saved (58, p.46). For $100,000 we 
could therefore, at a maximum, save 77 years of life.72 Treating childhood diseases is 
likely to increase overall life expectancy far more than treating cancers. The increase 
in life expectancy in children in the worst-off populations will have a greater impact 
on equality of life expectancy than if we were to devote the same monetary 
investment to extend the lives of a handful of better off, and generally older, cancer 
patients by a few years. 
I have argued that investing in the worst-off for health interventions is the best way to 
treat a set of people fairly, most of the time, since in most cases, following this 
prioritarian principle is also the best way to promote or serve both the utilitarian and 
egalitarian principles. It results in maximising overall health and increasing equality 
in health. 
 
                                                                                                                                       
necessarily be one year of “healthy” life. The disparity in the cost-effectiveness analyses listed above therefore might be 
even greater than these numbers would initially suggest. 
70 This intervention package includes exclusive breast-feeding; vitamin A and zinc supplementation; screening for 
immunization; and case management of pneumonia, malaria, and diarrhoea, including oral rehydration therapy. See p.50 of 
Bloom BR, Michaud CM, La Montagne JR, Simonsen L. Chapter 4: Priorities for global research and development 
interventions. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control 
priorities in developing countries. 2nd ed. Washington (DC): World Bank; 2006. 
71 Cancers of the cervix, breast, oral cavity, colon, and rectum. 
72 The data used in these examples comes from the DCPP, and some are reported as $ per DALY averted, while others are 
reported as $ per year of life saved. The difference in the measures used does not undermine the argument put forward here; 
in fact, it actually serves to strengthen it. In essence, 1 DALY could be considered more valuable than one year of life 
saved. The year of life saved measure fails to capture the morbidity and disability that are also important aims of health 
interventions. So one year of life saved might not necessarily be one year of “healthy” life. The disparity in the cost-
effectiveness analyses listed above therefore might be even greater than these numbers would initially suggest. 
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4.1.2 Allocating scarce resources for health research 
It is plausible to think that if investing in health interventions for the worst-off would 
be best, then investing in health research for the worst-off would also be best, since 
the objective of health research is to develop interventions that would enhance health 
and contribute to improved welfare.73 Applying the prioritarian principle, where our 
goal is to prioritise the global worst-off, we would target our limited global health 
research investments towards research that is most needed in these worst-off 
populations. Since the purpose of health research is to develop or adapt interventions 
that would enhance health, and since in most cases investing in health interventions 
for the worst-off is also the best way to promote or serve both the utilitarian and 
egalitarian principles, focusing on the research needs of the world’s poorest will 
likely also tend towards maximizing the total health benefits and increasing global 
health equality. 
A possible objection to this line of reasoning is that many of the diseases that burden 
the worst-off populations already have existing cures and proven interventions. Since 
this is the case, further research is not needed in many of these disease groups. 
Returning once again to the example of childhood illnesses above, someone might 
argue that there are not only existing intervention packages for childhood illnesses, 
but also cost-effective intervention packages. Treating non-severe pneumonia at 
health care facilities using a combination of oral antimicrobials and acetaminophen 
costs US$24 to US$424 per DALY averted. The more integrated intervention 
package for childhood illnesses costs approximately US$38 per DALY averted (58, 
p.50). Both of these intervention options represent examples of cost-effective 
approaches to improving health in children in low-income settings. If we already 
have these cost-effective interventions for the very diseases that affect the worst-off, 
and if these interventions are available and in use in other parts of the world, then it is 
                                            
73 The difficulty here is to show that investments in research will actually have an impact on health. For the purposes of this 
chapter, I assume that research into a particular disease is liable to benefit people with that disease. Where there is data that 
deviates from that model, I will of course take this into consideration. Otherwise this assumption is warranted, since it is 
plausible that there is research, cost-effective and feasible, that will improve health in low-income settings. 
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not research that we need. We should instead direct this research funding elsewhere, 
to other disease categories.74 
However, even though in some cases the first part of this statement is correct, it does 
not follow that because interventions exist and are in use in high-income countries, 
that these same interventions are successfully reaching and benefiting the worst-off 
populations that need them most. As evident from the priorities set by low-income 
countries, for example in Africa, there is in fact still a need for research into many of 
these disease areas. In particular, there are two types of research that are needed in 
low-income settings, even when there are successful interventions already available 
and in use in other parts of the world. The first is implementation and health systems 
research (56). These contribute to building the capacity of health systems themselves 
and enable effective uptake and scale-up of established interventions that we already 
know improve health elsewhere. For the world's poorest people, the benefits of these 
particular types of health research offer a potential for change that has gone largely 
untapped. Many who are poor lack access to basic health interventions that could 
save them from premature death and protect their ability to earn a living. However, in 
general not enough investment has gone into research to ensure successful 
implementation of these existing health interventions. We need more implementation 
and health systems research in low-income settings to improve the efficiency of 
available interventions. The second type of research needed for the global worst-off is 
research into products and technologies that have yet to be developed for use in low-
income settings. These include lower cost medicines, diagnostics, delivery 
technologies and devices that would be more relevant to the specific disease 
conditions and economic environments of poor countries. These two types of 
research, which would enable poor populations in diverse contexts to apply solutions 
                                            
74 It is also possible that, sometimes, countries just lack the money to implement interventions that we are pretty certain 
would work. In these cases, what may be needed is aid. Alternatively, it might be that practitioners don’t know about what 
they should do because the research findings didn’t get to them. This WHO Bulletin details some of these issues: 
http://www.scielosp.org/scielo.php?pid=S0042-96862004001000005&script=sci_arttext. I acknowledge these possibilities. 
However my focus here is on the need for research, and there’s a compelling case to be made for doing different kinds of 
research to address the problems in lower income countries.  There may also be a compelling case for more aid to be 
distributed to lower-income countries, but assuming that countries have already made allocations between research and aid 
budgets that are justifiable, I am focusing on the allocations within research budgets. 
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that are already available elsewhere, are no less important than biomedical research, 
and are extremely valuable to improve the effectiveness of existing programs, 
optimise efficiency, and effectively transfer interventions from one setting to another. 
They are also in many cases cheaper or more cost-effective than biomedical 
research.75 
Allocating scarce health research resources to more cost-effective health research 
produces a larger overall health benefit than an equivalent resource investment in less 
cost-effective research. Investing in the cost-effective health research most needed by 
the worst-off therefore maximises total benefit, promoting the principle of health 
maximisation. The types of health research needed in the world’s worst-off 
populations are also targeted at those populations with the lowest life expectancies. 
As stated earlier, variation in life expectancy is a marker for inequality in health. 
Narrowing the gap in global life expectancies therefore increases global health 
equality. Allocating scarce health research resources to those with the lowest life 
expectancy is therefore the most efficient way of increasing global health equality. It 
follows that investing in the worst-off increases global health equality, promoting the 
equality principle. Successful implementation of the products of these two types of 
health research relevant to the worst-off would therefore be analogous to the 
successful implementation of health interventions for the worst-off. It would serve to 
maximise total health benefits and increase global health equality. Prioritising the 
worst-off is then surely the fairest way to allocate scarce health research resources, at 
least in most cases. 
Ultimately, no principle is sufficient on its own to recognise all morally relevant 
considerations applied to all cases. There will invariably be a certain number of cases 
where not all the plausible principles for allocating resources coincide in their 
judgments i.e. in these cases, adhering to the prioritarian principle does not serve to 
maximise total health benefits and increase global health equality. One example is 
                                            
75 For example, the Global Fund encourages fund recipients to devote 5–10% of their budget to monitoring & evaluation 
(which may include implementation research). 
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that of “resource black holes,” a situation in which no matter how many resources are 
invested into a particularly badly-off person or population, there is little to no 
improvement in health outcomes. In these cases the right way to allocate resources 
might involve limiting one’s investment in the “resource black hole” so that other 
people also receive a share of the available resources. So while the argument in this 
chapter provides a principled commitment to assisting the worst-off, this commitment 
could be overridden when groups are especially expensive to assist. Investments 
should discriminate in favour of the worst-off who can be cheaply helped and thus 
against badly-off people whom it would be really expensive to help. This entails a 
willingness to, for example, prioritise the second-worst-off group over the worst-off 
group if the gains in overall health benefits would be much greater. However, these 
cases are rare; for the most part investing in the worst-off is the right way to allocate 
limited resources for health research. 
 
4.2 Who are the worst-off? 
In section 4.1, I argued that in most cases of scarce resource allocation for health 
research, prioritizing the worst-off is the fairest way to treat the global population, 
since it is also serves the other two principles. In this section I outline which 
populations are likely to be representative of the world’s worst-off, as well as point to 
some of the health research priorities for these populations. 
Defining exactly who are the global worst-off is complex. Those who are worst-off 
might be thought to be those who are poorest, or those whose health is the most 
severely affected. In some cases almost the whole population of a country might be 
neatly classified into the category of the world’s worst-off. In other cases it might be 
only a segment of a country’s population. This will be the case for many countries 
where there are distinct populations, some wealthy, some middle-income and some 
absolutely poor, such as India and South Africa. In section 4.1, I argued that directing 
our limited health research resources to populations in low-income countries would 
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be a way of adhering to the prioritarian principle. This is true whether we define the 
worst-off as those populations who are poorest, or as those populations who are 
sickest over a lifetime. At first glance it makes sense to think that the diseases 
affecting the worst-off might be fairly represented by the diseases affecting the 
category of low-income countries. I argue instead that the disease burden of the 
global worst-off is much more accurately represented by a smaller set of people than 
all those who live in low-income countries. This is because while the category of 
low-income countries would certainly include within it populations of people who are 
among the global worst-off, it is also likely to include other, better-off populations as 
well. Since this is the case, and since we want to focus our limited resources on the 
worst-off, it is helpful to delineate this narrower population representative of the 
worst-off.  
In the following section, I attempt to delineate a group of people that we are certain 
are amongst the worst-off and that can therefore serve as a population representative 
of the global worst-off. In section 4.1, I located health as an important component of 
overall well-being and wealth as a key indicator of well-being. Given this, it is 
certainly true that those populations who are the poorest economically, and who have 
the poorest health indicators, are among the worst-off. There are a small number of 
countries, almost all in Africa, whose population almost exclusively consists of 
people in this category. Africa is home to 18 of the world’s 20 poorest countries by 
GDP (80). Africa also bears the largest burden of disease and death in the world 
(Figure 4.1). 
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Figure 4.1 YLL, YLD and DALYs by region (2004) 
 
Source: WHO Global Burden of Disease 2004 Update. Available at: 
www.who.int/healthinfo/global_burden_disease/2004_report.../en/ Figure 20: YLL, YLD and 
DALYs by region, 2004 p.41. 
 
Note: DALYs for a disease or health condition are calculated as the sum of the Years of Life Lost 
(YLL) due to premature mortality in the population and the Years Lost due to Disability (YLD) 
for incident cases of the health condition 
 
Table 4.2 provides a visual mapping of the world’s economically poorest countries 
that also suffer the largest numbers of DALYs and deaths. The DALYs and death 
rates in all three categories in this table are extremely high by global standards. As a 
comparator, the US suffers <15 DALYs per 1000 population and <649 deaths per 100 
000 population. When we map poverty against health indicators in this way, we see 
twelve African countries that are both amongst the twenty poorest countries by GDP 
and suffer the worst health as indicated by their significantly high DALYs and death 
rates. 
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Table 4.1 Mapping a population representative of the worst-off 
 
Health Indicators 
>45 DALYs per 1000 pop 
AND 
>1850 Deaths per 100 000 pop 
 30-45 
AND 
1350-1850 
20-29 
AND 
980-1350 
20 poorest countries 
by GDP 
Burkina Faso 
Burundi 
CAR 
DRC 
Liberia 
Malawi 
Mali 
Niger 
Rwanda 
Sierra Leone 
Uganda 
Zimbabwe 
 
Ethiopia 
Guinea 
Madagascar 
Mozambique 
Togo 
Nepal 
Haiti 
Eritrea 
Better off populations 
(not among 20 poorest 
countries) 
Afghanistan 
Angola 
Botswana 
Chad 
Cote d’Ivoire 
Equatorial 
guinea 
Guinea Bissau 
Iraq  
Kenya (30-45 
DALYs) 
Lesotho 
Nigeria 
Somalia 
South Africa 
Swaziland 
Tanzania 
Zambia 
 
Benin 
Ghana 
Mauritania 
Namibia 
Sudan 
 
Bangladesh 
 
     
A population representative of the worst-off (12 countries with the poorest health and wealth) 
 
 
Source: I sourced data for this table from: WHO. (2010). Age standardised death rates 2004. Available 
at: http://gamapserver.who.int/mapLibrary/Files/Maps/Global_asdeaths_2004.png; and 
McInTyre D, Stockdale C, Sauter B. The Twenty Poorest Nations in the World. 24/7 Wall St.; 
2010 [cited 2010 October 12]; Available from: http://247wallst.com/2010/07/06/the-twenty-
poorest-nations-in-the-world/  
 
While the populations in these countries do not constitute all those who are worst-off, 
they are likely to be representative of worst-off populations. Mapping out the health 
issues most severely affecting this representation of the worst-off will allow us a 
clearer idea of the health issues unique to worst-off populations, and distinct from 
some of the health issues that affect other, better-off populations. 
 
4.2.1 What is the disease burden of the worst-off? 
In the following section, I use available data to broadly map out the major disease 
burden of the twelve countries identified in Table 4.2. I have labelled the composite 
data for these twelve countries “worst-off” - representing those who fall within the 
categories of both poorest health and poorest wealth. In each case, the reported 
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numbers for the category “worst-off” is an average of the data for the twelve 
countries combined (see Appendix B for detailed health statistics). The comparisons 
that follow give us an idea of the major disease players in this population. 
Figure 4.2 below shows the distribution of years of life lost (YLL) by major cause of 
disease burden i.e. either by communicable diseases, non-communicable diseases or 
injuries. The years of life lost in high- and middle-income countries are dominated by 
non-communicable causes, with communicable diseases and injuries accounting for a 
much smaller proportion. The opposite is true for low-income countries where most 
years of life lost are due to communicable diseases (approximately 70%). The 
distribution of years of life lost in Africa, while more similar to low-income countries 
than to high- and middle-income countries, is still distinct from the distribution in 
low-income countries as a whole. Close to 80% of years of life lost are due to 
communicable diseases and only around 15% are due to noncommunicable; there is 
noticeably less noncommunicable disease burden in African countries than in the 
broader category of low-income countries. The distribution of causes in the worst-off 
is more similar to Africa’s distribution of causes than to that of any other group, 
including that of low-income countries. Communicable diseases dominate the 
landscape, accounting for 80% of the total years of life lost amongst the worst-off. 
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Figure 4.2 Distribution of years of life lost (YLL) by broader causes for 
selected regions and income groups (2008) 
 
Source: I sourced data for this figure from: World Health Organisation (2011). World Health Statistics 
2011: Distribution of years of life lost by broader causes (%) in 2008. WHO Press: Geneva. 
Available online: http://www.who.int/whosis/whostat/2011/en/index.html  (pages 58-76). See 
Table in Appendix B for raw data. 
 
In this analysis, the 12 countries representing the worst-off in the world are all 
African countries. One can imagine that the distribution of disease burden of the 
worst-off sub-populations in other parts of the world might be fairly distinct from the 
worst-off in the world. Since these 12 countries are all in Africa, we can anticipate 
that their disease burden is most similar to Africa’s regional statistics. We might also 
anticipate that the worst-off populations in other parts of the world might have a 
somewhat different distribution than that of my selected sample. For example, close 
to 40% of the total years of life lost in the WHO’s South East Asia region are due to 
noncommunicable diseases. Given this, it might be that the worst-off in South East 
Asia suffer a similar distribution of disease burden to South East Asia’s regional 
statistics.76 There is no data specifically for the worst-off subpopulation in South East 
                                            
76 This regional statistic might however be swayed by the large population of India, whose population (like South Africa’s) 
is composed of a mix of worst-off, low-, middle- and high-income subpopulations. It is likely that large, better-off, 
subpopulations in larger countries like India pull the South East Asia regional statistics in one direction, to show a greater 
proportion of noncommunicable diseases. The worst-off in this region might therefore have a different distribution of 
disease burden than that of the regional South East Asia statistic. 
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Asia, but Bangladesh could serve as a good proxy for the worst-off in the region. 
Figure 4.3 maps the distribution of years of life lost for Bangladesh compared to 
selected regions and income-groups. Bangladesh’s distribution of years of life lost 
(52% communicable, 34% noncommunicable, 14% injuries) is more similar to that of 
the regional distribution for South East Asia (49% communicable, 36% 
noncommunicable, 15% injuries) than to that of Africa’s worst-off (81% 
communicable, 12% noncommunicable, 7% injuries). 
 
 
 
Figure 4.3 Distribution of years of life lost (YLL) by broader causes: 
Bangladesh compared to selected regions and income-groups 
(2008) 
 
Source: I sourced data for this figure from: World Health Organisation (2011). World Health Statistics 
2011: Distribution of years of life lost by broader causes (%) in 2008. WHO Press: Geneva. 
Available online: http://www.who.int/whosis/whostat/2011/en/index.html  (pages 58-76). See 
Table in Appendix B for raw data. 
 
Since there are still a significant proportion (52%) of years of life lost among the 
South East Asian worst-off due to communicable disease, it is worth comparing the 
communicable diseases suffered by the worst-off in this region with those suffered by 
the worst-off in Africa. Figure 4.4 shows adult mortality rates for selected 
communicable diseases and indicates similar tuberculosis mortality rates amongst the 
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worst-off in Africa (62 per 100 000) and South East Asia (51 per 100 000). Malaria 
and HIV mortality rates in South East Asia’s worst-off are however negligible 
compared with the high rates in Africa. 
 
 
 
Figure 4.4 HIV, TB and Malaria mortality rates (per 100 000 population) 
 
Source: Cause-specific mortality rate (per 100 000 population) in 2008 for Malaria, in 2009 for TB and 
HIV. World Health Organisation (2011). World Health Statistics 2011. WHO Press: Geneva. 
Available online: http://www.who.int/whosis/whostat/2011/en/index.html (pages 58-76). See 
Table in Appendix B for raw data. 
 
Figure 4.5 shows the distribution of selected communicable causes of death in 
children under five years. Again, malaria and HIV, significant causes of death for 
children in Africa, are almost absent in Bangladesh, our proxy for South East Asia’s 
worst-off. For the worst-off in both regions diarrhoea and pneumonia are significant 
contributors to under-five mortality. 
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Figure 4.5 Distribution of selected causes of death among children <5yrs 
 
Source: I sourced data for this figure from: World Health Organisation (2011). World Health Statistics 
2011: Distribution of years of life lost by broader causes (%) in 2008. WHO Press: Geneva. 
Available online: http://www.who.int/whosis/whostat/2011/en/index.html  (pages 58-76). See 
Table in Appendix B for raw data. 
 
From the data presented above, two important observations are apparent:  
1) The disease burden in Africa’s worst-off is different from that of worst-off 
populations elsewhere, in this case South East Asia. 
The most apparent difference is that the worst-off in South East Asia suffer a much 
higher proportion of noncommunicable disease than the worst-off in Africa, who are 
burdened predominantly by communicable diseases. The communicable disease 
category in South East Asia is still significant, and within this category there is some 
overlap with the disease burden of the worst-off in Africa. Pneumonia and diarrhoea 
are leading causes of death among children under five years for the worst-off in both 
regions and tuberculosis adult mortality rates are similar amongst the worst-off in 
both regions. The striking difference is that malaria and HIV, which heavily burden 
the worst-off in Africa, are negligible contributors to disease burden for South East 
Asia’s worst-off. 
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2) The disease burden in Africa’s and South East Asia’s worst-off is different from 
the disease burden in the broader category of low-income countries 
While it might be easy to assume that low-income country data is a good 
representation of the worst-off, the disease burden for low-income countries is a mix 
of those of the subpopulations within these countries. Some subpopulations are 
poorer and some are richer, and large sub-populations that are not amongst the worst-
off skew the “low-income country” disease distribution to include diseases that are 
not those of the worst-off. While specific data for all disease groups is not available 
for Africa’s worst-off, if we look at some of the data that is available, we can see that 
there is a distinction between what the worst-off are suffering from and what low-
income countries are suffering from. The disease burden in Africa’s worst-off is more 
similar to the disease burden for the African region than to the disease burden for the 
category of low-income countries. The disease burden for Bangladesh, our “worst-
off” proxy for South East Asia, is also more similar to the disease burden for the 
South East Asian region than to the disease burden for low-income countries. This 
data suggests that the worst-off in Africa are not most accurately represented by the 
broad category of low-income countries, but rather are more accurately represented 
by the statistics available for Africa. Therefore, if South Africa or other nations want 
to focus resources on the worst-off in Africa, they will do better to focus resources on 
the regional health research priorities than on the priorities for low-income countries 
as a whole. Likewise, an entity that wants to focus on the worst-off in South Asia will 
do better to focus resources on the regional health research priorities for this region. 
In chapter two I argued that South Africa is permitted to focus on the worst-off in 
Africa. For this reason, the rest of this section will focus exclusively on the worst-off 
in Africa. If we accept that the disease burden of Africa’s worst-off is most similar to 
that of the African region, then in cases where there is not data available for the 
worst-off, African77 data can be used as a more representative proxy than the broader 
                                            
77 Statistics for the WHO African Region include data from all the sub-Saharan African countries (except for Sudan, 
Djibouti and Somalia). In addition they include data from one country outside of sub-Saharan Africa, Algeria. The WHO 
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category of low-income countries.78 The next section provides an overview of the 
distribution of death by different diseases in Africa, pointing to how this distribution 
is distinct from the distribution in low-income countries and mapping out which 
specific diseases are major players (measured in DALYs) in the African region. Since 
the data for Africa can be used as a reasonable proxy for the data on the worst-off in 
Africa I will from here on refer to “worst-off proxy” when describing these data. 
 
 
 
Figure 4.6 Distribution of death by specific diseases 
 
Source: I sourced data for this graph from: WHO deaths LMIC by region 2004 
http://apps.who.int/ghodata/?vid=100001; and WHO deaths by World Bank income group 
http://apps.who.int/ghodata/?vid=100001 
 
When we look at the overall distribution of death by specific diseases, the worst-off 
predominantly die of infectious diseases. Figure 4.6 again confirms that the burden of 
disease in the worst-off is not the same as the burden of disease in low-income 
                                                                                                                                       
data for “Africa” essentially represents sub-Saharan Africa, rather than the broader African region. See Appendix A for a 
map and list of countries in the WHO African Region.  
78 The WHO Global Burden of Disease Report provides the most recent and detailed data on burden of disease by region 
and by income sector. They do not categorise the worst-off as an independent income sector, but they do in many cases 
provide data on the African region. 
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countries. There is certainly not the same proportion of non-communicable disease. 
In low-income countries the top four causes of death are lower respiratory infections, 
ischemic heart disease, diarrheal disease, and HIV. Cerebrovascular disease is a close 
fifth. This represents a mix of both infectious and non-communicable disease. 
However, in the worst-off the four top causes of death are all infectious diseases: 
HIV, lower respiratory infections, diarrheal disease and malaria. Non-communicable 
diseases do feature as causes of death in this population, but account for a very small 
proportion. The proportion of deaths from infectious diseases far exceeds that from 
non-communicable diseases. 
 
 
 
Figure 4.7 Distribution of age at death by region 
 
Source: p.9 of World Health Organisation (2008). The Global Burden of Disease: 2004 update. 
Available online: 
http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html 
 
Figure 4.7 shows the distribution of death for different age groups by region. Over 
80% of deaths in high-income countries are people aged 60 years and older, yet only 
20% of deaths in the worst-off countries are people in the same age category. This is 
because in high-income countries death takes the old, but in the worst-off countries 
death takes the young. Almost 50% of deaths in the worst-off countries are children, 
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most of which are children under 5 years. This is a large proportion compared to 
high-income populations where close to 1% of all deaths are children. What is clear is 
that young children in the worst-off populations have a proportionally greater disease 
burden than any other age group. Dying as a child is worse than dying as an older 
person because dying as a child means losing more potential life. You are worse-off 
if you have fewer years of life than if you have more, so if a person lives to a 
relatively healthy 60 years and then falls ill, he or she is not one of the worst-off (81). 
If we accept that dying as a child is worse than dying as an older person, and if 50% 
of the disease burden among the worst-off are children, then prioritising these 
diseases would certainly be in line with the prioritarian principle. Figure 4.7 shows 
the child mortality rate in Africa (our proxy for the worst-off) compared to other 
regions. Respiratory and diarrheal diseases constitute a significant proportion of child 
mortality in the worst-off. In fact, around 20% of the under-five mortality rate is from 
diarrhoea and another 20% is from pneumonia.79 Malaria and perinatal deaths are 
also leading causes of death amongst children under 5 years. 
 
                                            
79 These percentages reflect the data in the table in Appendix C. This is aggregate data for the 12 countries representative of 
the worst-off. Data for this table was sourced from: World Health Organisation (2011). World Health Statistics 2011: 
Distribution of years of life lost by broader causes (%) in 2008. WHO Press: Geneva. Available online: 
http://www.who.int/whosis/whostat/2011/en/index.html  (pages 58-76). 
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Figure 4.8 Child mortality rate by cause and region (2004) 
 
Source: World Health Organisation, Health Statistics and Informatics Department (2004). Global 
Burden of Disease 2004 Update: Selected figures and tables. Available at: 
http://www.who.int/topics/global_burden_of_disease/en/ 
 
Deaths directly attributable to malaria occur almost entirely in the African region, 
representing 16% of all under-five deaths in the region. HIV and measles are also 
important causes of death in the “other” category. Pneumonia, diarrhoea, malaria and 
neonatal complications are easily avoidable causes of death in children. 
 
4.2.2 What are the health research priorities of the worst-off? 
Earlier in this section I stated that if we accept that the disease burden of the worst-
off in Africa is most similar to the regional statistics for Africa, then in cases where 
there is not data available for the worst-off, African data can be used as a more 
representative proxy than data from the broader category of low-income countries. 
Here I assume that a similar line of argument applies to health research priorities. If 
we accept that the disease burden of the worst-off in Africa is most similar to that of 
Africa, then we might accept that the health research priorities of the worst-off in 
Africa are most similar to those for Africa. Then, since we do not have a list of health 
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research priorities for the worst-off in Africa, the health research priorities for Africa 
can be used as a more representative proxy than the health research priorities for the 
broader category of low-income countries. 
In chapter 3 I reported that there has been one priority-setting exercise conducted for 
the African region. Table 4.3 shows the key domains for health research identified at 
a high-level ministerial meeting on health research in Africa in Abuja in 2006 (48). 
These key domains for health research are the only list of health research “priorities” 
available for the region. They are broadly aligned with the burden of disease in the 
region. Mapped against DALYs for the region, we can see that items one through 
three dominate the agenda. The top three health research priorities for the worst-off 
are infectious diseases, reproductive and sexual health, and child health. 
 
Table 4.2 Priorities for health research mapped onto disease burden, Africa 
(2006) 
 
Key domains for health research in Africa DALYs % of total DALYs 
    1 Infectious diseases,  
including malaria, tuberculosis, HIV and AIDS, emerging 
infections and neglected tropical diseases (e.g. African 
trypanosomiasis, Buruli ulcer, leishmaniasis and lymphatic 
filariasis) 
177.5 47.1
2 Reproductive and sexual health 24.7 6.6 
3 Child health 25.9 6.9 
4 Non-communicable diseases,  
including cardiovascular disease, diabetes, cancers, sickle 
cell disease, injuries etc. 
15.6 4.1 
5 Malnutrition 7.1 1.9 
6 Mental health, 
 including drug and substance abuse 
5.7 1.5 
 
Health research on non-communicable diseases is also listed but represents only 4% 
of the disease burden in the worst-off. This is significantly different from the broader 
category of low-income countries, where around 20% of disease burden is due to 
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non-communicable disease.80 Low-income countries suffer a dual burden of disease 
and investment in non-communicable disease research that is specifically targeted at 
low-income country needs is important. However, if we were to have limited funds 
for health research and would like to direct these funds at research to benefit the 
worst-off, then non-communicable diseases may not be a top priority.81 
 
4.2.3 What types of health research are most needed for the worst-
off? 
Table 4.3 gives us a good sense of the health research priorities for the worst-off by 
health area or disease category. We know, however, that even within a specific 
disease, the types of research needed in low-income settings might be different from 
the types of research being conducted in higher-income settings. For example, in 
chapter three I presented data to show that less than one fifth of total U.S. 
investments in HIV research were specifically targeted at developing country needs. 
So, only a small percentage (17%) of total funding into a disease that affects 
predominantly low- and middle-income countries is actually spent on the research 
and development needed in these low- and middle-income countries. The majority of 
the funding we can assume is directed to HIV/AIDS research targeted at high-income 
markets. This example illustrates that if health research is to truly meet the needs of 
the worst-off, it is not only important for global health research funding to be directed 
at particular diseases, but also at particular types of research related to those diseases. 
In chapter three I argued that low-income countries specifically need three types of 
research: 1) research into products that can be used specifically in low-income 
settings i.e. products that are more affordable, accessible, or less dependent on hi-tech 
infrastructure; 2) implementation research to ensure that already existing 
interventions are successfully integrated into resource-poor health systems; and 3) 
                                            
80 See Figure 4.3 in the previous section. 
81 There will always be a trade-off between meeting current health research needs and generating future health benefits. 
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research to improve health systems themselves. Below I outline a few examples of 
the types of health research needed for some of the diseases most heavily burdening 
the worst-off. This is not a comprehensive overview or list of the health research that 
should be prioritized for this population, it merely demonstrates that there is evidence 
out there that could be used to ensure a better distribution of funding to the types of 
research that are needed the most in this population. 
For the first category of product development, Kaplan and Laing (2004) articulate a 
useful set of distinctions for identifying pharmaceutical gaps in global research. 
Where there are pharmaceutical gaps, health interventions and treatments either do 
not exist (lack of basic scientific knowledge or limited market value/market failure) 
or are inadequate (lack of efficacy, safety concerns, or the delivery mechanism or 
formulation is not appropriate for the target group). Many of the health interventions 
most needed by the worst-off fall into the latter category. In some the biology of the 
disease is well understood but interventions have limited market value. Kaplan and 
Laing list malaria, tuberculosis, trypanosomiasis, and leishmaniasis in this category. 
In others the biology is complex and there is limited market value. Orphan diseases 
and some neglected diseases like Buruli ulcer are listed in this category. 
For many of the diseases that predominantly affect the worst-off, successful 
interventions and products already exist and are readily available in high-income 
settings. However, these interventions do not reach the worst-off. Two of the more 
obvious examples are pneumonia and diarrheal diseases, the two biggest killers of 
children under 5 years old. Africa and South East Asia experience the highest burden 
of mortality due to pneumonia and diarrhoea, and, according to the World Health 
Statistics Report for 2011, include numerous countries that are not on track to achieve 
the Millennium Development Goal 4 target of reducing child mortality by two-thirds 
(82). This is not because there are no successful interventions available to combat 
these diseases; it is rather a result of inadequate coverage of crucial child health 
interventions against them. Oral rehydration therapy and zinc for diarrhoea, and case 
management with antibiotics for pneumonia are effective interventions. Most child 
deaths due to pneumonia and diarrhoea could be avoided if effective interventions 
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were implemented on a broad scale and reached the most vulnerable populations. The 
types of research that are most needed in these cases are implementation research on 
how to successfully integrate these existing interventions into local contexts, and 
health systems research to ensure successful integration and scale-up of interventions 
into a country’s health infrastructure. 
If we would like to prioritise the worst-off, then we should focus our resources on 
Group I causes. Effective interventions for many of these diseases exist and have 
successfully lowered the disease burden, and in some cases entirely eradicated these 
diseases, in many wealthier populations around the world. The health research most 
needed for these disease categories is implementation and health systems research on 
how to effectively implement existing interventions in the worst-off populations. To 
ensure that we successfully direct resources to the worst-off, the key here would be to 
adequately distinguish what proportion of global funding is directed towards these 
specific types of research needed in the worst-off populations, rather than merely 
look to the total amount of global spending directed at any particular disease group. 
 
4.3 Applying the prioritarian principle to current methods of 
priority-setting 
In section 4.1, I argued that the best way to treat a set of people fairly, most of the 
time, is to prioritise the worst-off. To determine whether global health research 
priority-setting methods are adhering to this prioritarian principle, we need to assess 
whether their recommended priorities for health research are aligned with the actual 
health research priorities of the worst-off. In section 4.2, I defined a population that is 
likely to be representative of the worst-off in Africa and identified some of the health 
research priorities relevant to this population. In this section I give an overview of 
global health research priority-setting exercises to illustrate that there are common 
processes and methods that have been used over time for setting health research 
priorities to capture some of their central features and results (section 4.3.1). I then 
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analyse a selection of the major exercises conducted by the World Health 
Organisation (WHO) over the last two decades (section 4.3.2). This analysis looks at 
the major disease areas and types of research recommended by the WHO to see 
whether they capture the priorities of the worst-off. 
 
4.3.1 Methods for setting health research priorities 
Scarce health research funding is a challenge for all countries, but is particularly 
acute in low- and middle-income countries, who have limited financial resources to 
fund necessary research themselves and a low priority given to their national health 
problems by the global research community. This dynamic has contributed to the 
striking contrast between the global distribution of sickness and death and the 
allocation of health research funding we see today. In an attempt to effectively utilize 
limited resources for health research and to guide both domestic and foreign research 
investments to the unmet needs of the world’s most disadvantaged, several 
international organisations have conducted global health research priority-setting 
exercises. Since the late 1980’s there have been several attempts by international 
organisations and other less formal groups to set global priorities for health research. 
Because it is considered essential to base health research resource-allocation 
decisions on a rational priority-setting process, many have focused on the 
development of methods for setting health research priorities (see Table 4.1 for a 
comparative overview of some of the major global health research priority-setting 
exercises. See Appendix B for a more detailed overview of each exercise). 
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 Table 4.1 compares the criteria for research priority-setting developed by these 
different groups, along with their aims, results and recommendations. What is 
apparent is that the criteria used by these different groups are similar. The common 
features and criteria of most of the tools and methods for priority-setting include: 1) 
estimates of health problems; 2) identification of gaps in the knowledge about ways 
to eliminate them and of research needed to control them; 3) the possibility of 
addressing the problem through research; 4) the feasibility and cost of the research; 
and 5) the potential outcome, impact and cost-effectiveness of interventions resulting 
from the research. These criteria for priority-setting make sense intuitively, and at 
least provide a framework for health research priority-setting on a global level. The 
question that remains is: Do the priorities recommended by each of these exercises 
point to a fair allocation of resources for global health research? If we accept that the 
fairest way to treat a set of people is to prioritise the worst-off, then in order to 
determine whether global health research priority-setting methods are pointing to a 
fair allocation of scarce resources involves determining whether they are adhering to 
this prioritarian principle.  
 
4.3.2 Have WHO’s global health research priority-setting exercises 
prioritised the worst-off? 
A recent report by the World Health Organisation (WHO) offers an overview and 
analysis of a wide variety of WHO-led research priority-setting exercises since 2005. 
The majority of these exercises were undertaken with a view to identifying global 
health research priorities (83). The review reports that the use of an established 
priority-setting tool was rare and a need for more guidance on research prioritization 
was regularly expressed in discussions with WHO representatives. Additionally, the 
review reports a need, and an expressed demand by WHO staff conducting these 
exercises, for normative work in this area. 
According to my account, if an organization’s goal is to maximize global health 
benefit and increase global health equality, then it should prioritise the health 
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research needs of the worst-off. This prioritarian account offers normative guidance 
for the fairest allocation of scarce global health research resources. I have already 
pointed to some of the diseases affecting the worst-off (section 4.2.1) and, where data 
was available, to some of the health research priorities, and types of research, that 
have been recommended for these disease areas (sections 4.2.2 and 4.2.3). The health 
research priorities of the worst-off are likely most accurately represented by the 
health research priorities of Africa, rather than the health research priorities of the 
broader category of low-income countries. Having outlined what it is we should be 
researching in order to prioritise the worst-off, in the following section I assess the 
results of the major WHO global priority-setting exercises to see to what extent they 
captured these research priorities. Finally, I recommend that future exercises ought to 
focus on a more specific subset of research priorities in order to adhere to the 
prioritarian principle. 
Over the past two decades the WHO has conducted a number of global health 
research priority-setting exercises, each an attempt to guide global health research 
towards the promotion of health development for the world’s underprivileged. The 
first exercise was in 1996. The WHO Ad Hoc Committee conducted a global review 
of health needs and related research priorities in low- and middle-income countries. 
The committee explicitly stated that a central aim underlying the exercise was to 
explore systematic approaches to resource allocation in order to make the best use of 
limited funds. Their focus was on strategic research and on intervention development 
and evaluation, rather than fundamental research. The recommendations that came 
out of this priority-setting exercise included four priority areas: 1) childhood 
infectious disease and poor maternal and perinatal health; 2) continually changing 
microbial threats; 3) non-communicable disease and injuries; and 4) health care 
systems and policy. 
The committee made detailed recommendations within each of the four categories, 
including recommendations for essential packages of cost-effective interventions for 
maternal and child health and the reallocation of funds for microbial threats from 
duplicated testing of therapeutics in the established market economies to the 
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development of affordable and cost-effective interventions in low-income settings. 
The committee also recommended implementation and health policy research to 
improve the efficiency of health care systems in low-income settings. While this 
exercise certainly captured some of the priorities of the worst-off, the scope of their 
recommendations extended beyond these priorities to include detailed research 
recommendations for noncommunicable diseases. The double burden of disease is a 
reality in low-income countries generally, but noncommunicable diseases do not 
feature as prominently in Africa. And since Africa’s disease burden is a more 
accurate representation of the disease burden of the worst-off than that of low-income 
countries, it seems that the large scope of WHO’s recommendations detracts from 
prioritising the worst-off in Africa. If we only have a limited pot of funds to 
distribute, and distributing those funds to prioritise the worst-off is the fairest way to 
treat the global population, most of the time, then the funds would be better spent 
invested more narrowly i.e. in those diseases and types of health research that are 
priorities for the worst-off.82 
The second global health research priority-setting exercise led by the WHO was 
carried out by the WHO Advisory Committee in 1998. The committee’s vision was 
one of global health, reviewing the problems of critical significance to health and 
suggesting ways of using research to contribute to their resolution. They explicitly 
stated that what was needed was a global strategy of concerted action to ensure that 
the required research initiatives were undertaken by the global research community. 
The committee set out to outline the range of research needed for global health 
development and to provide a strategy to mobilise the research community towards 
improving global health. The scope of recommendations for health research was 
therefore very broad, including: respiratory infections, tuberculosis, diarrhoea, 
sexually transmitted diseases, malaria and HIV, tropical diseases (including 
schistosomiasis, onchocerciasis, trypanosomiasis, and leishmaniasis), deadly disease 
outbreaks (e.g. Ebola), noncommunicable diseases, cancer, cardiovascular diseases, 
                                            
82 This is not to say that other types of health research and disease areas in low-income countries are not important. If we 
had a lot more money to distribute, then the relevant types of health research for communicable diseases would not be the 
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other chronic diseases (e.g. diabetes), other health impairments (e.g. blindness, 
hearing impairment, accidents, burns), oral health, and more.  So while the 
recommendations did indeed capture some of the priorities of the worst-off, their 
recommendations were not focused on these, but rather included a plethora of 
research recommendations applicable to a large range of diseases. 
The committee acknowledged that their review highlights a number of research 
opportunities rather than providing an ordered list of priorities. However, if the point 
of this exercise was to give direction to the international health research community, 
it might have been more useful to narrow this list to a set of priorities that can direct 
limited resources in the best way. Again it seems that the broad scope of WHO’s 
recommendations detracts from prioritising the worst-off. 
The third global priority-setting exercise led by the WHO focused exclusively on 
infectious diseases. In 2001, the WHO-IFPMA Working Group on medicines and 
R&D83 convened to identify definitively those infectious diseases that are most in 
need of new medicines or vaccines, and to give some sense of the priority areas for 
additional research. The working group identified some infectious diseases e.g. HIV 
and sexually transmitted diseases, for which they judged that a substantial level of 
research was already underway. They also identified a contrasting group of diseases, 
namely malaria and tuberculosis, which in their view had scientifically tractable 
targets, but insufficient product research.  
Further disease prioritisation revealed a second tier of neglected diseases requiring 
additional research, after malaria and tuberculosis. These included African 
trypanosomiasis, Chagas disease, leishmaniasis, lymphatic filariasis, onchocerciasis, 
and schistosomiasis. African trypanosomiasis, Chagas disease and leishmaniasis were 
identified as those most in need of new research since the existing treatments mostly 
needed multiple administrations, had multiple side-effects and were becoming 
                                                                                                                                       
only thing we should invest resources in. Also, while this applies in the short term, it may change over time. 
83 WHO-IFPMA refers to the working group of the International Federation of Pharmaceutical Manufacturers and 
Associations (IFPMA) and the World Health Organisation (WHO). 
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increasingly compromised by acquired resistance. By contrast, the exercise suggested 
that further research is not needed on pneumonia and diarrhoea as tools are already at 
hand. 
This exercise focused exclusively on infectious diseases, so was on target when it 
comes to the particular category of diseases most severely affecting the worst-off. 
However, its focus was on those diseases in need of new medicines or vaccines and 
so it excluded from the outset particular types of research needed in worst-off 
populations, namely implementation and health systems research. Implementation 
and health systems research are two types of research needed in worst-off 
populations, particularly for diseases like pneumonia and diarrhoea where tools are 
already at hand but are not reaching the populations that most need them. This is then 
an additional area that should be focused on in future exercises of this kind. 
This analysis of three of WHO’s global health research priority-setting exercises 
reveals that recommended priorities match the disease burden of low-income 
countries. Since the health research priorities of the worst-off are narrower than those 
of low-income countries, these exercises recommend certain kinds of health research 
that are not priorities for the worst-off. This suggests that WHO ought to narrow the 
scope of their recommended health research priorities to more accurately reflect the 
health research needs of the worst-off. Similarly, governments with limited resources 
should also narrow their focus to that of the health research priorities of the worst-off. 
Following the guidance of these WHO priority-setting exercises will result in 
governments thinly spreading their limited health research resources across a range of 
disease areas, including some disease categories and types of research that are not 
relevant to the worst-off. If the best way to treat a population fairly is to invest in the 
worst-off, then governments with limited resources, who would like to treat their own 
population fairly, ought to focus their limited health research resources on the health 
research priorities of the worst-off.
 5 Conclusions  
This thesis provides the first account of the duties middle-income countries have to 
the global poor. More specifically, it establishes South Africa’s duty to support health 
research for the global poor. In this concluding chapter, first I summarise my account 
of middle-income country duties to the global poor. Second, I review South Africa’s 
existing health research priorities to examine whether South Africa might already be 
fulfilling its duties in some ways on my account. Third, I recommend “next steps” for 
South Africa. Finally, I offer suggestions for data collection, recommendations for 
future global health research priority setting, and insights on the duties of middle-
income countries more generally. 
 
5.1 South Africa’s duty to support health research for the 
global poor 
In chapter two, I explored whether South Africa only has duties to the poor within its 
borders or whether it also has duties to the poor beyond. Many theories of global 
justice accept that very rich countries have some obligation to those who are poor. 
South Africa, and countries like it, occupy a unique position that has been neglected 
in the global justice literature. A middle-income country might have significantly 
more resources and research capacity than low-income countries, but still struggle to 
meet internal needs that high-income countries have largely addressed. It is therefore 
not immediately apparent what the global justice duties of middle-income countries 
should be. I set out two questions that lie at the heart of determining South Africa’s 
duties to the global poor. The first question, which I labelled the general allocation 
question, asked, “What is the best way to treat a set of people fairly?” I made the 
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assumption in chapter two that, in most cases, investing in the worst-off84 is the 
fairest way to treat a set of people when allocating scarce health research resources, 
since, in most cases, adhering to this principle also serves to maximise total health 
benefits and increase global health equality. I defended this assumption in chapter 
four. 
The second question, which I labelled the global justice question, asked, “Who 
counts from the standpoint of justice?” Addressing this question determined to which 
populations South Africa has duties, including those outside of its borders. I reviewed 
statism, nationalism and cosmopolitanism and presented their respective takes on 
how principles of global distributive justice ought to apply. I then set out what I 
believe is a plausible interpretation of each of their positions regarding how the 
limited resources of a middle-income country ought to be distributed. Each position 
delineates which set of people count, and therefore which set of people has a claim on 
South Africa’s resources. Assuming that, in most cases, prioritising investment in the 
worst-off results in treating this set of people fairly, the absolutely poor within this set 
are then prioritised. Cosmopolitans recognise equal justice duties to the absolutely 
poor domestically and abroad. Moderate statists might also recognise equal justice 
duties to both. Strong statists and nationalists, however, insist that priority is given to 
the absolutely poor within the state or nation. 
Reframing these different viewpoints as two separate questions clarified the scope of 
South Africa’s duties. The first question is: Do political boundaries matter? The 
second: Do allegiances, such as national allegiances matter? I argued that, even if one 
is a strong statist or committed nationalist, there is reason to accept that when 
distributing limited resources to the absolutely poor, duties to foreigners are not 
weaker than duties domestically. Currently, when theorists draw a distinction 
between duties of justice and duties of humanity, they assume that duties of humanity 
                                            
84 The term “worst-off” is sometimes used as an indicator of relative deprivation. In this thesis, my reference to the worst-
off is to the global worst-off. Since the global worst-off are absolutely poor, I do not use “worst-off” as a relative term. 
Those populations who are worst-off are those whose well-being, as indicated by measures of wealth and/or health, is the 
lowest of all populations. Since large sections of the populations of low-income countries survive with the bare minimum or 
less, reliance on an absolute rather than a relative measure of poverty is more relevant. 
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are weaker. The basic assumption is that duties of justice trump humanitarian duties. 
However, when we talk about the absolutely poor, or the world’s worst-off, it could 
be argued that the relevant duty of humanity is the very specific duty to rescue. Those 
living in absolute poverty fall below some absolute standard of what a person should 
have in order to meet their basic needs. When it does not cause death, it still causes 
misery of a kind not often seen in rich nations. If this duty of humanity is in fact a 
duty to rescue those in absolute poverty, either to prevent death or merely allow the 
fulfilment of basic needs, then it is not clear that this duty of humanity is trumped by 
the duty of justice. I argued that the specific duty to rescue is so pressing that it 
trumps duties of justice and special duties to co-nationals, even if other more general 
duties of humanity do not. I concluded that both political boundaries and national 
allegiances are not morally important when determining whom, among the world’s 
worst-off, counts. Political boundaries and national allegiances therefore cannot be 
used to prioritise the needs of some over those of others. Since the specific duty to 
rescue trumps both duties of justice and special duties to co-nationals, cosmopolitans, 
statists and nationalists alike should recognise equal claims to rescue, based on need, 
by all the world’s absolutely poor. The effect of recognizing this rescue duty 
essentially brings the worst-off outside our political borders inside our scope of moral 
concern. As a result, South Africa has equal duties to the worst-off everywhere, both 
inside and outside of its borders. 
Ultimately, a middle-income country cannot meet its duties to everyone who is 
amongst the world’s worst-off. What is needed, then, is an ethically sound method for 
further prioritising the distribution of its limited resources within this population. I 
argue that a morally defensible way for South Africa to prioritise within this set is to 
prioritise the worst-off in sub-Saharan Africa over the worst-off elsewhere. This 
prioritisation of sub-Saharan Africans is not, however, based on political boundaries, 
nor is it based on regional allegiances. It is morally defensible for South Africa to 
prioritise the support of health research for sub-Saharan Africa because it will, in 
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most cases, produce a larger overall benefit. Therefore, although South Africa has 
equal obligations to all the world’s worst-off, it is at least morally permissible for it 
to focus on the worst-off in sub-Saharan Africa. South Africa’s duties to the worst-off 
in the region would be equal to its duties to its own citizens who are among the 
worst-off, and would be prioritised over duties to the worst-off elsewhere. 
 
5.2 Is South Africa currently fulfilling its duty to support 
health research for the global poor? 
In this section, I apply what I have argued in this thesis in order to determine to what 
degree South Africa is currently fulfilling its duty by my account. I briefly consider 
what South Africa’s list of health research priorities would look like if generated by a 
more traditional statist account of justice. South Africa’s currently documented 
priorities are clearly not set according to statist principles, or else malaria would not 
be included. I then review South Africa’s currently documented health research 
priorities to see to what degree South Africa might already be fulfilling its duty to the 
region. 
 
5.2.1 South Africa’s health research priorities according to 
different accounts of justice 
Setting priorities for health research is a way to legitimately decide where limited 
funding for health research ought to be directed. Health research priority setting 
exercises are traditionally conducted within the health ministry of a particular 
country, and are geared towards addressing the most pressing health needs of 
citizens. Thus they implicitly take a statist view of the country’s obligations. If South 
Africa set its health research priorities according to this statist account, these 
priorities would reflect only the health research priorities of South African citizens. 
They would exclude research on diseases that do not affect South African citizens, 
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even if these diseases are very important for other Africans. Based on burden of 
disease estimates for South Africa, health research priorities generated according to 
statist principles would not include malaria, a disease that is not highly prevalent in 
South Africa. Since South Africa’s currently documented health research priorities do 
include malaria, it is clear that they are not set solely according to statist principles 
(Table 5.1). 
On my account, South Africa has equal duties to the worst-off both within and 
outside of its borders, but may prioritise the worst-off in sub-Saharan Africa. If South 
Africa set its health research priorities according to this account, there are two ways 
in which its priorities would be different from the current ones. The first is that the 
list would be narrowed to focus on the worst-off in the region. In chapter 4, I showed 
that infectious diseases, reproductive and sexual health, and child health dominate the 
disease burden of the worst-off and account for 60% of DALYs in the region. Given 
this, the list should be narrowed to prioritise these Group I causes. The second 
difference is that the list would be expanded to include health research that is a 
priority for other Africans, even if it is not a priority for South African citizens. For 
example, malaria, neglected tropical diseases and sickle cell disease would be 
priorities (Table 5.1).85 
 
 
 
 
 
 
                                            
85 For the sake of argument, and to illustrate how my account might be operationalized, this is a simplification. Determining 
which diseases are included in this duty-fulfilling list of health research priorities would require a regional health research 
priority-setting exercise. I discuss this in more detail in section 5.3. 
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Table 5.1 South Africa’s health research priorities according to different 
accounts of justice 
 
Statist account Currently documented My account 
HIV and AIDS HIV and AIDS HIV and AIDS 
Injuries Injuries Injuries 
Tuberculosis Tuberculosis Tuberculosis 
Diarrhoea Diarrhoea Diarrhoea 
Perinatal and neonatal 
mortality 
Perinatal and neonatal 
mortality 
Perinatal and neonatal 
mortality 
Nutrition Nutrition Nutrition 
Common risk factors  
(Hypertension, smoking, 
overweight, alcohol etc.) 
Common risk factors  
(Hypertension, smoking, 
overweight, alcohol etc.) 
Common risk factors  
(Hypertension, smoking, 
overweight, alcohol etc.) 
Cardiovascular diseases Cardiovascular diseases Cardiovascular diseases 
Orphans and child-headed 
households 
Orphans and child-headed 
households 
Orphans and child-headed 
households 
Maternal morbidity and 
mortality 
Maternal morbidity and 
mortality 
Maternal morbidity and 
mortality 
Mental Health Mental Health Mental Health 
Cancer Cancer Cancer 
Malaria Malaria Malaria 
Respiratory infections Respiratory infections Respiratory infections 
Sexually Transmitted 
Infections 
 
Sexually Transmitted 
Infections 
 
Sexually Transmitted 
Infections 
 
  Neglected tropical diseases  
  Sickle cell disease 
 
5.2.2 Doing a lot right: South Africa is already supporting health 
research relevant to the worst-off in the region 
South Africa’s currently documented health research priorities seem to reflect some 
intermediate version of priorities that might be established under each of these 
accounts (Table 5.1). These documented health research priorities, established during 
a series of Essential National Health Research meetings, include at least one of the 
diseases that are relevant to Africa but not South Africa, namely malaria (47). Based 
on prevalence alone, malaria would not be a health research priority for South Africa. 
So, why is South Africa already prioritising malaria research? Is it for self-interested 
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reasons or for so called other-regarding reasons, in this case, to support health 
research relevant to other Africans? 
Since malaria in South Africa is primarily a border and population movement 
problem, some might argue that malaria is targeted as a form of national protection. It 
could be that South Africa’s inclusion of malaria as a health research priority is 
merely a self-interested attempt to prevent malaria from entering the country. 
However, on my account there are also other good reasons for South Africa to 
support malaria research relevant to other African countries. Since South Africa has 
equal duties to all the worst-off in the region, and malaria is a priority for many 
African countries, on my account South Africa is at least partially fulfilling its duty to 
meet the claims of worst-off Africans. 
South Africa is actively pursuing regional collaborations for malaria. The Lubuntu 
Spatial Development Initiative is a collaborative program between South Africa and 
bordering countries, Swaziland and Mozambique.  Malaria control is a core 
component of this regional program. Perhaps more importantly, one of South Africa’s 
National Malaria Policy’s stated goals is “to progressively improve and strengthen 
district, provincial, national and southern African capabilities for malaria control” 
(84, p.4). Since the stated goal is to improve and strengthen capabilities in southern 
Africa, and not just to control malaria, we can assume that South Africa’s reasons 
might go beyond those of self-interested protection. My argument would support 
South Africa in this endeavour. 
South Africa is in fact doing a lot right. In its currently documented health research 
priorities, South Africa already includes the diseases of the worst-off in South Africa, 
which are also the diseases of the worst-off elsewhere in Africa. HIV, tuberculosis, 
diarrhoeal diseases and respiratory infections are examples of diseases that affect the 
worst-off in both South Africa and the broader region similarly. They are documented 
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national health research priorities for South Africa, and health research on these 
diseases is already underway.86 
These actions are however not sufficient, on my account, for South Africa to fulfil its 
duty to the worst-off in the region. This is because South Africa has equal duties to 
all the worst-off in sub-Saharan Africa. If South Africa wants to fulfil these duties 
then other diseases that are priorities for the worst-off in Africa but not South Africa 
should be included in South Africa’s list of health research priorities. At the very 
least, this expanded list ought to include the cluster of neglected tropical diseases and 
sickle cell disease. 
I have not been able to identify a robust priority-setting process that has been carried 
out for the worst-off in the African region.  It is beyond the scope of this thesis to 
conduct an empirical assessment of the research South Africa is currently conducting 
and determine fully whether South Africa is meeting the obligations identified herein.  
Instead, I propose that South Africa engage in a new priority-setting process to better 
meet its obligations to the global poor.  In the following section, I suggest factors that 
ought to be considered in such a priority-setting exercise by a regionally concerned 
South Africa. 
 
5.3 Next steps for South Africa: A regional health research 
priority setting exercise 
Commonly accepted criteria for health research priority setting include: 1) estimates 
of the magnitude and urgency of the health problem; 2) the extent of previous 
research and identification of gaps in knowledge about ways to address the health 
                                            
86 There is a chance that South Africa’s current research effort in these disease areas does not count towards 
fulfilling its duty to the worst-off in sub-Saharan Africa. This would only be true if the type of research South 
Africa is conducting is not likely to benefit the worst-off beyond its own borders. What would need to be 
assessed is whether the type of research being conducted is relevant to the needs of other countries in the 
African region or only to South Africa. 
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problem; 3) the possibility of addressing the problem through health research; 4) the 
feasibility and cost of the proposed health research; and 5) the potential outcome, 
impact and cost-effectiveness of interventions resulting from the proposed research 
(see Chapter 4). While these five principles provide a framework for health research 
priority setting nationally, they equally provide guidance on how to set health 
research priorities regionally or globally. Essentially, the scope of these principles 
depends on who counts from the standpoint of justice. A regionally concerned South 
Africa would need to adapt these criteria and apply them to a broader regional 
priority setting exercise. 
In chapters three and four it became apparent that health statistics about the worst-off, 
as well as data on global investments in health research for the worst-off, are scarce. 
For many diseases, data has not yet been collected or reported, or has only been 
reported for a selection of countries or funders. In the following section, I summarise 
the data presented in chapters three and four. This data points to how South Africa 
might begin to fulfil its duties to the worst-off. What follows is by no means an 
exhaustive discussion of what ought to be considered in a regional priority-setting 
exercise. Rather, based on available data, I have selected three of the five commonly 
accepted criteria for health research priority-setting to develop illustrative examples 
of the next steps South Africa ought to take. The first is the magnitude and urgency of 
the disease burden regionally. The second is the extent of previous global research 
into these health problems and the identification of gaps in knowledge about ways to 
address them. This also includes a snapshot of the current global investment in these 
health problems, and a sense of which health problems are currently underfunded 
relative to others. The third is the feasibility and cost of proposed research, in this 
case limited by South Africa’s capabilities. 
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5.3.1 Regional disease burden 
In chapter four I outlined which disease categories are priorities for the worst-off in 
Africa. The top three health problems for the worst-off in Africa are: 1) infectious 
diseases, including malaria, tuberculosis, HIV and AIDS, emerging infections and 
neglected tropical diseases, such as African trypanosomiasis, Buruli ulcer, 
leishmaniasis and lymphatic filariasis; 2) reproductive and sexual health; and 3) child 
health. These three disease categories account for 60% of DALYs in the region 
(Table 5.2). A focus on research for these disease categories would then be a good 
starting point for South Africa. 
  
Table 5.2 Priorities for health research mapped onto disease burden, Africa 
(2006) 
 
Key domains for health research in Africa DALYs 
% of 
total 
DALYs 
 
     1 Infectious diseases,  
including malaria, tuberculosis, HIV and  AIDS, 
emerging infections and neglected tropical diseases 
(e.g. African trypanosomiasis, Buruli ulcer, 
leishmaniasis and lymphatic filariasis) 
177.5 47.1
60,6% 
2 Reproductive and sexual health 24.7 6.6  
3 Child health 25.9 6.9  
4 Non-communicable diseases,  
including cardiovascular disease, diabetes, cancers, 
sickle cell disease, injuries etc. 
15.6 4.1  
5 Malnutrition 7.1 1.9  
6 Mental health, 
 including drug and substance abuse 
5.7 1.5  
 
5.3.2 Regional health research and investment gaps 
To correctly identify gaps where South Africa should pursue health research relevant 
to the worst-off in Africa will require empirical evidence. Data on investments in 
health research globally provide an indicator of where various funders are currently 
prioritising their investments, as well as where there are gaps. The G-Finder reports 
specifically on global investment into research for new products to prevent, diagnose 
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and manage the diseases of the developing world. The total reported funding for the 
31 diseases identified by G-Finder constitutes 1.8 % of total global spending on 
health research.87 South Africa would clearly be filling an important gap if they were 
to pursue health research relevant to developing countries, given the relatively low 
proportion of global funding being directed to it. 
Since it is morally permissible for South Africa to prioritise the worst-off in sub-
Saharan Africa, South Africa’s duties may be narrowed to focus on the worst-off in 
this region. One way to further focus these resources would be to pursue health 
research relevant to the worst-off in sub-Saharan Africa that is relatively 
underfunded. In chapter three, I identified some of the diseases relevant to the global 
poor that are most underfunded. These diseases fall into one of two categories: 1) 
diseases that are shared as health problems by Africa and South Africa; and 2) 
diseases that are health problems in Africa but not in South Africa. 
 
Health problems shared by South Africa and Africa 
 
South Africa and Africa have many health problems in common, including many 
infectious diseases and maternal and perinatal conditions. Examples include HIV, 
tuberculosis, diarrhoeal disease and respiratory infections. For many of these shared 
health problems, South Africa is already conducting health research, some of which 
is likely to benefit other African populations. Benefit to other African populations is, 
of course, contingent on whether the types of research being conducted by South 
Africa are relevant to other African populations. Two of these diseases, HIV and 
tuberculosis, are receiving relatively substantial funding, relative to other neglected 
diseases. The other two, lower respiratory infections and diarrhoeal diseases, are 
                                            
87 See chapter 3, section 3. 
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receiving disproportionately low health research investments compared to the others 
(Table 5.3).  
Therefore, to begin to fulfil its duty to the worst-off in the region, South Africa 
should ensure that the funds it already receives for research into these shared diseases 
are used to conduct research that will benefit all the worst-off in sub-Saharan Africa, 
and not only South African citizens. South Africa will need to assess to what extent 
its ongoing research is relevant to populations beyond its own borders. Since lower 
respiratory infections and diarrhoeal disease are receiving disproportionately low 
health research investments compared to the others, South Africa could advocate, 
and/or secure funding, for needed research into these two relatively underfunded 
disease groups, an action that will benefit the worst-off in its own population and the 
broader region.88  
 
Health problems for Africa but not South Africa 
 
Since South Africa has equal duties to all the worst-off in sub-Saharan Africa, it 
cannot only focus on the shared health research priorities that are in its national 
interest. This narrow focus would exclude many diseases that are significant health 
problems for the worst-off in the region. To meet the equal claims of sub-Saharan 
Africa’s worst-off, it is necessary for South Africa to include sub-Saharan Africa’s 
priority health problems, even if these are not priorities domestically. Examples of 
these diseases include malaria, sickle cell disease and the so-called neglected tropical 
diseases: Helminth infections, rheumatic fever, and kinetoplastids. These are the 
category of diseases that likely do not stand to benefit either directly or indirectly 
from any research that South Africa is already conducting. Also, because other 
African countries in general receive less donor funding than South Africa, these 
                                            
88 This will only follow if these disproportionately low health research investments represent serious gaps in the research 
needed for these diseases. 
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diseases have greater potential to be underfunded generally. Kinetoplastids were 
identified as the highest earners of research funds amongst neglected diseases of 
developing countries. Measured in dollars-per-DALY, this disease group receives 
more than HIV, tuberculosis, or malaria. But helminth infections and rheumatic fever 
receive very little funding. Measured in dollars-per-DALY, helminth infections and 
rheumatic fever combined receive less than one fifth the funding per DALY that 
kinetoplastids do (Table 5.3). 
To begin to fulfil its duty to the worst-off in the region, South Africa should expand 
its own list of health research priorities to include those relevant to the worst-off in 
the region. Since helminth infections and rheumatic fever receive low health research 
investment compared to the others, South Africa could advocate, and/or secure 
funding, for these relatively underfunded diseases.89 Additionally, South African 
researchers could work with researchers in other African countries and apply for 
grants for research on these diseases—thereby using South Africa’s greater research 
capacity to build capacity in the region. 
 
Table 5.3 Investments in the 8 leading neglected diseases in G-Finder 
 
Neglected disease 
DALYs 
2004 
(millions) 
Global 
funding 
2008 
(millions) 
$ per 
DALY 
     
1 Bacterial pneumonia (lower respiratory infections) 93.3 90.8 1.0 
2 Diarrhoeal diseases 72.3 132.2 1.8 
3 HIV/AIDS 57.8 1164.8 20.2 
4 Tuberculosis 34.0 445.9 13.1 
5 Malaria 33.9 541.7 16.0 
6 Helminth infections  12.0 66.8 5.6 
7 Rheumatic  5.1 2.2 0.4 
8 Kinetoplastids (Chagas, leishmaniasis and African 
trypanosomiasis) 
4.1 139.2 34.0 
 
Source: Data for table sourced from: Health Policy Division (2009). G-Finder: Neglected disease 
research and development: New times, new trends. The George Institute for International 
Health: Sydney, Australia. Available at: http:www.georgeinstitute.org/monitoring-global-rd-
investment-neglected-diseases 
                                            
89 Again, this will only follow if these low health research investments represent serious gaps in the research needed for 
these diseases. 
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Types of research relevant to the region 
 
It is perhaps easy to assume that, since many infectious diseases can be prevented, 
diagnosed and treated with a combination of already existing and available tools and 
interventions, there is no more research needed in these disease areas. In many cases, 
this is likely true. I showed in chapter 3, however, that even within a specific disease, 
the types of research needed in low-income settings might be different from the types 
of research being conducted in higher-income settings. For example, in chapter three 
I presented data to show that less than one fifth of total U.S. investments in HIV 
research were specifically targeted at developing country needs. So, only a small 
percentage (17%) of total funding into a disease that predominantly affects low- and 
middle-income countries is actually spent on research and development needed in 
these countries. The majority of the funding is directed to HIV/AIDS research 
targeted at high-income markets. This example illustrates that if health research is to 
truly meet the needs of the worst-off, it is not only important for global health 
research funding to be directed at particular diseases, but also at particular types of 
research within a particular disease. The proportion of global health research 
spending relevant to low-income settings is staggeringly low. So, even though there 
are investments in research for the diseases predominantly affecting the poor, the 
fruits of that research will not necessarily benefit the poor. This illustrates that not 
only does global spending fall short on global health research needs by disease group, 
but also within disease groups. Since global spending does not, in fact, reflect the 
types of research needed in low-income settings, one way in which South Africa may 
be able to instantiate its duty to the absolutely poor would be to advocate, and/or 
secure funding, for a shift to the types of health research needed to address diseases 
affecting these populations. In chapter four I outlined a few examples of the types of 
health research needed for some of the diseases most heavily burdening the worst-off. 
These include research into products specifically targeted at low-income country 
needs, implementation research and health systems research. 
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5.3.3 The feasibility and cost of research 
I have argued that South Africa has equal duties to all the worst-off in sub-Saharan 
Africa. A likely objection to this position is that South Africa simply cannot fulfil this 
obligation. South Africa is a middle-income country and has a relatively limited 
amount of resources directed at health research. Also, South Africa’s disease burden 
is four times larger than that of developed countries on average. This means we can 
reasonably expect a larger burden on finances, facilities and human resources in 
South Africa, compared to these same requirements in other countries. A plausible 
objection to my argument might go something like this: Given South Africa’s 
relatively limited resources for health research, and the gravity of their own disease 
burden, the resources they can plausibly direct at health research for other Africans 
are not going to make a difference and South Africa therefore does not have this 
obligation. 
There are various actions that South Africa might take in order to begin fulfilling its 
duty to support health research for the worst-off. In chapter three, I discussed how 
some of these would impact on South Africa’s limited pot of research resources more 
than others. Expanding its health research focus to include some combination of both 
national and regional health research priorities would impact South Africa’s research 
budget the most. This would require redirecting some of its budget to diseases that it 
might not yet be investing in, and that are not important for its own citizens. There 
are however many duty-fulfilling actions that South Africa can undertake that do not 
entail spending their limited health research resources. South Africa could at least 
partly fulfil its duties without paying for the needed research itself, for example, by 
directing grants or donor funding towards these diseases, by advocating for increased 
global investments where appropriate, or by disseminating its relevant research 
findings to researchers in other countries. South African researchers could 
additionally work with researchers in other African countries and apply for grants for 
research on neglected diseases—thereby using South Africa’s greater research 
capacity to build capacity in other places. These actions are separate from those that 
require sharing the pot of health research resources. They would impact less directly 
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on South Africa’s own health research budget, but are still going to be necessary for 
research to happen. Therefore, even given South Africa’s relatively limited resources 
for health research, and the gravity of their own disease burden, the resources they 
can plausibly direct at health research for other Africans will make a difference and 
South Africa therefore does have this obligation. 
When it comes to the limited pot of resources, it is morally permissible for South 
Africa to prioritise sub-Saharan Africa’s worst-off. This does not, however, mean that 
South Africa ought to stop here. The entire world’s worst-off have equal claims on 
South Africa. Since there are actions that South Africa can take that do not require 
sharing their pot of health research resources, South Africa can at least partly fulfil 
some of its duties to the global worst-off beyond the African region. In chapter three I 
reported on the distribution of global health research funding to give some insight 
into the proportion that goes towards diseases and types of research relevant to the 
poor. I identified gaps in health research spending, particularly gaps in health 
research spending relevant to the worst-off. Where the traditional big donors are not 
carrying out this needed research, there is room for South Africa to contribute 
towards filling these gaps. 
My theory does not say how much South Africa should do, only that it has an 
obligation. However, it should be remembered that, on my account, the worst-off in 
sub-Saharan Africa, both within and beyond South Africa’s borders, have an equal 
claim on South Africa’s health research resources. Thus, South Africa would have to 
give a powerful argument to justify not pursuing research on the disease areas 
relevant to this population. Given what I have argued here, this duty cannot simply be 
ignored. 
 
5.3.4 Next steps for South Africa 
My account of global justice offers a way to focus health research resources, but at 
present there is not enough data to work out the details. This of course has 
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implications for the certainty with which I can make recommendations. In many 
cases there is not comprehensive data to state with absolute certainty the amount of 
investment into a particular disease, or type of research relevant to that disease. The 
recommendations I make for how South Africa can begin to fulfil its duty then 
represent examples of the kinds of research or advocacy that South Africa ought to 
undertake. While the recommendations provided here are certainly not 
comprehensive, they do provide a starting point for South Africa’s support of health 
research for the global poor. 
 
Table 5.5 Next steps for South Africa 
 
Actions that a duty-fulfilling South Africa ought to undertake 
 
For global health research 
1. Advocate for a shift in global funding to the comparatively neglected burden of disease 
affecting the absolutely poor.  
2. Advocate for a shift to the type of research needed to address diseases affecting the worst-
off. This could include research into products that are targeted at low-income country 
research needs as well as implementation and health systems research so direly needed in 
these economic sectors. 
 
For those disease that are shared health problems for South Africa and the region 
3. Ensure that the funds it receives for research into these diseases are used to conduct 
research that will benefit not only the worst-off in its own population but also those in sub-
Saharan Africa. 
4. Commit to conducting the type of research relevant to both South Africa and the region on 
these overlapping health research priorities. 
5. Specifically advocate and secure funding for the types of research that are the most 
underfunded. Examples in this category include diarrhoeal and respiratory infections. 
6. Work with researchers in other African countries and apply for grants for research on these 
diseases—thereby using South Africa’s greater research capacity to build capacity in other 
places. 
 
For diseases that are health problems for Africa but not South Africa 
7. Continue on-going malaria research. 
8. Incorporate sub-Saharan Africa’s established health research priorities into its own 
research agenda. This would entail a shift in its research focus to one that is some 
combination of national and regional health research priorities. 
9. Specifically advocate and secure funding for the types of research that are the most 
underfunded. Examples include helminth infections and rheumatic fever. 
10. Work with researchers in other African countries and apply for grants for research on these 
diseases—thereby using South Africa’s greater research capacity to build capacity in other 
places. 
   
 
Nicola W Barsdorf 
175 
!
Table 5.6 South Africa’s health research priorities: a place to start 
 
South Africa’s health research priorities* 
Diarrhoea 
HIV and AIDS 
Malaria 
Maternal morbidity and mortality 
Neglected tropical diseases  
Nutrition 
Orphans and child-headed households 
Perinatal and neonatal mortality 
Respiratory infections 
Sexually Transmitted Infections 
Sickle cell disease 
Tuberculosis 
  
* In alphabetical order 
 
5.4 Implications 
5.4.1 A narrowed focus for future global health research priority-
setting 
In chapter four I argued that, when distributing limited health research resources, the 
fairest way to treat a population, most of the time, is to prioritise the worst-off. In 
order to determine whether global health research priority-setting exercises have 
endorsed this fair allocation of scarce resources, I analysed a selection of WHO 
global priority-setting exercises to establish whether they adhered to this prioritarian 
principle. 
The analysis revealed that the WHO generally recommended priorities that match the 
disease burden found in low-income countries. Since the health research priorities of 
the worst-off are different from those of low-income countries, these exercises 
recommended certain kinds of health research that are not priorities for the worst-off. 
Since the fairest way to allocate scarce resources, most of the time, is to prioritise the 
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health research needs of the worst-off, future global health research priority setting 
exercises ought to narrow the scope of their recommended health research priorities 
to more accurately reflect this. 
Similarly, governments with limited resources are also encouraged to narrow their 
focus to that of the health research priorities of the worst-off. Following the current 
guidance of these WHO priority-setting exercises will result in governments thinly 
spreading their limited health research resources across a broad range of disease 
areas, including some disease categories and types of research that are not relevant to 
the worst-off. If the best way to treat a population fairly is to invest in the worst-off, 
then governments with limited resources who would like to treat their own population 
fairly ought to rather narrow the focus of their limited health research resources on 
the health research priorities of the worst-off. 
 
5.4.2 Data is scarce, research is needed 
When searching for data on health research priorities and funding, it became apparent 
that in many cases these data have not yet been collected or reported. To my 
knowledge, there has been no priority setting exercise conducted on a global scale for 
health research, and global health research priorities have therefore not been 
established. This in itself is telling of a general lack of alignment in global efforts 
relevant to health research planning, activities and resource allocation. A similar lack 
of globally compiled data is evident when it comes to spending. In many cases, to 
illustrate a trend, I would assume that data on U.S. funding was a “good-enough” 
proxy for global investment. Reports on composite global health research spending in 
different disease categories would, however, be more informative. 
While organisations such as the Global Forum for Health Research and G-Finder 
have continued to track where and on what health research resources are spent, there 
are important pieces of information that are not currently part of their reporting. The 
first is an indication of how much more investment is needed for health research for 
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specific diseases, particularly the diseases most prevalent in low-income settings. The 
second is data on spending for types of research other than product research, such as 
reporting on investments in implementation and health systems research. 
 
5.4.3 The duties of middle-income countries 
The global justice literature has been silent on the duties of middle-income countries 
towards the global poor. Middle-income countries have limited resources and a 
section of their own population still living in absolute poverty. Thus, unlike very rich 
countries, they do not have the means to assist everyone in need. In this thesis I 
explored whether South Africa has duties to the global poor. More specifically, the 
central question of this thesis was whether South Africa has a duty to support health 
research for the global poor.90 I addressed the question of how a resource distributor 
(in this case a South African health ministry) should distribute its limited pool of 
resources for health research. 
While the focus of this thesis has been on South Africa, the conclusions I draw are 
relevant for any resource distributor (or government department) tasked with 
allocating a limited pool of resources for health research. Other middle-income 
countries, such as Thailand, India, China, and Brazil, have the same health research 
duties to the global poor. All the world’s worst-off have an equal claim on middle-
income country health research resources. Given that middle-income countries, with 
limited resources, are not able to assist everyone in absolute poverty, it will be 
necessary to find morally defensible ways to prioritise within this set. It might be that 
prioritising the worst-off in their region is morally permissible, because, similar to the 
                                            
90 The difficulty here is to show that investments in health research will actually have an impact on welfare. Like Sen and 
Nussbaum, I believe that health is an important component of overall well-being, and Sen and Nussbaum call components 
of well-being capabilities. Following this approach, poor health is understood as a form of capability-deprivation. Those 
who have poor health could then be described as those who are lacking a certain basic capability, which negatively affects 
their well-being. Poor health is therefore an indicator of low welfare. Since the very purpose of health research is to develop 
or adapt interventions that would enhance health and contribute to improved welfare, for the purposes of this thesis, I 
assume that health research is liable to benefit the well-being of populations. Where there is data that deviates from that 
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case of sub-Saharan Africa, it will in most cases produce a larger overall benefit. 
There might alternatively be other morally defensible ways to prioritise within this 
set that are dependent on the specific middle-income country. 
From the data presented in chapter four, two important observations were apparent. 
The first was that disease burden in Africa’s worst-off is different from that of worst-
off populations elsewhere. The second was that disease burden of the worst-off is 
different from the disease burden in the broader category of low-income countries. 
These findings have two implications for middle-income country obligations more 
generally. First, the data presented in this thesis, particularly the disease categories 
and types of research relevant to the worst-off in Africa, will not be relevant to the 
worst-off in other regions. Data on the diseases and types of research relevant to the 
worst-off in other regions would have to be collected independently and used to 
inform duty-fulfilment in the respective region. Second, while it might be easy to 
assume that low-income country data is a good representation of the worst-off, the 
disease burden for low-income countries is a function of the disease burden of the 
subpopulations within these countries. Some subpopulations are poorer and some are 
richer, and large sub-populations that are not amongst the worst-off skew the “low-
income country” disease distribution to include diseases that are not those of the 
worst-off. The disease burden in Africa’s worst-off is more similar to the disease 
burden for the African region than to the disease burden for the category of low-
income countries. The disease burden for Bangladesh, our “worst-off” proxy for 
South-East Asia, is also more similar to the disease burden for the South-East Asian 
region than to the disease burden for low-income countries as a whole. This data 
suggests that the worst-off are not most accurately represented by the broad category 
of low-income countries. Therefore, if a duty-fulfilling middle-income country wants 
to focus its resources on the worst-off in a particular region, it is better for it to focus 
its resources on the regional health research priorities than on the priorities for the 
more general category of low-income countries. 
                                                                                                                                       
model, I will of course take this into consideration. Otherwise this assumption is warranted, since it is plausible that there is 
feasible health research that will improve the health and consequently welfare of a population. 
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Beyond these basic principles, future research ought to address the obligations of 
countries like India and China, which are middle-income countries but are rapidly 
rising. Additionally, future research ought to explore the global obligations of 
middle-income countries with respect to aid more generally. 
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Appendices 
Appendix A: Countries in the World Health Organisation’s African 
Region 
 
 
 
  Countries in the WHO African Region* 
 
  Commonly accepted dividing line between sub-Saharan Africa and North Africa** 
 
 
* Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, 
Chad, Comoros, Congo, Côte d’Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, 
Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, 
Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, 
Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia, 
Zimbabwe. 
 
** Sudan and South Sudan are classified as North Africa by the United Nations. North Africa, Somalia and Djibouti 
are generally considered a part of the Arab world, even though Somalia and Djibouti are geographically part of 
sub-Saharan Africa.
 Appendix B: An overview of selected global health research 
priority-setting exercises 
In 1990, the International Commission on Health Research for Development, out of 
concern that the health needs of poor countries were not addressed adequately by the 
major health research funding agencies, was the first to undertake an exercise in 
priority-setting for health research on a global scale (40). The commission asked how 
well current research investments were addressing the world’s major health problems 
and meeting priority health research needs in developing countries. Their analysis 
drew attention to what was then referred to as the “10/90 gap,” the recognised 
imbalance in the global application of research resources to address the health needs 
of poor and disadvantaged populations. This imbalance essentially indicated that 90% 
of worldwide resources for health research were being spent on 10% of the global 
disease burden. The ultimate goal of the commission’s recommendations was to 
guide both foreign and domestic research investments to meet the needs of the most 
disadvantaged i.e. worst-off, and accelerate progress towards the goal of equity in 
health. Based on this, the commission recommended a five-step priority-setting 
approach to health research funding allocation that could informatively guide the use 
of both domestic and external resources. The five factors that they recommended 
ought to shape the research agenda included: 
1. Problem significance (disease prevalence and anticipated health impact of 
intervention). Investment in research should be relative to the size of the 
health problem, and should not divert funds from research urgently needed 
on other health problems that are causing greater morbidity and mortality. 
Alongside this assessment, priorities should be strongly influenced by the 
anticipated health impact of the interventions expected to result from the 
research. Problems that are not classified by disease - such as financing 
health services, building research capacity and infrastructure, and the 
development of health information systems - also require research attention. 
2. Cost of intervention (cost-effectiveness measures of health impact per unit 
expenditure). The cost-effectiveness of the health impact is an estimate of the 
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costs of addressing various health problems. Using this measure, health 
problems could be ranked according to years of potential life lost due to 
specific diseases. This kind of data could provide a framework to assist in the 
allocation of resources to address the diseases with the most years of 
potential life lost. 
3. Factors that favour successful execution. The likelihood that research will be 
successful is based on a composite assessment of scientific feasibility, 
intellectual challenge, and the human and organizational capability of the 
research community. 
4. Who sets priorities for whom? International research priorities should reflect 
national priorities weighted to help countries with the greatest health needs 
and the fewest resources. In order to weight these appropriately, any priority-
setting process has to address the fundamental questions of whose voices are 
heard, whose views prevail, and therefore whose health interests are 
advanced. 
5. The time horizon of benefits. There will always be a trade-off between meeting 
current health research needs and generating future health benefits. Priority-
setting will involve balancing these types of research. 
 
To move toward a greater coherence of research responses to high-priority problems 
at the national and global levels, the commission made additional recommendations, 
including that every country, especially developing countries, should develop a plan 
for Essential National Health Research (ENHR) containing some mix of country-
specific health research and global health research; and that donors and international 
programs should earmark funds for capacity building – at least 5% of any project 
budget by donors should go to both individual and institutional research capacity 
building (40). 
In 1993 the same commission established the Council for Health Research and 
Development (COHRED), an international non-governmental organization, to 
monitor and promote financial and technical support for health research relevant to 
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developing countries (85). COHRED has coordinated a number of country-level 
activities to develop ENHR plans, as well as general recommendations for the 
priority-setting process. Ten years after the original 10/90 report, COHRED 
conducted its first review of the processes and methods being used for priority-
setting. The analysis suggested that priority-setting processes had an ideological 
focus on “scientific autonomy” that resulted in a research agenda that was expert-
driven, and detached from the public arena. This kind of dependence on scientific 
experts and directors of Medical Research Councils was not only at the country level 
but was also prevalent in the WHO’s advisory committee on health research, at both 
the global and regional levels. The methods for setting research priorities had focused 
on the metrics of disease burdens. Less attention had been given to who sets the 
priorities and how choices are made. 
COHRED therefore proposed a strategy of priority-setting that had the ENHR 
strategy as its basis, with equity in health and development as its goal. Instead of 
being expert-driven, this method was demand-driven in that it focused on an analysis 
of health needs, people’s expectations and societal trends. Additionally, it involved 
multi-dimensional inputs (i.e. quantitative and qualitative scientific inputs, social, 
economic, political, ethical and management considerations) and multiple stakeholder 
inputs (i.e. communities, districts, sub-national and national levels). COHRED’s 
criteria for setting priorities largely mirrored those of the original recommendations 
of the CHRD. Setting priorities was based on: 
1. The magnitude and urgency of the health problem 
2. The extent of previous research and the potential contribution of research in 
discovering, developing or evaluating new interventions 
3. The feasibility of carrying out the research in terms of the technical, 
economic, political, socio-cultural and ethical aspects 
4. The expected impact of the research (direct and indirect effects, short and 
long-term benefits and implications on issues of affordability, efficacy, 
equity and coverage). 
 
South Africa’s duty to support health research for the global poor 
184 
COHRED emphasised the importance of seeing ENHR in the global context. While 
individual countries ought to weigh the resources they direct at key national problems 
they should also stay well informed about the international research effort. Of course, 
poor countries would need to focus their limited resources on their own research 
priorities, but should also be open to opportunities to advance jointly held concerns. 
Common health problems shared with other developing countries could be 
opportunities for collaborative, multi-country research efforts. COHRED also 
indicated that a number of middle-income countries such as Brazil, South Africa, 
Malaysia and Thailand are in a position to carry out the basic research on developing 
country health issues. In addition, the systematic formulation and articulation of 
national research agendas are important inputs into the global research agenda and 
there should be an emphasis on ensuring an upward synthesis of national priorities at 
the regional and global levels (86). COHRED does not currently endorse one 
particular method for priority-setting above any others but rather recommends 
choosing from among methods that are best suited to the local context and needs. 
Building on the recommendations made by the International Commission on Health 
Research for Development, the WHO established the Ad Hoc Committee on Health 
Research (87), which published its report in 1996. Charged with the task of 
identifying health needs and related research priorities in low- and middle-income 
countries, the committee identified specific high-priority product development 
opportunities using a systematic five-step process, similar to that used by COHRED: 
1) Calculate the burden of the condition or risk factor; 2) Identify the reasons why the 
disease burden persists; 3) Judge the adequacy of the current knowledge base; 4) 
Assess the promise of the research effort; and 5) Assess the adequacy of the current 
level of effort.91 The Ad Hoc Committee proposed a global research agenda based on 
this 5-step priority-setting process. This process was later taken forward by the 
Global Forum on Health Research at the global level in order to address identified 
research gaps. This same process was also used as a foundation in the development of 
                                            
91 See page 5 of the 1996 WHO Ad Hoc Committee report for more detail on the approach and methods used. See also 
Table 4.2.1 for a comparison of the priority-setting criteria used by different groups. 
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a conceptual model for a later WHO health research priority-setting exercise, Priority 
Medicines for Europe and the World in 2004 (88). 
In 1998 the WHO’s Advisory Committee on Health Research (ACHR) published a 
research policy agenda for science and technology to support global health 
development (89). Since billions of people, particularly poorer populations in low-
income countries, do not benefit from many current advances in science and 
medicine, the underlying motivation for this work was to work towards re-orienting 
at least part of global research towards global problem-solving and the promotion of 
health development for the world’s underprivileged. Their report suggested that an 
acceptable list of criteria for global health research priority-setting still needs to be 
agreed upon, but as a starting point, relevant criteria were considered and proposed. 
These include: The scale and urgency of the need, based on health level assessment 
and on an understanding of the fundamental causes of the health problem; the 
likelihood of success in any research; the availability of human and other resources to 
do the work; the likely time scale; the consequences in subsequent years of the 
possible interventions likely to follow from the research; and the existence of other 
options for intervention outside the health sector. 
The WHO-IFPMA Working Group92 convened in 2001 to identify definitively those 
infectious diseases that are most in need of new medicines or vaccines, and to give 
some sense of the priority areas for additional research. The approach employed was 
to establish a working list of infectious diseases and apply a combination of 17 
assessment criteria (90, p.9). These criteria can be broadly grouped into three 
categories: 1) Disease burden and future trends, including DALYs, mortality, costs 
to society, proportion of population treated per annum, and projected trends over the 
next 20 years; 2) Existing interventions, including non-drug interventions, effective 
available drugs, whether treatment prevents secondary cases, and limitations of 
                                            
92 The WHO-IFPMA Round Table was a joint task force comprising representatives of the World Health Organization 
(WHO) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). The final results and 
recommendations were never published. For more information see: WHO-IFPMA Round Table. Working paper on priority 
infectious diseases requiring additional R&D. Geneva: World Health Organisation; 2001 [cited 2011 March 9]. Available 
from: http://www.who.int/intellectualproperty/documents/en/IFPMA.pdf  
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existing drugs; and 3) Medicines research and development needs and priorities, 
including desirable non-drug interventions, new drugs needed, the technical 
feasibility of new drugs, current industry levels of engagement, and the public sector 
support needed to engage industry in new research. Using these assessment criteria, 
the working group established a list of priority diseases with scientifically tractable 
targets but insufficient product research. 
More recently, several other organisations, agencies and forums have continued to 
build on previous efforts to establish priorities for global health research. The Global 
Forum for Health Research (GFHR) (91) created a priority-setting tool called the 
Combined Approach Matrix (CAM) (92) that systematically brings together current 
knowledge on a particular disease or risk factor and allows identification of common 
factors by looking across diseases or risk factors. The tool has recently been further 
refined into a Three-Dimensional Combined Approach Matrix (3D CAM) (93). This 
revised approach aims to capture forms of discrimination, marginalization and 
vulnerability with a view to research priority-setting benefiting those with greatest 
need. The UNICEF-UNDP-World Bank-WHO Special Programme for Research and 
Training in Tropical Diseases (TDR) prioritises research by using an adapted version 
of the Global Forum’s framework for priority-setting (63). 
The WHO’s Priority Medicines for Europe and the World combined a number of 
methods to produce a methodology that they intend for use in priority-setting at 
country, regional and global levels (88). The project used the systematic five-step 
process of the Ad Hoc Committee on Health Research as a basis for its own 
conceptual priority-setting model. The approach was also based, in part, on the 
methodology employed by the GFHR and the TDR. Specifically the Priority 
Medicines Project used three complementary approaches: 1) an evidence-based 
approach (where adequate data were available on burden of disease and the efficacy 
or lack thereof of existing treatments or interventions); 2) projection or trend analysis 
methods (where data on burden of disease or efficacy did not exist, which is based 
primarily on consensus judgments and observational and clinical evidence); and 3) 
principles of social justice, social solidarity, and equity (for orphan and neglected 
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diseases, diseases affecting vulnerable groups such as women, children and the 
elderly, or where there was market failure). 
Finally, in 2006 the Child Health and Nutrition Research Initiative (CHNRI) 
conducted a priority-setting exercise with a more specific focus on global child health 
(94). The group assessed global child health research priorities within particular 
disease categories and conditions. The basic components used in their exercise 
included the: 1) Likelihood that it would be ethical to do this research; 2) Likelihood 
that the resulting intervention would be effective in reducing disease burden, 3) 
Deliverability, affordability and sustainability of resulting intervention, 4) Maximum 
potential of intervention to reduce disease burden; and 5) Effect of disease burden 
reduction on improving equity in the population. The scope of the exercise was also 
broad, capturing not only research designed to produce new products and knowledge, 
but also research aimed at the implementation of this knowledge to reduce disease 
burden.
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